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Abstract
The effectiveness and cost-effectiveness of minimal 
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randomised arm of the trial (178 allocated to surgical 
management, 179 allocated to continued, but optimised, 
medical management) and 453 recruited to the parallel 
non-randomised preference arm (261 chose surgical 
management, 192 chose to continue with best medical 
management). The type of fundoplication was left to the 
discretion of the surgeon.
Main outcome measures: Participants completed a 
baseline r e f l u x  questionnaire, developed specifically 
for this study, containing a disease-specific outcome 
measure, the Short Form with 36 Items (SF-36), the 
EuroQol-5 Dimensions (EQ-5D) and the Beliefs about 
Medicines and Surgery questionnaires (BMQ/BSQ). 
Postal questionnaires were completed at participant-
specific time intervals after joining the trial (equivalent 
to approximately 3 and 12 months after surgery). 
Intraoperative data were recorded by the surgeons and 
all other in-hospital data were collected by the research 
nurse. At the end of the study period, participants 
completed a discrete choice experiment questionnaire.
Results: The randomised groups were well balanced at 
entry. Participants had been taking GORD medication 
for a median of 32 months; the mean age of participants 
was 46 years and 66% were men. Of 178 randomised 
to surgery, 111 (62%) actually had fundoplication. 
There was a mixture of clinical and personal reasons 
why some patients did not have surgery, sometimes 
Objectives: To evaluate the clinical effectiveness, cost-
effectiveness and safety of a policy of relatively early 
laparoscopic surgery compared with continued medical 
management amongst people with gastro-oesophageal 
reflux disease (GORD) judged suitable for both policies.
Design: Relative clinical effectiveness was assessed 
by a randomised trial (with parallel non-randomised 
preference groups) comparing a laparoscopic surgery-
based policy with a continued medical management 
policy. The economic evaluation compared the cost-
effectiveness of the two management policies in order 
to identify the most efficient provision of future care and 
describe the resource impact that various policies for 
fundoplication would have on the NHS.
Setting: A total of 21 hospitals throughout the UK 
with a local partnership between surgeon(s) and 
gastroenterologist(s) who shared the secondary care of 
patients with GORD.
Participants: The 810 participants, who were identified 
retrospectively or prospectively via their participating 
clinicians, had both documented evidence of GORD 
(endoscopy and/or manometry/24-hour pH monitoring) 
and symptoms for longer than 12 months. In addition, 
the recruiting clinician(s) was clinically uncertain about 
which management policy was best.
Intervention: Of the 810 eligible patients who 
consented to participate, 357 were recruited to the Abstract
iv
related to long waiting times. A total or partial wrap 
procedure was performed depending on surgeon 
preference. Complications were uncommon and 
there were no deaths associated with surgery. By the 
equivalent of 12 months after surgery, 38% in the 
randomised surgical group (14% amongst those who 
had surgery) were taking reflux medication compared 
with 90% in the randomised medical group. There 
were substantial differences (one-third to one-half 
standard deviation) favouring the randomised surgical 
group across the health status measures, the size 
depending on assumptions about the proportion that 
actually had fundoplication. These differences were the 
same or somewhat smaller than differences observed 
at 3 months. The lower the r e f l u x  score, the worse 
the symptoms at trial entry and the larger the benefit 
observed after surgery. The preference surgical group 
had the lowest r e f l u x  scores at baseline. These scores 
improved substantially after surgery, and by 12 months 
they were better than those in the preference medical 
group. The BMQ/BSQ and discrete choice experiment 
did distinguish the preference groups from each other 
and from the randomised groups. The latter indicated 
that the risk of serious complications was the most 
important single attribute of a treatment option. A 
within-trial cost-effectiveness analysis suggested that 
the surgery policy was more costly (mean £2049) 
but also more effective [+0.088 quality-adjusted 
life-years (QALYs)]. The estimated incremental cost 
per QALY was £19,000–£23,000, with a probability 
between 46% (when 62% received surgery) and 19% 
(when all received surgery) of cost-effectiveness at a 
threshold of £20,000 per QALY. Modelling plausible 
longer-term scenarios (such as lifetime benefit after 
surgery) indicated a greater likelihood (74%) of cost-
effectiveness at a threshold of £20,000, but applying a 
range of alternative scenarios indicated wide uncertainty. 
The expected value of perfect information was greatest 
for longer-term quality of life and proportions of surgical 
patients requiring medication.
Conclusions: Amongst patients requiring long-term 
medication to control symptoms of GORD, surgical 
management significantly increases general and reflux-
specific health-related quality of life measures, at 
least up to 12 months after surgery. Complications 
of surgery were rare. A surgical policy is, however, 
more costly than continued medical management. 
At a threshold of £20,000 per QALY it may well be 
cost-effective, especially when putative longer-term 
benefits are taken into account, but this is uncertain. 
The more troublesome the symptoms, the greater 
the potential benefit from surgery. Uncertainty about 
cost-effectiveness would be greatly reduced by more 
reliable information about relative longer-term costs and 
benefits of surgical and medical policies. This could be 
through extended follow-up of the r e f l u x  trial cohorts 
or of other cohorts of fundoplication patients.
Trial registration: Current Controlled Trials 
ISRCTN15517081.Health Technology Assessment 2008; Vol. 12: No. 31
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Background
The advent of less invasive fundoplication 
performed laparoscopically offers new 
opportunities for the management of people with 
chronic symptoms of gastro-oesophageal reflux 
disease (GORD).
Objectives
To evaluate the clinical effectiveness, cost-
effectiveness and safety of a policy of relatively 
early laparoscopic surgery compared with 
continued medical management amongst people 
with GORD judged suitable for both policies.
Methods
Design
A randomised trial (with parallel non- (a) 
randomised preference groups) comparing 
a laparoscopic surgery-based policy with a 
continued medical management policy to 
assess their relative clinical effectiveness.
An economic evaluation of laparoscopic  (b) 
surgery for GORD, comparing the cost-
effectiveness of the two management policies, 
to identify the most efficient provision of 
future care and describe the resource impact 
that various policies for fundoplication would 
have on the NHS.
Setting
A total of 21 hospitals throughout the UK with 
a local partnership between surgeon(s) and 
gastroenterologist(s) who shared the secondary care 
of patients with GORD.
Participants
The 810 participants, who were identified 
retrospectively or prospectively via their 
participating clinicians, had both documented 
evidence of GORD (endoscopy and/or 
manometry/24-hour pH monitoring) and 
symptoms for longer than 12 months. In addition, 
the recruiting clinician(s) was clinically uncertain 
about which management policy was best.
Intervention
Of the 810 eligible patients who consented to 
participate, 357 were recruited to the randomised 
arm of the trial (178 allocated to surgical 
management, 179 allocated to continued, but 
optimised, medical management) and 453 
were recruited to the parallel non-randomised 
preference arm (261 chose surgical management, 
192 chose to continue with best medical 
management). The type of fundoplication was left 
to the discretion of the surgeon.
Main outcome measures
Participants completed a baseline questionnaire 
containing a disease-specific outcome measure 
(the R e f l u x  questionnaire, developed specifically 
for this study), the Short Form with 36 Items (SF-
36), the EuroQol-5 Dimensions (EQ-5D) and the 
Beliefs about Medicines and Surgery questionnaires 
(BMQ/BSQ). Postal questionnaires were completed 
at participant-specific time intervals after joining 
the trial (these were at times equivalent to 
approximately 3 and 12 months after surgery). 
Intraoperative data were recorded by the surgeons 
and all other in-hospital data were collected by 
local research nurses. At the end of the study 
period, participants completed a discrete choice 
experiment questionnaire.
Results
The randomised groups were well balanced 
at entry. Participants had been taking GORD 
medication for a median of 32 months; the mean 
age of participants was 46 years and 66% were 
men. Of 178 randomised to surgery, 111 (62%) 
actually had fundoplication. There was a mixture 
of clinical and personal reasons why some patients 
did not have surgery, sometimes related to long 
waiting times. A total or partial wrap procedure 
was performed, depending on surgeon preference. 
Complications were uncommon and there were no 
deaths associated with surgery.
Executive summaryExecutive summary
x
By the equivalent of 12 months after surgery, 
38% in the randomised surgical group (14% 
amongst those who had surgery) were taking reflux 
medication compared with 90% in the randomised 
medical group. There were substantial differences 
[one-third to one-half standard deviation (SD)] 
favouring the randomised surgical group across 
the health status measures, the size depending on 
assumptions about the proportion that actually had 
fundoplication. These differences were the same or 
somewhat smaller than differences observed at 3 
months. The lower the R e f l u x  score the worse the 
symptoms at trial entry and the larger the benefit 
observed after surgery.
The preference surgical group had the lowest 
R e f l u x  scores at baseline. These scores improved 
substantially after surgery and by 12 months 
they were better than those in the preference 
medical group. The BMQ/BSQ and discrete 
choice experiment did distinguish the preference 
groups from each other and from the randomised 
groups. The latter indicated that the risk of serious 
complications was the most important single 
attribute of a treatment option.
A within-trial cost-effectiveness analysis suggested 
that the surgery policy was more costly (mean 
£2049) but also more effective [+0.088 quality-
adjusted life-years (QALYs)]. The estimated 
incremental cost per QALY was £19,000–£23,000, 
with a probability between 46% (when 62% 
received surgery) and 19% (when all received  
surgery) of cost-effectiveness at a threshold of 
£20,000 per QALY. Modelling plausible longer-
term scenarios (such as lifetime benefit after 
surgery) indicated a greater likelihood (74%) of 
cost-effectiveness at a threshold of £20,000, but 
applying a range of alternative scenarios indicated 
wide uncertainty. The expected value of perfect 
information was greatest for longer-term quality of 
life and proportions of surgical patients requiring 
medication.
Conclusions
Amongst patients requiring long-term medication 
to control symptoms of GORD, surgical 
management significantly increases general 
and reflux-specific health-related quality of life 
measures, at least up to 12 months after surgery. 
Complications of surgery were rare. A surgical 
policy is, however, more costly than continued 
medical management. At a threshold of £20,000 
per QALY it may well be cost-effective, especially 
when putative longer-term benefits are taken into 
account, but this is uncertain. 
Implications for health care
Extending the use of laparoscopic fundoplication 
to people whose GORD symptoms require long-
term medication would provide health gain. 
However, it is more costly and so judgements 
are required about cost-effectiveness. The more 
troublesome the symptoms, the greater the 
potential benefit from surgery.
Recommendations for research
Uncertainty about cost-effectiveness would be 
greatly reduced by more reliable information about 
relative longer-term costs and benefits of surgical 
and medical policies. This could be through 
extended follow-up of the R e f l u x  trial cohorts or of 
other cohorts of fundoplication patients.
Trial registration
This trial is registered as ISRCTN15517081.Health Technology Assessment 2008; Vol. 12: No. 31
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The NIHR Health Technology Assessment 
Programme identified the need to evaluate and 
compare the advent of minimal access surgery for 
gastro-oesophageal reflux disease (GORD) with 
medical management. This report describes the 
work commissioned to address this issue.
Gastro-oesophageal 
reflux disease
GORD causes some of the most frequently seen 
symptoms in both primary and secondary care; 
between 20% and 30% of a ‘Western’ adult 
population experience heartburn and/or reflux 
intermittently.1–3 There is a clinical spectrum. The 
majority has only mild symptoms and requires little 
if any medication. A minority has severe reflux 
and develops overt complications, despite full 
medical therapy, and requires surgical intervention. 
Amongst the remainder, control of symptoms 
requires regular or continuous medical therapy, 
and it is from this intermediate group of patients 
with significant disease that most of the treatment 
costs for the health service arise.
Treatment of GORD includes a range of options, 
both medical and surgical. The simplest is self-
administered antacids with advice to alter lifestyle 
factors such as dietary modification, smoking 
cessation and weight reduction. Many will require 
acid suppression therapy using either histamine 
receptor antagonists (H2RAs) or proton pump 
inhibitors (PPIs). Initial high-dose therapy may 
be followed by maintenance treatment using these 
drugs either intermittently or continuously at 
reduced doses sufficient to suppress symptoms. 
The role of surgery has traditionally been confined 
to the treatment of those with severe symptoms not 
responding to medication in appropriate dosage 
and medically fit for surgery. There has, however, 
been a paradigm shift since the introduction of 
laparoscopic techniques, with surgery suggested as 
an alternative treatment to long-term medication. 
The NHS costs of GORD are considerable. The 
yearly drug budget for H2RAs is in excess of £200M 
and for PPIs it is £300M. Of this budget, most of 
this prescribing occurs within the primary care 
setting.4,5 Once started on PPIs, the majority of 
patients with significant GORD remain on long-
term treatment,6 and an estimated 4–5 patients 
(age 18–60) per 10,000 are taking maintenance 
PPIs for oesophagitis and reflux. 
Although PPIs are increasingly assumed to be 
safe there is a spectrum of short-term symptoms 
caused by PPIs7 and there are concerns regarding 
the impact of long-term use through profound 
acid suppression. PPIs cause hypergastrinaemia, 
the long-term significance of which is unknown 
but potentially important. Conditions associated 
with chronic hypergastrinaemia and low acid 
levels have been linked to a long-term increased 
risk of developing gastric cancer. There is some 
evidence of the formation of gastric carcinoid 
tumours in patients taking long-term PPIs8 and 
also of vitamin B12 deficiency.9 Adenocarcinoma 
of the lower oesophagus is a complication of 
long-term GORD,10–13 and the incidence of this 
highly malignant disease has trebled in Western 
communities in the last 25 years. Whilst the 
overall incidence of gastric cancer is falling, 
adenocarcinoma of the gastro-oesophageal junction 
is now a common cause of death, especially in 
men. The reasons for this change are probably 
multifactorial, but there is a clear relationship 
between Helicobacter pylori infection with migration 
to the gastric fundus and acid suppression, whether 
naturally occurring or induced by drug therapy.14,15
Laparoscopic fundoplication
Interest in surgery as an alternative to long-term 
medical therapy for GORD has been considerable 
since the introduction of the minimal access 
approach in the early 1990s. The operative 
method, whether using an open or a laparoscopic 
approach, involves performing a fundoplication 
by wrapping the fundus of the stomach around 
the lower oesophagus to create a high-pressure 
zone, thus reducing gastro-oesophageal reflux. 
The wrap created can be either complete (360°) 
or partial. Many operative variants have been 
described. The commonest operation is a 1-cm 
complete wrap fashioned over a large bougie, 
the so-called ‘short floppy Nissen’.16,17 The use 
of a partial fundoplication has a number of 
potential advantages but several controlled studies 
have shown broad equivalence between the two 
Chapter 1  
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approaches.18,19 For the purpose of this study they 
are therefore regarded as equivalent. Although 
fundoplication will produce resolution of reflux 
symptoms in upwards of 90% of patients, there is 
continuing debate regarding the risks, side effects 
and durability of surgical therapy. 
Medical management
There is no doubt that PPIs, sometimes combined 
with prokinetic agents, are the most effective 
treatment for moderate to severe GORD. For 
the purpose of this study, medical therapy has 
been taken to mean long-term therapy with 
PPIs (or H2RAs if intolerant to PPIs). Although 
fundoplication is highly effective for controlling 
GORD, there has been considerable uncertainty 
whether exchanging symptoms associated with 
the best medical management of GORD for those 
of the side effects of surgery is advantageous for 
the patient and cost-effective for the health-care 
provider. 
The costs of laparoscopic fundoplication appear to 
be equivalent to those of 2–3 years of maintenance 
treatment with PPIs, although it is acknowledged 
that the costs of PPIs are falling.20 The costs of 
surgery are related largely to two factors – the 
incidence of complications/length of hospital stay 
and the number of patients requiring long-term 
medical interventions after surgery.
Rationale for the 
study design
The study described in this report aimed to clarify 
the place of laparoscopic fundoplication in the 
belief that decisions about the management of 
GORD should be based on unbiased, statistically 
precise comparisons of alternative policies. All 
patients in this study fulfilled three criteria: they 
were on long-term acid suppression with PPIs; they 
had symptoms that were thought to be adequately 
controlled; and they  were suitable in terms of 
fitness and co-morbidity for either surgical or 
continuing medical treatment for their GORD.
The most likely sources of bias were in the ways in 
which the groups being compared were selected, 
the ways in which their outcomes were assessed, 
and how the management was actually delivered. 
This is the basis for using a pragmatic randomised 
controlled trial design. Random allocation protects 
against selection bias. Confining the trial to 
those with no clear treatment preference limits 
biased patient-centred assessment of outcome, 
and pragmatic comparison of alternative policies 
(with intention to treat analysis) avoids bias 
introduced by non-compliance. This approach 
has limitations, however, and for this reason we 
chose to incorporate two parallel, non-randomised 
preference groups. 
Excluding those with a clear preference for one 
policy or the other limits extrapolation and 
generalisation. Study of this group may give 
insights into the reasons for preference and 
hence give pointers to patient choices after the 
study.21 Furthermore, preference may influence 
outcome and, if so, this may also help when 
making treatment decisions.21,22 A third reason for 
including the parallel, non-randomised preference 
groups23 is that the addition of data from the 
preference groups may reduce imprecision around 
the estimates from the randomised comparison and 
this may be particularly useful for rare events, such 
as complications, that can be confidently ascribed 
to one or other treatment. (The limitation is that 
these groups are not derived by random allocation 
and hence the comparisons are prone to the biases 
of non-randomised studies.)
The decisions about, and comparisons between, 
randomised and preference groups require valid 
measurement of treatment outcome. Although 
there are a number of quality of life tools available, 
none was sufficiently specific to assess the spectrum 
of gastrointestinal symptoms associated with the 
treatment of GORD, particularly surgery. For this 
reason the development and validation of a new 
outcome measure (the R e f l u x  questionnaire; see 
Chapter 4) was an essential component of the 
study.24 
GORD and its management represent a very 
significant call on NHS resources. Although 
clinical effectiveness, acceptability and safety will 
be important determinants of future policy, the 
issues of cost and resource use may be over-riding. 
A prospective, multicentre study25 found that the 
total cost for chronic PPI (omeprazole) therapy 
over 5 years was less than the cost of an open 
fundoplication; however, two other studies26,27 
found laparoscopic surgery to be less expensive in 
the long run than daily treatment with 20–40 mg of 
omeprazole. In one of these studies27 laparoscopic 
fundoplication became more cost-effective at 1.4 
years post procedure. A Canadian Markov model 
comparing medical management with laparoscopic 
fundoplication concluded that laparoscopic Health Technology Assessment 2008; Vol. 12: No. 31
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fundoplication became cost-effective at 3.3 years 
post operation.28 
A recent UK trial-based economic analysis 
comparing laparoscopic fundoplication with PPIs 
using data on 100 GORD patients29 reported 
that the incremental cost per point improvement 
in combined gastrointestinal and psychological 
well-being scores at 12 months for laparoscopic 
fundoplication versus PPI was £293, and the 
incremental cost per additional patient returned 
to a physiologically normal acid score at 3 months 
was £5515.29 There are, however, no existing 
studies in the UK that have compared laparoscopic 
fundoplication with PPIs using a generic measure 
of health, such as quality-adjusted life-years 
(QALYs). Expressing health benefits in terms of 
QALYs would provide decision-makers with a 
basis for comparison with other uses of health-
care resources in a range of disease areas and 
specialties. 
There is little doubt that PPIs are the most effective 
pharmacotherapy30 for moderate to severe GORD 
and, for the purpose of this analysis, medical 
therapy will be taken to mean long-term therapy 
with PPIs. Although fundoplication is a highly 
effective therapy for controlling GORD, the 
question is whether surgery, which can alleviate 
GORD symptoms but may have unwanted side 
effects, is advantageous for the patient and cost-
effective for the health-care provider.
This is the reason for the economic evaluation. 
Policy should be guided by both assessment of the 
relative cost-effectiveness of alternative policies 
and assessment of the impact that possible policy 
changes would have for the NHS and for patients 
with GORD. Health Technology Assessment 2008; Vol. 12: No. 31
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Chapter 2  
Methods
Study population
Potential participants, who were identified both 
retrospectively and prospectively, were invited to 
attend an outpatient appointment (see Appendix 
3). The participating clinician reviewed each 
patient’s symptoms and treatment regimen and 
assessed eligibility (see Appendix 4).
Eligible patients were those for whom care had 
been provided by a participating clinician who 
was uncertain which management policy (surgical 
or medical) was better. In addition, patients had 
to have documented evidence of GORD (based 
on endoscopy and/or manometry/24-hour pH 
monitoring) as well as symptoms for more than 
12 months requiring maintenance PPI therapy for 
reasonable symptom control. Patients who were 
intolerant to PPIs and who therefore required 
H2RA therapy to control their symptoms were 
also included. Patients who were morbidly obese 
[body mass index (BMI) > 40 kg/m2], patients 
with Barrett’s oesophagus of more than 3 cm or 
who had evidence of dysplasia, patients who had 
a para-oesophageal hernia and patients with an 
oesophageal stricture were all excluded.
If eligibility was confirmed the patient was invited 
to see the local research nurse who described the 
trial, giving supplementary information describing 
the operation (see Appendix 5) and answering any 
questions or concerns. This process is summarised 
in Figure 1.
Consent to participate
The randomised trial
Some potential participants made a decision 
about participation at this appointment. Those 
who wished to participate in the randomised trial 
were asked to sign a consent form (see Appendix 
6). On this, they confirmed that they had been 
given the information they required and that the 
study had been explained to them. They also 
confirmed that they understood that they would 
be sent questionnaires at participant-specific time 
intervals after joining the study (this would be 
at times equivalent to around 3 months and 12 
Study design
The study had two complementary components:
 a multicentre, pragmatic randomised trial  (a) 
(with parallel non-randomised preference 
groups) comparing a laparoscopic surgery-
based policy with a continued medical 
management policy to assess their relative 
clinical effectiveness
 an economic evaluation of laparoscopic  (b) 
surgery for GORD comparing the cost-
effectiveness of the two management policies 
to identify the most efficient provision of 
future care and describe the resource impact 
that various policies for fundoplication would 
have on the NHS.
Patients who consented to participate in the 
randomised trial were randomly allocated to 
either laparoscopic surgery or continued medical 
management. Those patients who had a strong 
preference for one or other of the two treatment 
options could be recruited to the preference 
study. Clinical history at trial entry was recorded 
on participants’ entry forms (see Appendix 1). 
Participants completed health status questionnaires 
at the time of recruitment to the study and then at 
specified times equivalent to 3 and 12 months after 
surgery (see Appendix 2).
Approval for this study was obtained from the 
Scottish Multicentre Research Ethics Committee 
and the appropriate local research ethics 
committees.
Clinical centres
Clinical centres were based on local partnerships 
between surgeons with experience of laparoscopic 
fundoplication and the gastroenterologists with 
whom they shared the secondary care of patients 
with GORD. Centres were eligible if they included: 
a surgeon who had performed at least 50  1. 
laparoscopic fundoplication operations
one or more gastroenterologists who agreed to  2. 
collaborate with the surgeon(s) in the trial.Methods
6
months after surgery). They were also told that it 
was anticipated that further follow-up would be 
performed periodically thereafter for some years.
The preference study
A person who did not want to take part in the 
randomised trial because of a strong preference 
for one type of treatment management or the 
other was asked to take part in the preference 
arm of the study. Those who wished to participate 
in the preference study were given a preference 
information leaflet and asked to sign a consent 
form (see Appendix 7) confirming their preferred 
treatment allocation. For logistical reasons 
and to maintain a balance between the sizes of 
FIGURE 1  Flow chart describing patient recruitment.
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randomised and preference groups, the numbers 
of participants recruited to preference arms was 
limited to 20 per arm in each centre. 
Anyone who was uncertain was given at least 
48 hours to consider participation. 
Health technology policies 
being compared
Laparoscopic surgery policy
For those participants allocated or recruited to the 
surgical arms of the trial, subsequent deferring or 
declining of surgery, by either the participant or 
the surgeon, was always an option (i.e. even after 
trial entry), particularly amongst those recruited 
by a gastroenterologist and referred to a surgeon 
for consideration of surgery within the trial. 
Participants who had not had manometry/pH 
studies performed underwent these tests before 
surgery to exclude achalasia.
The surgery was performed either by a surgeon 
who had undertaken more than 50 laparoscopic 
fundoplications or by a less experienced surgeon 
working under the supervision of an experienced 
surgeon. It was recommended that crural repair 
be routine and that non-absorbable, synthetic 
sutures (not silk) be used for the repair. The type 
of fundoplication used was left to the discretion of 
the experienced surgeon. For the purposes of the 
main comparisons, the different surgical techniques 
for laparoscopic fundoplication were considered 
as part of a single policy. The study design, 
however, allowed for indirect comparisons between 
techniques.
Medical therapy policy
Those allocated to the medical therapy policy 
had their therapy reviewed and adjusted as 
necessary by the local gastroenterologist to be ‘best 
medical management’. It was recommended that 
management conformed to the principles of the 
Genval Workshop Report.31 These include stepping 
down anti-secretory medication in most patients to 
the lowest dose that maintains acceptable symptom 
control. However, patients with severe oesophagitis 
were not managed on the basis of symptoms alone. 
Although trial participants allocated to medical 
management were managed in this way, the 
protocol did include the option of surgery if a clear 
indication for it subsequently developed.
Study registration (and 
treatment allocation 
when randomised)
The entry procedure distinguished between those 
who agreed to randomisation and those who 
agreed to participate in the preference part of the 
study. 
Once a participant had agreed to join the trial 
the research nurse recorded basic identifying and 
descriptive information on a standard form (see 
Appendix 1). A letter was sent to each participant, 
confirming their participation and whether they 
were taking part in the randomised or preference 
component of the trial. At this point the participant 
was also asked to complete a baseline questionnaire 
(see Appendix 2). 
The treatment allocation for participants in the 
randomised component of the trial was computer 
generated in the trial office; it was stratified 
by centre, with balance in respect of other key 
prognostic variables – age (18–49 years or 50+ 
years), sex (male or female) and BMI (≤ 28 or 
> 29 kg/m2) – by a process of minimisation. 
Randomisation was organised centrally at the 
Health Services Research Unit, Aberdeen, and was 
independent of all clinical collaborators. 
Clinical management
The first 146 randomised participants (70 allocated 
surgery and 76 allocated medical management) 
were sent details of their allocation at the same 
time as the baseline questionnaires. This was 
changed for subsequent participants at the request 
of the Data Monitoring Committee (DMC; see page 
10 ) such that the allocation was only generated 
once completed baseline forms had been returned. 
This was to ensure that there was no possibility 
that knowledge of the allocation might influence 
responses to the baseline questionnaire (as well as 
ensuring that a completed baseline questionnaire 
would be received from all randomised 
participants). A summary of the trial procedure 
pathways is illustrated in Figure 2.
Participants who were allocated to the surgical 
arm were invited to a consultation with the 
collaborating surgeon. During this consultation 
the surgeon confirmed that there were no Methods
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contraindications to surgery and discussed the 
operation in more detail, before arranging an 
operation date. The intraoperative details were 
recorded by the surgeon on specially designed 
study forms (see Appendix 8). All other in-hospital 
data collection was the responsibility of the local 
research nurse. In all respects, other than the trial 
interventions, clinical management was left to the 
discretion of the clinician responsible for care. 
Data collection
Follow-up by postal questionnaire was performed 
at least twice at participant-specific time intervals 
after joining the study. This was around 3 and 
12 months after surgery or at an equivalent time 
amongst those who did not have surgery. The latter 
times were chosen through a process of matching 
participants in the various groups. Participants 
FIGURE 2  Flow chart showing trial procedures post recruitment.
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received up to two reminder telephone calls or 
letters to encourage non-responders to return their 
postal questionnaires. On occasion, and at the 
convenience of participants, questionnaires were 
completed over the phone. 
All data were sent to the trial office in Aberdeen 
for processing and staff in Aberdeen worked closely 
with participants’ local research nurses to secure as 
complete and accurate data as possible. A random 
10% sample of all data was double entered to check 
accuracy. Extensive range and consistency checks 
further enhanced the quality of the data.
The principal study 
outcome measures 
The primary outcomes for measuring the 
differences in effects between medical and surgical 
treatment were:
a ‘disease-specific’ measure incorporating  •	
assessment of reflux and other gastrointestinal 
symptoms and the side effects and 
complications of both therapies (the R e f l u x  
questionnaire was developed specifically for 
this study as described in Chapter 4)
NHS costs including treatments, investigations,  •	
consultations and other contacts with the 
health service.
The secondary outcome measures were:
health-related quality of life (HRQoL) –  •	
EuroQol-5 Dimensions (EQ-5D) and Short 
Form with 36 Items (SF-36)
patient costs including loss of earnings,  •	
reduction in activities, and the costs of 
prescriptions and travel for health care
other serious morbidity, such as operative  •	
complications
mortality. •	
The instruments for collecting this information are 
shown in Appendix 2. 
Sample size 
The original aim was to recruit 600 participants to 
the randomised trial to give 80% power to identify 
a difference between the two groups of 0.25 of a 
standard deviation in respect of the disease-specific 
instrument and other continuous variables such as 
EQ-5D or SF-36, using a significance level of 5%. 
Based on the same arguments it was planned that 
300 people would be recruited to each arm of the 
preference study. The cost savings of a surgical 
policy largely depend on the number of patients 
managed surgically who no longer require PPI 
treatment, and a trial with 300 surgically managed 
patients would have estimated this proportion to 
within about 5% with 95% statistical confidence.
However, prompted by a lower rate of recruitment 
than expected, this target was revised in 
January 2003 in consultation with the DMC and 
representatives of the HTA programme. It was 
agreed that a larger benefit (0.3 of a standard 
deviation) was clinically plausible based on 
improvements seen after surgery amongst more 
severely affected people. This was calculated to 
require 196 in each group to give 80% power 
(p = 0.05). On this basis it was agreed that 
recruitment would be extended for an extra year, 
aiming for this revised sample size. 
Statistical analysis
A single principal analysis of the randomised 
trial was planned when all participants had been 
followed up for 12 months after surgery (or an 
equivalent time if managed medically). The 
primary outcome measure [R e f l u x  quality of life 
(QoL) score at 12 months] and secondary outcome 
measures (R e f l u x  QoL score at 3 months; SF-36, 
EQ-5D, R e f l u x  symptom scores and use of reflux-
related drugs at 3 months and 12 months) were 
analysed using general linear models that always 
adjusted for the minimisation covariates (age, 
BMI and sex) and where appropriate (defined 
by significant at the 5% significance level) also 
adjusted for baseline score and baseline score by 
treatment interaction. A secondary, pre-stated, 
subgroup analysis explored the differential effects 
of surgeons’ preferred operative procedures on the 
primary outcome measure. All analyses used 95% 
confidence intervals. 
The primary analysis of the randomised trial 
was by intention to treat. The intention to 
treat approach gives the least biased estimate 
of effectiveness of the two interventions. As a 
secondary comparison we were also interested in 
estimating the efficacy of the treatment received. 
Given that a relatively large proportion of the 
randomised surgical participants did not receive 
surgery, we used two approaches to estimate the 
efficacy of the treatment – a per protocol analysis 
and an adjusted treatment received analysis.32 
In the per protocol analysis, participants who 
were randomised to surgery and actually received Methods
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surgery were compared with participants who were 
randomised to medication and actually received 
medication (i.e. the compliers in the surgical group 
were compared with the compliers in the medical 
group). In an open trial design the per protocol 
estimate can have substantial selection bias. One 
way to estimate the effect when the allocation was 
complied with while adjusting for possible selection 
biases is to use a latent variable approach.33 We 
used the method of adjusted treatment received as 
described by Nagelkerke et al.32 The method used a 
two-stage least squares approach whereby treatment 
randomised was regressed onto treatment received 
and the residuals from that model were used as an 
independent variable in a second model together 
with the treatment received to estimate the effects 
on the various primary and secondary outcome 
measures.
For the preference group, only the primary 
outcome was analysed statistically. The analysis 
compared the preference surgical group with 
the preference medical group and adjusted for 
the minimisation factors. As described above, 
for logistical reasons and to maintain balance 
between the randomised and preference groups, 
we capped the number of preference participants 
at 20 per group per centre. The study design was 
not therefore a true comprehensive cohort. We 
did consider modelling differences between the 
randomised and preference groups; however, it 
is not universally accepted that formal modelling 
is appropriate in this context. In this case we 
knew from the randomised arms that there was a 
strong interaction with baseline reflux QoL, and 
in addition we also knew that there was a large 
difference in QoL between preference arms at 
baseline (and patient demographics). We therefore 
decided that formal modelling of the arms would 
not add much to the comparison given the large 
confounding between preference groups. 
Missing items in the health-related outcome 
measures were treated as per the instructions for 
that particular measure. No further imputation for 
missing values was undertaken.
Data monitoring
In March 2003 an independent DMC met for 
the first time to review the overall conduct of 
the trial, patient accrual, data collection and an 
interim analysis of the data. They considered data 
available to them up to January 2003. At that 
time 146 participants had been recruited to the 
randomised trial, 76 allocated to the randomised 
medical group and 70 allocated to the randomised 
surgical group. Of the 177 preference participants, 
77 chose the medical group and 100 chose the 
surgical group. On the basis of the data available to 
them they requested that the treatment allocation 
procedure be investigated. This led the DMC to 
instruct that the entry procedures be amended (as 
described on page 7) so that participants were only 
randomised once the trial office had received the 
baseline questionnaire and all of the other baseline 
paperwork (see Appendices 2, 4, and 6). 
The DMC met on two further occasions (July 
2003, January 2004) and were happy with the trial 
progress and interim analyses and saw no reason to 
recommend any further changes to the protocol.Health Technology Assessment 2008; Vol. 12: No. 31
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Background
Early in the study we chose to develop a 
preliminary economic model. Using the best 
evidence then available we developed a decision 
analytic model to provide preliminary estimates 
of costs and outcomes for medical and surgical 
management prior to the R e f l u x  trial reporting.34,35 
This chapter describes the preliminary economic 
model. 
Methods
Description of the model
The model was probabilistic and took the 
perspective of the UK NHS. Health outcomes 
were expressed in terms of QALYs with a lifetime 
horizon. The model related to a 45-year-old 
patient as this is the peak age of presentation with 
GORD.36 There proved to be very little difference 
between men and women; thus, only the results for 
males are presented here. Costs and QALYs have 
been discounted at a rate of 3.5% per annum.37 
The structure of the model can be seen in Figure 3. 
Two strategies were compared: long-term medical 
management and immediate laparoscopic surgery 
for GORD. Medical management was assumed 
to be prescribed for the remainder of a patient’s 
lifetime (30 years for a 45-year-old patient). 
Surgery was assumed to occur immediately 
following entry into the surgical arm of the model. 
The model was also split into short-term and long-
term elements. The short-term model related to 
the period immediately following allocation to 
surgery or medical management. The longer-term 
element tracked the patient’s progression through 
a series of states over the remainder of their 
lifetime. Patients were assumed to stay in a ‘wait’ 
state before surgery, during which they would have 
received a maintenance dose of PPIs. The effects 
of alternative waiting times for surgery were also 
explored using alternative scenarios (1 month and 
1 year) to represent the possible length of delay. 
In these cases it was still assumed that surgery 
following relapse would occur immediately, 
that is there would be no delay. Monthly cycles 
represented the monthly transition probabilities 
between states in the model.
For patients receiving surgery a small mortality 
risk is associated with laparoscopic fundoplication 
(approximately 5 per 10,000 patients)38–47 and this 
was included in the model. If patients survived 
surgery the outcomes could be success (cured) or 
failure (relapse). In addition, patients could relapse 
from a successful surgery each month. This rate 
was constant and lasted for only one cycle, during 
which a patient received a double dose of PPI. 
A scenario is also presented in which the risk of 
failure from surgery (and the need for revision) 
ended at 5 years after initial surgery. Patients could 
be given a reoperation following surgery failure. If 
the reoperation failed, surgery was deemed a total 
failure and patients were considered to have been 
prescribed long-term medical management with 
PPIs. For patients offered medical management 
following initial surgical failure, medical 
management was deemed a total failure if there was 
subsequent relapse from medical management, and 
patients were placed on a double dose of PPIs for 
the remainder of their lives.
Medical management patients had a risk of 
relapsing each month. They could be offered 
surgery or could receive a double dose of PPIs 
for a cycle, followed by a return to a stable (well) 
medical management state at a normal dose of 
PPIs. Patients receiving surgery following relapse 
on medical management faced the same transition 
probabilities as surgical patients post surgery. 
They could also receive one reoperation following 
surgery failure. Medical management following two 
operations was deemed a total failure and patients 
were placed on a double dose of PPIs for the 
remainder of their lives. 
Chapter 3  
Preliminary economic modelling
A preliminary comparison of the cost-effectiveness of 
pharmacotherapy and surgery (laparoscopic fundoplication) 
in the treatment of gastro-oesophageal reflux diseasePreliminary economic modelling
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For both surgical and medical management 
patients there was a monthly risk of all-cause 
mortality. The age-specific death rate for men 
aged from 45 to 54 years was obtained from the 
UK Office of National Statistics (ONS)48 and used 
to calculate the probability of death from natural 
causes from one cycle to the next. 
Evidence to populate the model
Literature searches were undertaken to identify 
studies attempting to measure quality of life 
(measured by the EQ-5D) in relation to GORD or 
those providing information on the probability 
of movement between transition states during 
treatment. Searches were restricted to MEDLINE, 
EMBASE and internet sources, such as the 
Database of Abstracts of Reviews of Effectiveness 
(DARE). Studies carried out before 1995 were 
not included as medical and surgical treatments 
for GORD were expected to have advanced 
significantly in the past 10 years, particularly in 
relation to relapse rates from surgery. The search 
strategies are shown in Appendix 9. This research 
was conducted in December 2005.
Fixed-effects meta-analysis techniques were used 
to synthesise data from multiple sources. Further 
details of the studies identified in the review are 
available from the author on request. Table 1 
describes the probabilities and distributions of 
parameters used in the model.
TABLE 1  Probabilities and distributions of parameters used in the model (probabilities are monthly unless stated otherwise)
Parameter Probability Distribution Sources
Probability of death from 
surgery (instantaneous risk)
0.0005 Beta (4–3997) Multiple studies: Contini et al., 2002;38 Gotley et 
al., 1996;39 Dallemagne et al., 1998;40 Kiviluoto et 
al., 1998;41 Booth et al., 2002;42 Landreneau et al., 
1998;43 Finley and McKernan, 2001;44 Pessaux et al., 
2002;45 van der Peet et al. 1998;46 Bais et al. 200047
Probability of surviving surgery (1–above)
Probability of surgery failure 0.0044 Beta (78–1429) Multiple studies: Contini et al., 2002;38 Gotley et 
al., 1996;39 Dallemagne et al., 1998;40 Kiviluoto et 
al., 1998;41 Booth et al., 2002;42 Landreneau et al., 
1998;43 Pessaux et al., 2002;45 Watson et al., 1995;49 
Lundell et al., 2001;50 Lundell et al., 1996;18 Anvari 
and Allen, 2003;51 Ludemann et al., 2005;52 Hunter 
et al., 1999;53 Graziano et al., 2003;54 Soper and 
Dunnegan, 199955
Probability of surgery success (1–above)
Probability of reoperation after 
surgery failure (instantaneous 
risk)
0.1034 Beta (55–477) Multiple studies: Contini et al., 2002;38 Finley and 
McKernan, 2001;44 Pessaux et al., 2002;45 Anvari 
and Allen, 2003;51 Soper and Dunnegan, 1999;55 
Eshraghi et al., 1998;56 Bammer et al., 2001;57 
Jamieson et al.,199458
Probability of medical 
management after surgery 
failure 
(1–above)
Probability of a relapse on 
medical management
0.0256 Beta (78.8–207) Multiple studies: Lundell et al., 2001;50 Hatlebakk 
and Berstad, 1997;59 Festen et al.,1999;60 Bate et 
al., 199561
Probability of stable 
maintenance on medical 
management
(1–above)
Probability of surgery to treat 
relapse on medical management 
(instantaneous risk)
0.1133 Beta (23–180) Multiple studies: Lundell et al., 2001;50 Myrvold et 
al., 200162
Probability of returning to 
medical management after 
relapse
(1–above)Preliminary economic modelling
14
Resource use
Resource use associated with surgery consisted of: 
(1) procedures for screening for the presence of 
GORD (endoscopy, manometry pH monitoring, 
etc); (2) theatre staff; (3) surgical disposables; 
(4) length of surgery; (5) length of hospital stay; 
(6) postoperative procedures; and (7) surgical 
revision or conversion to open fundoplication 
when needed. The resources used were estimated 
through a survey of five of the hospitals involved 
in the R e f l u x  trial. The lengths of surgery and of 
hospital stay were taken from the laparoscopic 
fundoplication baseline data for the R e f l u x  trial. An 
additional 15 minutes was added to the duration of 
operation to derive a total length of surgery, as the 
time from anaesthesia to recovery recorded in the 
R e f l u x  trial did not allow for preparation time. 
Typical daily dosages of PPIs and other medicines 
used in medical maintenance of GORD were 
also obtained from the R e f l u x  trial baseline 
questionnaire using data for the month before 
study entry. An average daily dose was calculated 
for each drug and used to derive an average daily 
cost of medical treatment.
Costs
Table 2 shows the estimated monthly cost of 
drugs or surgery per patient and their associated 
distributions, which reflect the heterogeneity 
between centres and differences in pack sizes for 
medications.
Costs of all medicines were taken from the British 
National Formulary (2005)63 and an assumption was 
made that lowest cost prescribing was used (e.g. 
generic formulations and tablets). The average 
daily cost of medical treatment was calculated and 
the model assumed that, in the event of a relapse 
on medical treatment, the dose would be doubled 
for a period of 1 month. Direct surgical treatment 
costs included the costs of preoperative screening 
for GORD, surgery and hospital stay. For theatre 
staff costs, salaries were taken as the mid-point on 
the relevant scale for each grade or professional. 
Costs of perioperative procedures were taken from 
provider-to-provider tariffs for various hospitals 
or from published sources,64,65 and the frequency 
of such procedures was calculated from the 
laparoscopic fundoplication baseline data in the 
R e f l u x  trial. Costs of surgical revision or conversion 
to open fundoplication were assumed to be the 
same as those of the original operation. In the 
case of open fundoplication, a hospital stay of 6 
days was assumed and a cost loading (average cost 
was inflated to account for the expected number 
of high-cost rare events) applied based on a meta-
analysis of published information.45,51,58,66,67
The cost of oesophageal dilatation for dysphagia 
(swallowing difficulties), the most commonly 
occurring postoperative corrective surgery 
encountered, was taken from Leeds General 
Infirmary and a cost loading was added to the 
total cost of surgery. Along with death, this was 
the only complication of surgery considered in 
these analyses. Costs of endoscopic disposables 
were obtained from a manufacturer, Ethicon Endo-
Surgery. Costs of disposable drapes and gowns 
came from Kimberly-Clark Health Care, UK. 
Capital costs associated with standard laparoscopic 
surgery installations were obtained from Karl Storz 
GmbH and Ethicon Endo-Surgery. An assumption 
was made that the service life of a laparoscopic 
installation was 5 years and the capital costs were 
amortised (3.5% per annum) over that period. 
Furthermore, a capital cost for laparoscopic 
fundoplication was calculated assuming 200 
operations were undertaken in that period in each 
centre. 
Appendix 10 summarises the costs associated with 
surgery. Variation between centres largely reflects 
differing staff mix and variation in the use of 
disposables.
Health outcomes
Outcomes were expressed as QALYs with patients’ 
HRQoL measured by the EQ-5D. This is a 
generic measure of health status in which health 
TABLE 2  Costs used in the preliminary economic model
Parameter Cost (£) Distribution Sources
Monthly cost of medications 18.25 Gamma (1.77–0.33) re f l u x  study baseline data and British 
National Formulary63
Cost of medications during months 
relapse (maintenance dose doubled)
36.50
Cost of surgery 2787.39 Gamma (113.60–16.50) Survey of r e f l u x  centres (see Appendix 10)Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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is characterised on five dimensions (mobility, 
self-care, ability to undertake usual activities, 
pain, anxiety/depression).68 Each response to this 
instrument locates an individual into one of 245 
mutually exclusive health states, each of which 
has previously been valued on the 0 (equivalent 
to dead) to 1 (equivalent to good health) ‘utility’ 
scale based on interviews with a sample of 3395 
members of the UK public.69 
EQ-5D values for patients who were on medical 
treatment were obtained from the available (as 
of December 2004) baseline data (surgical and 
medical management patients) collected in the 
R e f l u x  trial. EQ-5D values obtained for the UK 
general population (population norms) aged 
from 45 to 54 years were taken from Kind et 
al.70 and were considered to represent a ‘cured’ 
state (successful surgery). HRQoL in the month 
immediately following laparoscopic fundoplication 
was taken from EQ-5D values as measured in 
patients following laparoscopic cholecystectomy.71 
Patients with unresolved symptoms of GORD 
(relapse) were assigned a utility based on the 
decrement between stable medical management 
and reflux symptoms estimated in a published 
expert opinion (0.53).72 The utility values used and 
their sources are summarised in Table 3. 
Analysis
The model was developed in Excel with the 
Crystal Ball ‘add-on’. Monte Carlo simulation 
was used to propagate the prior distributions 
assigned to model inputs and estimate the 
expected costs and outcomes associated with each 
alternative therapy; incremental cost-effectiveness 
ratios (ICER) were calculated. Distributions for 
parameters were selected on the basis of the 
nature of the parameter concerned.73 To conduct 
the simulations, the distributions reported in 
Table 1 were assigned to the model inputs to 
characterise the current uncertainty surrounding 
their values. The simulation recalculated the 
results over 10,000 iterations. For each iteration, 
the value of each variable was sampled at random 
from the distributions specified. By repeating the 
calculations of expected costs and outcomes in this 
way, distributions of estimates are obtained, which 
allow estimation of the mean expected costs and 
QALYs and associated distributions. 
The results of the model are presented in two 
ways. First, mean costs and QALYs for the various 
comparators are presented and their cost-
effectiveness compared, using standard decision 
rules to estimate ICER as appropriate. Second, 
given that mean costs and QALYs gained are 
estimated with uncertainty, the output from the 
simulations have been used to generate cost-
effectiveness acceptability curves. These curves 
illustrate the probability of surgery being more 
cost-effective than medical management given a 
range of values that an NHS decision-maker might 
attach to an additional QALY. Threshold values of 
cost-effectiveness ranging from £0 to £100,000 per 
additional QALY were used in the analysis. This 
is a Bayesian approach to the presentation of cost 
effectiveness, although this is not a full Bayesian 
analysis.74,75
The output of these simulations was also used to 
estimate the expected value of perfect information 
(EVPI).76,77 The cost in terms of health benefits 
and resources forgone if a wrong decision is made 
can be described using the probability of making 
an error based on current knowledge and the 
consequences of a wrong decision. Thus, the 
expected costs of uncertainty can be interpreted 
as the EVPI, as perfect information would obviate 
decision error. The EVPI is, therefore, the 
maximum that the health-care system should be 
willing to pay for additional evidence to inform 
this decision in the future, that is, the maximum 
expenditure in relevant future research. Per patient 
EVPI was calculated and, in addition, an analysis 
of the EVPI associated with particular items of 
evidence used in the model was also conducted. 
TABLE 3  EQ-5D values, distributions and sources
State Utility Distribution Sources 
QoL on stable medical maintenance 0.72 Gamma (0.02–8.38) re f l u x  study baseline data
QoL during relapse 0.56 Gamma (0.02–5.29) re f l u x  study baseline data; Heudebert 
et al., 199772
QoL following surgery 0.61 Fixed Ainslie et al., 200371
QoL in cured post-surgical state 0.84 Gamma (0.25–11.29) UK male (45–54 years) population norms 
(Kind et al., 199970)
QoL, quality of life.Preliminary economic modelling
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This can be used to focus research on those 
elements in the decision for which more precise 
estimates would be most valuable.76–78 
Results
Base-case cost-effectiveness
The base-case estimates of costs and QALYs 
associated with surgery are shown in Table 4. Over 
a lifetime, medical management (£4890) was 
estimated to cost less than surgery (£5014) but it 
was associated with fewer QALYs than surgery: 
12.36 compared with 13.04.
The lifetime ICER for surgery versus medical 
management is thus £180. Based on this, as long 
as decision-makers are willing to pay more than 
£180 for an additional QALY, surgery would be 
regarded as the more cost-effective treatment 
option. However, mean costs and QALYs were 
estimated with uncertainty. Figure 4 shows the 
potential impact of the uncertainty in mean 
differences (surgery minus medical management) 
in costs and QALYs gained between the two groups 
(i.e. it shows mean costs and QALY differences 
based on the 1000 simulations). Figure 5 represents 
this uncertainty in the form of a cost-effectiveness 
acceptability curve. The probability that surgery is 
cost-effective at a threshold of cost-effectiveness of 
£30,000 per QALY is 0.639. 
Expected value of 
perfect information
The per patient EVPI for adults with GORD 
is illustrated in Figure 6. At a cost-effectiveness 
threshold of £30,000, EVPI is substantial at 
£15,106. At a threshold of £20,000, the EVPI is 
£10,081. EVPI for groups of parameters showed 
that all of the value of further research (£11,346 
at a threshold of £30,000 for cost-effectiveness) is 
associated with the quality of life implications of 
medical or surgical therapies, indicating that this is 
where future research should focus.
Alternative model assumptions
Alternative assumptions regarding the model 
structure were explored, specifically the effect of 
any delay to receiving surgery (1 month and 1 
year) and the risk of relapse from surgery 5 years 
postoperatively. 
Assuming that there is no risk of surgical failure 
5 years post operation reduces the total cost of 
surgery (to £4121) and increases QALYs (to 13.48). 
Although total costs (£4887) and QALYs (12.38) 
change for medical management, because of the 
small number of people receiving surgery following 
medical management relapse, the effect of this 
is only minor. Surgery now dominates medical 
management as it has lower costs and higher 
QALYs. Decision uncertainty is, however, relatively 
insensitive to this structural change, with the 
probability that surgery is cost-effective increased 
from 0.639 in the base-case model to 0.642 at a 
threshold of £30,000. As we are somewhat more 
certain about the decision to recommend surgery as 
the most cost-effective treatment, per patient EVPI 
decreases by a small amount from £15,106 in the 
base-case model to £15,078.
Incorporating any delays to surgery had very little 
effect on both the costs and the QALYs. This is 
because time spent in the ‘wait’ state was assigned 
a relatively small cost of medical management 
and the utility of stable management. Decision 
uncertainty and EVPI was also largely unaffected by 
delays to surgery.
Discussion
This was the first investigation of the cost-
effectiveness of lifelong medical treatment 
compared with immediate laparoscopic 
fundoplication for the treatment of GORD. The 
results of this model suggest that, even when the 
risk of spontaneous failure of surgery exists for a 
patient’s lifetime, surgery for GORD is more cost-
effective than lifelong management with drugs. 
TABLE 4  Cost-effectiveness of surgery versus medical management for the treatment of gastro-oesophageal reflux disease
Total costs (£) Total QALYs ICER
Surgery 5014.17 13.04 £180.61
Medical management 4890.59 12.36
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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FIGURE 4  Representation of the uncertainty in differential mean costs and quality-adjusted life-years (QALYs).
FIGURE 5  Cost acceptability curve for surgery versus medical management.
However, the true cost-effectiveness of surgery is 
uncertain and, at a threshold for cost-effectiveness 
of £30,000 per additional QALY, the value of 
information surrounding the decision problem is 
high. The number of people with GORD suitable 
for surgery is likely to be sizeable and therefore 
the EVPI of £15,106 at a threshold of £30,000 per 
QALY implies that the EVPI will exceed the cost of 
further investigation. This, in turn, suggests that 
further research will be potentially cost-effective. 
EVPI analysis on groups of parameters suggested 
that further research should focus on collecting 
evidence relating to the HRQoL of patients on 
medical management and following surgery.
It was necessary to make a number of assumptions 
in the model. First, in the absence of applicable 
data, it was necessary to simplify the dosing 
adjustment used to deal with relapse. In clinical 
practice a more complicated titration of dose 
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and duration of step-up or step-down dosing 
would be used. The effect of this would probably 
be that patients in relapse spend more than 1 
month on a higher dose (and at higher cost) and 
simultaneously experience lower HRQoL for 
longer than modelled here. At present, given that 
equal consequences of relapse have been applied to 
those patients relapsing on medical management 
or surgery, it is unlikely that applying a more 
complex relapse dosing structure would have a 
significant effect on the results of the model.
Second, the costs of surgery only partially capture 
true cost. Surgery may have unwanted side effects 
or may spontaneously fail at some point in the 
future. Treatment of side effects or surgical failure 
has costs both in monetary and quality of life terms. 
A common side effect, temporary difficulty with 
swallowing (dysphagia), has been considered in 
the model and a probabilised cost loading used to 
incorporate its treatment. However, no disutility of 
dysphagia, bloating, flatulence or other unwanted 
side effects following surgery has been included in 
the model because of a lack of data and consensus 
on the magnitude of effect. Related to this is the 
availability of data for other states in the model. 
In the absence of other suitable data, the utility 
values used to reflect the post-surgical state were 
based on patients measured following laparoscopic 
cholecystectomy,71 which has some surgical 
similarities to laparoscopic fundoplication but 
may not have the same spectrum of postoperative 
discomfort or complications. The utility value 
associated with a surgical cure has been taken from 
UK age-specific population norms.70 Also, it is 
unclear to what extent the post-surgical state can be 
likened to the utility of an average member of the 
UK population, that is, whether surgery actually 
generates a cure in utility terms. 
Finally, because of the focus on those patients 
currently maintained on medical management, 
the analysis reported here did not consider 
management strategies other than medical 
management or surgery. In many clinical settings 
lifestyle management advice is being favoured as 
a first-line option, with medical management or 
surgery considered only as second-line therapies in 
patients who do not respond to lifestyle changes. 
This may limit the applicability of this model in 
certain settings.
Despite these necessary assumptions, the model 
presented here represents the first attempt to 
generate estimates of cost per QALY for surgical 
and medical management strategies for the 
treatment of GORD patients in the UK. The 
results of the model suggest that, on the basis of 
current evidence, laparoscopic fundoplication may 
well represent a cost-effective means of treating 
GORD rather than lifelong medical management. 
Coupled with the apparent safety of the surgical 
procedure (in experienced hands), patients and 
the health service may benefit from increased 
substitution of surgery for medical management. 
What this preliminary analysis confirmed was the 
need for more robust data, especially in respect of 
HRQoL, and these data were being generated in 
the R e f l u x  trial. 
FIGURE 6  Per patient expected value of perfect information (EVPI).
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Chapter 4  
re f l u x  outcome measure
The development of a new measure of quality 
of life in the management of gastro-oesophageal 
reflux disease: the r e f l u x  questionnaire
Introduction
Although several GORD-specific or 
gastrointestinal-specific symptom scales and quality 
of life scales have been developed,79–87 we found 
that none captures the experience of patients 
receiving alternative treatments in sufficient detail 
for evaluating outcomes in the R e f l u x  trial. Of 
particular concern was that these measures do 
not reflect patients’ experiences of the side effects 
of surgery for GORD, which include general 
gastrointestinal symptoms as well as oesophageal 
reflux itself.85 A new condition-specific outcome 
measure was therefore developed for use within 
the R e f l u x  trial. The aim of this measure was not 
only to assess the symptoms of GORD but also the 
side effects of both medical and surgical treatment 
for GORD and the effects that these have on 
HRQoL. There were two requirements for the new 
measure: it had to measure HRQoL and not merely 
symptom experience; and its content had to cover 
the effects of treatment for GORD as well as the 
symptoms of GORD. This chapter describes the 
development and assessment of the new measure. 
Method
Questionnaire development
Between May and September 2000, a series of one-
to-one interviews and focus groups were conducted 
with patients in two cities, Leeds and Aberdeen, 
to identify those themes and issues related to 
GORD and its treatment that were important to 
people affected by GORD. In total, 31 people were 
interviewed, 15 receiving medical treatment and 
16 who had received surgery. In addition, two focus 
groups were conducted, each with six patients, one 
in Aberdeen and one in Leeds. Both focus groups 
included only patients who had received surgery 
for their GORD symptoms, identified via their 
gastroenterologist or surgeon.
Both the interviews and focus groups followed the 
same general format. Patients were asked questions 
about the types and severity of symptoms they 
experienced, how best to describe their symptoms, 
whether they felt that their symptoms were best 
described by their frequency, duration or level of 
distress, and about the impact that their symptoms 
had on their daily lives. 
All interviews and focus groups were audiotaped 
and transcribed. These transcripts underwent 
thematic analysis by three members of the trial 
team. Emerging themes and issues suggested 
potential questionnaire items. Whenever possible 
the language used by patients was used when 
devising the questionnaire items. The transcripts 
showed that the frequency of symptoms and 
their effects on quality of life were the two most 
commonly reported themes by patients. This led to 
the development of 31 possible questions. 
Piloting 
The initial version of the questionnaire (with the 
31 items) was piloted on a sample of 21 patients 
from Aberdeen, some of whom had taken part in 
the interview phase. The questionnaire was posted 
out to the patients asking them to complete it. 
At a later date they were interviewed about its 
readability and acceptability. Specifically, they 
were asked about whether they had any problems 
understanding the items, whether the response 
categories were appropriate for them and whether 
they thought that anything was missing from the 
questionnaire. The questionnaire was modified 
following the feedback from these interviews. At 
this stage a small number of items (three) were 
discarded as unsuitable or potentially ambiguous, 
others were reworded and three items that were 
not originally included in the initial version of 
the questionnaire, but were repeatedly mentioned 
by the patients and felt to be of importance, were 
added. The new version therefore also had 31 
items. Re f l u x outcome measure
20
Final questionnaire
The 31 items that were included in the formally 
evaluated version of the questionnaire were 
grouped into seven categories (heartburn; acid 
reflux; wind; eating and swallowing; bowel 
movements; sleep; and work, physical and 
social activities) describing symptoms relating to 
GORD or side effects of treatment (Table 5). For 
each category respondents were asked to show 
how often they had experienced problems with 
specified symptoms over the past 2 weeks, followed 
by how much they felt that those symptoms had 
affected their quality of life over the past 2 weeks. 
The symptom items offered five responses, from 
‘not at all’ to ‘every day’, and the quality of life 
items offered five responses – ‘not at all’, ‘a little’, 
‘moderately’, ‘a lot’ and ‘extremely’. Items in the 
least clinical of the categories, work, physical and 
social activities, offered six responses including ‘not 
applicable’ (see the R e f l u x  questionnaire within 
Appendix 2). 
Data
The new measure, along with two generic measures 
of HRQoL (EQ-5D88 and SF-3689) and information 
on background, demographics and use of 
medicine, was included in a postal questionnaire, 
which was sent to all R e f l u x  trial participants. 
Trial participants were sent a questionnaire at 
baseline after they had agreed to take part in the 
trial, at first follow-up (3 months after surgery or 
its equivalent for non-surgical participants) and 
at second follow-up (12 months after surgery or 
equivalent). This chapter reports on data received 
by December 2004. Most of the analysis presented 
here was performed on the baseline data, but 
analysis of sensitivity to change also used the first 
follow-up data.
Analysis
Developing a scoring system
We planned that the new measure would produce 
two different types of score:
a  •	 R e f l u x  quality of life score (RQLS) 
summarising the extent to which respondents’ 
symptoms affect their quality of life, where 0 is 
the worst quality of life and 100 is the best
a series of seven  •	 R e f l u x  symptom scores that 
profile respondents’ experiences of these 
groups of symptoms over the past 2 weeks. 
Although it is possible to generate summary scores 
by merely summing the raw scores on each item, 
this assumes that all items in the measure are 
equally important. This disregards the possibility 
that some items are more important than others 
and should therefore have a larger emphasis in the 
final score. We chose to use two distinct methods 
of weighting the contribution of items to the total 
score.
The R e f l u x  questionnaire contains seven quality 
of life items, each relating to one of its seven 
categories, that require participants to indicate 
how much they feel their symptoms on a particular 
dimension in the past 2 weeks have affected their 
general quality of life. Weights for the RQLS were 
estimated by assessing the influence of these items 
on participants’ assessments of their general quality 
of life. We used the seven baseline quality of life 
items as independent variables in an ordinary least 
squares (OLS) regression model with participants’ 
assessments of their general HRQoL, as measured 
by the EQ-5D visual analogue scale (EQ-5D VAS), 
as the dependent variable. For modelling purposes 
we assumed that the data from these items were 
cardinal. EQ-5D VAS requires respondents to 
assess their current state of health on a 0–100 
visual analogue scale, where 0 represents worst 
imaginable health and 100 best imaginable health. 
To remain in the model, regression coefficients 
did not have to be statistically significant but they 
did have to have the correct (negative) sign, i.e. 
a reported detrimental effect on quality of life 
should be associated with a decrease in EQ-5D 
VAS score. The resulting coefficients were used as 
weighting factors to calculate a general quality of 
life summary score. 
In contrast, weights for the R e f l u x  symptom 
summary scores were generated by entering 
the 31 baseline symptom items into a principal 
components analysis (PCA) with a Varimax 
rotation. We judged how many components 
or factors to extract by using a combination of 
TABLE 5  Re f l u x categories
Category
Number of 
items
Heartburn 3
Acid reflux 6
Wind 5
Eating and swallowing 3
Bowel movements 5
Sleep 4
Work, physical and social activities 5Health Technology Assessment 2008; Vol. 12: No. 31
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the Kaiser criterion (include all factors with an 
eigenvalue greater than 1) and a scree plot of those 
eigenvalues. The resulting factor loadings were 
used as the item weights to calculate a number of 
symptom scores. 
Reliability, validity and 
sensitivity to change
We assessed the reliability of the R e f l u x  quality of 
life and symptom scores by internal consistency, 
as measured by Cronbach’s alpha. In contrast, our 
assessment of the validity and responsiveness or 
sensitivity to change concentrated on the quality 
of life score, as this was the main aim of the 
measure. The validity of the RQLS was assessed 
by comparing its performance against the SF-36. 
Sensitivity to change was assessed by the measure’s 
ability to reflect changes in the condition of 
participants, as assessed by self-reported change in 
prescribed medication between baseline and first 
follow-up. Participants were asked to give details of 
their prescribed medication use (PPIs, H2RAs and 
anti-emetics) at baseline and at first follow-up. This 
information was used to classify whether or not 
their medication use had changed between these 
times. 
Results
Sample characteristics 
Between March 2001 and June 2004 a total of 810 
participants had been recruited into the R e f l u x  
trial, of whom 799 had completed and returned 
their baseline questionnaires. By December 2004 
602 participants out of 649 (93%) had returned a 
first follow-up questionnaire, and 418 out of 447 
(94%) a second follow-up questionnaire. At baseline 
64% of the sample was male, and the median age at 
trial entry was 46 years (range 18–74 years). 
Scoring
Generating weights for the 
r e f l u x  quality of life score
All 727 participants with complete baseline data 
on the R e f l u x  quality of life items and EQ-5D VAS 
were included in the analysis. Although coefficients 
for three of the seven quality of life items were 
not statistically significant, we kept them in the 
regression model for completeness. In contrast, 
we excluded the wind item from the RQLS model 
as the coefficient consistently showed the wrong 
sign and was not statistically significant. In effect, 
the wind item will receive a weight of zero when 
calculating the final score. The work, physical and 
social activities item had the largest coefficient and 
thus had most effect on the EQ-5D VAS, and the 
sleep item had the smallest coefficient. The final 
model coefficients used to calculate the RQLS are 
given in Table 6.
The coefficients from this model were used as 
weights for calculating the quality of life score by 
multiplying the response to each quality of life 
item (coded from 0 ‘not at all’ to 4 ‘extremely’) 
by the corresponding weight (i.e. the coefficient 
from Table 6) and subtracting these values from the 
constant term as follows:
Raw RQLS = 90 – (heartburn quality 
of life × 1.35) – (acid reflux quality of 
life × 1.70) – (wind quality of life × 0) – (eating 
quality of life × 1.10) – (bowel movement 
quality of life × 1.95) – (sleep quality of 
life × 0.35) – (activities quality of life × 2.15).
The score was then standardised to a scale from 0 
(worst quality of life) to 100 (best quality of life) as 
follows:
Standardised RQLS = (raw RQLS – 55.6) × 2.91.
TABLE 6  Model coefficients used to calculate the R e f l u x quality of life score (RQLS)
Re f l u x  quality of life item B SE Significance
Heartburn –1.346 0.81 NS
Acid reflux –1.700 0.70 < 0.05
Eating and swallowing –1.103 0.68 NS
Bowel movements –1.954 0.61 < 0.01
Sleep –0.351 0.66 NS
Work, physical and social activities –2.147 0.84 < 0.05
Constant 89.995 1.51 < 0.001
B, beta; NS, not significant; SE, standard error.
Adj r2 = 0.22.Re f l u x outcome measure
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Figure 7 presents the frequency distribution of 
quality of life scores for patients at baseline. The 
mean score was 65.0 with a standard deviation of 
24.3. 
Generating weights for the 
r e f l u x  symptom scores
The PCA identified five components that 
accounted for 57% of the variance in the items 
(Table 7). In general, the component structure 
reflected the themes identified when the items 
were developed; however, component 1 grouped 
together heartburn-like symptoms and sleep 
disruption into general discomfort (Table 7). The 
first component after rotation explained 19% of 
the total variance and included seven items with 
loadings above 0.4. Component 2 explained 12% 
of the total variance and included six main items. 
The remaining three components accounted 
respectively for 10%, 9% and 8% of the total 
variance. Component loadings were used to 
construct a profile of five R e f l u x  symptom scores to 
summarise an individual’s symptom experience. In 
the first instance we suggested the following labels 
for these components: 1 = general discomfort; 
2 = wind and frequency; 3 = nausea and vomiting; 
4 = activity limitation; and 5 = constipation and 
swallowing.
Each symptom score was calculated by multiplying 
the response to each of the symptom items in that 
score (coded from 0 ‘every day’ to 4 ‘not at all’) 
by the corresponding weight (i.e. the component 
loading for that item from Table 7) and then 
summing across the items. For the four items in 
activity limitation we grouped the response codes 
‘not applicable’ and ‘no, my symptoms do not 
affect me’ as 4, and recoded the other categories 
from 0 ‘I no longer work/perform these activities 
because of my symptoms’ to 3 ‘my symptoms 
have affected me but I still work/perform these 
activities’. Symptom scores were then standardised 
to a scale from 0 (worst symptom score) to 100 (best 
symptom score) as follows:
General discomfort = 5.24 × [(item 
A1 × 0.674) + (item A2 × 0.643) + (item 
B1 × 0.654) + (item D2 × 0.421) + (item 
F1 × 0.777) + (item F2 × 0.814) + (item 
F3 × 0.791)].
Wind and frequency = 6.59 × [(item 
C1 × 0.738) + (item C2 × 0.553) + (item 
C3 × 0.568) + (item C4 × 0.515) + (item 
E1 × 0.722) + (item E3 × 0.696)].
Nausea and vomiting = 9.84 × [(item 
B2 × 0.734) + (item B3 × 0.556) + (item 
B4 × 0.541) + (item B5 × 0.709)].
Activity limitation = 9.58 × [(item 
G1 × 0.695) + (item G2 × 0.571) + (item 
G3 × 0.755) + (item G4 × 0.588)].
Constipation and swallowing = 13.72 × [(item 
D1 × 0.338) + (item E2 × 0.839) + (item 
E4 × 0.645)].
Table 8 presents the mean symptom scores at 
baseline. There were pronounced ceiling effects for 
nausea and vomiting, constipation and swallowing, 
and activity limitations: 26%, 25% and 17% 
respectively of the sample had a maximum score 
of 100. In contrast, wind and frequency showed a 
more normal distribution.
Both the RQLS and R e f l u x  symptom scores were 
calculated only for individuals with complete data. 
FIGURE 7  Distribution of R e f l u x quality of life scores (RQLS).
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However, there were few missing data. Re f l u x  
scores could be calculated for over 95% of patients 
at baseline. Missing data rates for symptom items 
ranged from 1% to 2%, and for quality of life items 
from 3% to 5%.
Reliability
The reliability coefficient (Cronbach’s alpha) 
measuring the internal consistency of the RQLS 
was 0.90. For the R e f l u x  symptom scores, alphas 
were as follows: general discomfort 0.87; wind and 
TABLE 7  Component loadings used to calculate the R e f l u x symptom scores
Item  Component 1 Component 2 Component 3 Component 4 Component 5
A1: Heartburn 0.674
A2: Discomfort in chest 0.643
B1: Acid reflux 0.654
B2: Vomiting 0.734
B3: Regurgitation 0.556
B4: Nausea 0.541
B5: Urge to be sick 0.709
C1: Flatulence 0.738
C2: Belching 0.553
C3: Feeling bloated 0.568
C4: Stomach gurgling 0.515
D1: Difficulty swallowing 0.338
D2: Eating restricted 0.421
E1: Diarrhoea 0.722
E2: Constipation 0.839
E3: Urgent need to go 0.696
E4: Feeling like bowels not 
emptied
0.645
F1: Difficulty sleeping lying 
down
0.777
F2: Difficulty getting to sleep 0.814
F3: Disrupted sleep 0.791
G1: Paid/unpaid work 0.695
G2: Less strenuous activities 0.571
G3: Strenuous activities 0.755
G4: Social activities 0.588
Factor loadings < 0.3 have been suppressed.
TABLE 8  Mean R e f l u x symptom scores at baseline 
Reflux symptom dimension Mean SD Median
General discomfort 59.4 25.6 60.3
Wind and frequency  50.7 22.1 49.6
Nausea and vomiting 81.7 19.6 89.0
Activity limitation 79.2 16.5 81.5
Constipation and swallowing 77.7 20.6 79.6Re f l u x outcome measure
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TABLE 9  Relationship (Pearson’s r) between RQLS and SF-36 
dimension scores
SF-36 dimension RQLS 
Physical functioning 0.42
Role limitations – physical 0.49
Bodily pain 0.56
General health perception 0.46
Energy/vitality 0.34
Social functioning 0.59
Role limitations – emotional 0.41
Mental health 0.18
TABLE 10  Percentage (n) of respondents with the maximum 
R e f l u x quality of life score (RQLS) with the maximum score on the 
SF-36 dimensions
SF-36 dimension % (n)
Physical functioning 96 (70)
Role limitations – physical 66 (48)
Bodily pain 31 (23)
General health perception –
Energy/vitality –
Social functioning 74 (54)
Role limitations – emotional 97 (71)
Mental health –
frequency 0.78; nausea and vomiting 0.75; activity 
limitations 0.68; and constipation and swallowing 
0.56. Apart from the last two items all alphas are 
greater than 0.70, which is generally considered 
satisfactory.90 
Validity
Table 9 presents the relationship (Pearson’s r) 
between the RQLS and the eight SF-36 dimension 
scores. Social functioning and bodily pain showed 
the best relationships with the RQLS, and mental 
health the worst. 
Table 10 presents the proportion of respondents 
who had a score of 100 (best health) on the SF-36 
dimensions as a percentage of those who had a best 
score of 100 on the RQLS. Whereas 96% of those 
who had the maximum score on the SF-36 physical 
functioning dimension also had a score of 100 on 
the RQLS, only 31% of those who had a score of 
100 on the SF-36 bodily pain dimension also had a 
score of 100 on the RQLS. 
Figure 8 plots the mean RQLS against the SF-36 
mental component score (MCS) and physical 
component score (PCS) grouped into fifths. The 
mean RQLS increases steadily and significantly 
between successive PCS groups. There is a similar 
pattern for MCS groups except that respondents 
in the highest fifth have a lower mean RQLS than 
those in the next lower fifth. 
Sensitivity to change
Participants reported whether they were being 
prescribed medication at baseline and first follow-
up. This information was used to classify them 
into four groups: those prescribed medication at 
baseline and follow-up (n = 293); those prescribed 
medication at baseline but not follow-up (n = 186); 
those prescribed medication at follow-up but 
not baseline (n = 3); and those not prescribed 
medication at all (n = 7). As the last groups are 
reassuringly small, Figure 9 presents mean change 
in RQLS (baseline score – follow-up score) for the 
first two groups. 
A negative score indicates an improvement in 
quality of life. Although the RQLS improved for 
both groups (paired t-tests showed significant 
change), patients whose medication status changed 
between baseline and follow-up (medication at 
baseline but not at follow-up) showed a greater 
improvement in their RQLS than patients whose 
medication status stayed the same (medication at 
baseline and follow-up). 
Discussion
Principal findings
This chapter describes a new outcome measure 
for use with patients being treated for GORD. 
The R e f l u x  questionnaire comprises 31 items and 
generates a single score (RQLS) measuring the 
extent to which individual participants feel that 
their GORD symptoms, and any side effects of 
treatment, affect their quality of life. The 31 items 
also generate five reflux symptom scores measuring 
the extent to which participants experienced 
clusters of symptoms over the previous 2 weeks. 
Thus, the RQLS provides a single index that can 
be used to record change for evaluation, whereas 
the symptom scores provide a descriptive profile 
that describes whether respondents experience 
problems in specific clusters. The data presented 
provide evidence that the new measure is valid, 
reliable and sensitive to change. Health Technology Assessment 2008; Vol. 12: No. 31
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Strengths of the study
The R e f l u x  questionnaire was designed 
as a patient-centred self-completed postal 
questionnaire. Items were generated by using 
GORD patients as key informants, rather than 
relying on the views of clinicians or other experts. 
Therefore the R e f l u x  questionnaire covers those 
elements of their illness that GORD patients 
indicated were important in determining their 
quality of life. A patient-centred approach also 
underlies the scoring system used to generate the 
RQLS. The weights used to create this score were 
based on the relationship between participants’ 
reports of their scores on seven quality of life 
items and of their general health status on a visual 
analogue scale. The score takes account of patients’ 
preferences through their self-reported effect on 
quality of life. In contrast, the R e f l u x  symptom 
scores, which were not intended as measures 
of HRQoL, used essentially statistical weights, 
generated from principal components analysis of 
symptom frequencies rather than patients’ views. 
FIGURE 8  Re f l u x quality of life score (RQLS) by SF-36 mental component summary score and physical component summary score 
(grouped into fifths).
FIGURE 9  Change in R e f l u x quality of life score (RQLS) by change in prescribed medication (baseline to follow-up).
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The performance of a measure may also be 
assessed by its acceptability to respondents. 
Although the R e f l u x  questionnaire has 31 items, it 
suffered very few reported difficulties or missing 
item responses within the R e f l u x  trial. During the 
pilot, modifications were based on patient feedback 
on the acceptability and readability of items. 
Weaknesses of the study
The most common method of establishing the 
validity of a measure is to analyse its association 
with a criterion of known validity that is accepted as 
a gold standard. However, there is no gold standard 
for quality of life, or disease severity, in GORD 
by which to determine validity. Nevertheless, 
the R e f l u x  trial does use SF-36 and EQ-5D, two 
reputable measures of generic HRQoL, although 
not designed for use with GORD patients. As we 
had used the EQ-5D VAS to generate the RQLS, we 
used the SF-36 to establish construct validity. The 
RQLS showed good correlations with the SF-36 
dimensions of bodily pain and social functioning, 
topics common to both measures, and weaker 
correlations with mental health and energy, topics 
not included in the R e f l u x  questionnaire. We used 
self-reported change in medication to assess the 
sensitivity of the RQLS to change, which assumes 
that changing from being prescribed medication to 
not being prescribed medication necessarily shows 
improved health status. 
The second issue in establishing the validity of the 
R e f l u x  questionnaire is that the analysis was based 
on patients with controlled symptoms, as one of 
the trial inclusion criteria was reasonable symptom 
control with medication. Thus, 10% of patients 
achieved the best possible RQLS at baseline, 
showing that their GORD was affecting quality 
of life ‘not at all’, probably because medication 
provided complete symptom control. There is 
scope to ameliorate these ceiling effects in future. 
The final issue relates to the interpretability of 
the five R e f l u x  symptom scores, derived through 
multivariate statistical analysis. To interpret the 
resulting weights we have suggested five labels: 
general discomfort; wind and frequency; nausea 
and vomiting; activity limitation; and constipation 
and swallowing. Although the first four are easy 
to interpret, the fifth contains only three items 
– difficulty in swallowing and two items relating 
to constipation. Although these appear to be 
heterogeneous, this is a common consequence of 
multivariate analysis, which takes full account of 
correlations between items. Furthermore, these 
items play little part in the other four dimensions 
and have been identified as potential side effects 
of surgical treatment. We have therefore retained 
this fifth dimension, more to assess changes after 
treatment than status at baseline.
Unanswered questions
The aim of this component of the study was to 
validate a new measure of the HRQoL of patients 
being treated for GORD. Further evidence about 
the performance of the measure will be available 
through detailed analysis of the R e f l u x  trial, some 
of which is described later in this report. Although 
our principal aim was to develop and validate an 
outcome measure for use in the R e f l u x  trial, we 
hope that the R e f l u x  questionnaire will prove more 
widely applicable. Health Technology Assessment 2008; Vol. 12: No. 31
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Chapter 5  
Beliefs about medicines and surgery
people’s cognitions about illness in the context 
of Leventhal’s model.92 This chapter reports the 
development and validation of a measure relating 
to beliefs about surgical treatments.
The treatment beliefs component of the Leventhal 
model has been investigated by Horne,94 who 
proposed that behaviour relating to treatment 
(e.g. adherence) is determined by perceptions 
about treatment rather than, or in addition to, 
perceptions about illness. There are two broad 
classes of treatments: those involving professional 
intervention (e.g. medicine, surgery, therapy) 
and those involving the adoption of different 
lifestyle behaviours (e.g. exercise, diet, stress 
management). The Beliefs about Medicines 
questionnaire (BMQ)93 developed by Horne and 
colleagues assesses perceptions about one form of 
treatment. The BMQ has been validated using a 
chronic illness sample (n = 524), including people 
diagnosed with asthma, diabetes, renal disease 
and psychiatric illness, and cardiac and general 
medicine inpatients. On the basis of principal 
components analysis and confirmatory factor 
analysis, four subscales were identified relating to 
beliefs about medications specific to the diagnosed 
condition (‘concerns’ about taking the medication 
and ‘necessity’ of taking the medication) and beliefs 
about medication in general (‘harmfulness’ of 
medication in general and ‘overuse’ of medication 
in general). The psychometric properties of these 
scales have been reported by Horne et al.93 and 
demonstrate high levels of discriminant validity, 
criterion-related validity and stability of the factor 
structure across the different illness groups. This 
chapter investigates the measure of beliefs about 
medicine amongst people with GORD and also a 
parallel measure of beliefs about surgery, in the 
context of the R e f l u x  trial. 
Because the R e f l u x  trial involved non-randomised 
preference groups, it was felt important from the 
start to include a measure that would investigate 
the process of patients’ decision-making about 
their treatment choices. Thus, this trial provided 
the opportunity to answer three questions relating 
to beliefs about treatment. First, would baseline 
measures provide support for the validity of the 
BMQ for individuals in a chronic illness group 
that was different from the groups investigated 
Background
This chapter describes a study that was conducted 
in addition to the research activities described 
in the trial protocol. It is the result of discussion 
among the trial team in which it was decided 
that it would be wise to check the validity of a 
questionnaire measure that was devised specifically 
for, and used for the first time in the context of, 
the R e f l u x  trial. We have called this measure the 
Beliefs about Surgery questionnaire (BSQ). It has 
the potential to be further developed as a tool 
for use by consultants and surgical teams. In the 
sections below we describe the initial analyses that 
were carried out to determine the validity of the 
measure. In the final section we suggest further 
work that could result in the development of a tool 
to support communication between consultants 
and patients with GORD as they discuss treatment 
preferences and decisions.
Introduction
Current health-care policy and practice 
acknowledge the importance of offering choice 
across the spectrum of health care to users of the 
health-care system.91 It is plausible that people’s 
choices about treatment will be influenced by 
their beliefs about the risks and benefits of 
various treatments, which in turn will be shaped 
by their experiences or anticipated experiences 
of treatment processes. Indeed, this link between 
beliefs (cognitions) and action is represented in 
Leventhal’s common sense model of self-regulation 
in the face of a threat to health92 as follows. People 
appraise a health threat situation with reference to 
cognitions about the illness and then implement 
coping procedures to restore their physical or 
emotional equilibrium. The model specifies the 
cognitive components of this appraisal process 
in terms of factors that have become known as 
the illness representations framework.93 The 
dimensions of this framework include beliefs about 
effective treatment or control of the illness (e.g. 
‘taking medication will be effective’; ‘surgery may 
be more effective than medication’; ‘recovery from 
surgery could take a long time’). A questionnaire 
measure about illness representations has been 
developed and is frequently used to investigate Beliefs about medicines and surgery
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in the original validation study, namely people 
suffering GORD? Second, if participants were 
asked to answer questions relating to beliefs about 
surgery (in the form of a BSQ), would their answers 
suggest that these beliefs relate to professional 
interventions in general (i.e. would the dimensions 
of the BSQ converge with dimensions of the 
BMQ) or would distinguishable factors emerge? 
The answer to this question could be important 
when treatment options include both medical and 
surgical interventions. Third, would data from 
the BMQ and the BSQ, administered at baseline, 
provide evidence of criterion-related validity? Such 
evidence would be provided if the profile of scores 
on the BMQ and BSQ distinguished between the 
surgery group and the medication group in the 
preference groups (the ‘criterion’) but not in the 
randomised groups.
Methods
Item development
During the development of the new GORD-specific 
outcome measure (the R e f l u x  questionnaire)24 
for use within the R e f l u x  trial as described in 
Chapter 4, a series of one-to-one interviews and 
focus groups were conducted involving a total of 
43 people (15 of whom were receiving medical 
treatment and 28 who had had surgery). In 
addition to the relevance of these discussions for 
the outcome measure, the feedback also suggested 
that patients had a range of views about medical 
and surgical treatments and that they invoked 
these views when discussing the decision about 
whether to have surgery to treat their GORD. This 
suggested that it would be informative to ask trial 
participants to report their beliefs about taking 
medications and about having surgery. We decided 
to use the previously validated measure of beliefs 
about medication93 referred to above, but no 
measure has been developed to assess beliefs about 
surgery. We decided therefore that additional items 
to assess patients’ beliefs about surgery should be 
added.
Items for a BSQ were generated in two ways. First, 
some questions from the BMQ lent themselves 
to a directly parallel version referring to surgery 
(e.g. ‘Doctors place too much trust in medicines’: 
‘Doctors place too much trust in surgery’). Second, 
additional items were included as a result of 
analysis of the interview data. Eight items were 
judged to be acceptable, answerable and relevant 
by this group. Similar to the BMQ, the response 
format for these items was from 1 (strongly agree) 
to 5 (strongly disagree).
Trial context
All 810 participants in the R e f l u x  trial were asked 
to complete the study baseline questionnaire. As 
described in detail in Chapter 6, 357 were recruited 
to the randomised component of the trial and 453 
to the preference study (261 of these choosing 
surgery and 192 medical management). 
In addition to the R e f l u x  questionnaire24 the 
baseline questionnaire contained the EQ-5D88 and 
the SF-36,89 and the BMQ and BSQ. 
Analytic strategy
To achieve a clear replication of the original 
validation study by Horne et al.,93 the same analytic 
procedures were used. That is, an exploratory PCA 
was conducted on the BMQ items and confirmatory 
factor analysis was performed by computing 
Pearson’s correlations for factor loadings against: 
(1) the theoretical model of predicted factor 
loadings; and (2) the empirical model of factor 
loadings reported by Horne et al.93 As described by 
Horne et al.,93 the theoretical model was defined by 
assigning a factor loading of 1 to all items expected 
to load on the factor, with all other items assigned a 
loading of 0. This strategy permitted a comparison 
of the expected pattern of factor loadings with the 
pattern derived from the R e f l u x  sample.
To assess the level of discrimination between 
beliefs about medication and beliefs about surgery, 
a further exploratory PCA was conducted on the 
combined items from the BMQ and BSQ using 
a non-orthogonal (direct oblimin) method of 
rotation. The factor scree plot and eigenvalues were 
used to select the number of factors.
Finally, discriminant function analysis was 
used to test the criterion-related validity of the 
combined BMQ/BSQ. This form of validity would 
be demonstrated if the profile of scores from the 
questionnaire enabled correct classification of 
cases to the surgery and medication groups in 
the preference groups but not in the randomised 
groups. 
Results
Of the people recruited to the trial, 329 (92.12%) 
in the randomised groups and 419 (91.48%) in 
the preference groups completed the baseline 
questionnaire. Data from these 748 participants 
were analysed in this validation study.Health Technology Assessment 2008; Vol. 12: No. 31
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Distributions of scores on the BMQ and BSQ 
items were generally acceptable. Skewness was 
greater than 1 for only two variables: ‘My health, 
at present, depends on my medicines’ (sk = 1.48); 
‘I would be willing to have an uncomfortable test’ 
(sk = 1.09). Kurtosis was greater than 1 for six 
variables: ‘My health at present depends on my 
medicines’ (ku = 2.20, modal value = 1); ‘Natural 
remedies are safer than medicines’ (ku = 1.48, 
modal value = 3); ‘Medicines do more harm than 
good’ (ku = 1.81, modal value = 4); ‘I would be 
willing to have an uncomfortable test’ (ku = 1.74, 
modal value = 2); ‘Surgery does more harm than 
good’ (ku = 1.10, modal value = 4); ‘Doctors are 
too quick to suggest surgery’ (ku = 1.40, modal 
value = 4).
Exploratory principal components 
analysis on BMQ items
Based on the structure of the instrument, as 
reported by Horne et al.,93 the BMQ was expected 
to comprise four factors (corresponding to the 
two subscales for each of the item pools relating 
to beliefs about general medicine and specific 
medicine). Using an eigenvalue cut-off of 1.1,95 
the R e f l u x  data yielded three factors that together 
accounted for 48.99% of the variance in the scores. 
Using a cut-off of 0.4 for item inclusion, every 
item in the item pool loaded on to a factor and 
none of the 18 items had diffuse loading. Factor 
1 corresponded to the combined ‘general harm’ 
and ‘general overuse’ scales of Horne et al.,93 and 
factors 2 and 3 corresponded exactly to their 
‘specific necessity’ and ‘specific concerns’ factors 
respectively. Table 11 presents the item loadings 
reported by Horne et al.93 and the item loadings 
derived from the R e f l u x  BMQ data.
Confirmatory factor 
analysis on BMQ items 
To test the consistency between the factor solution 
derived from the R e f l u x  sample and that of the 
chronic illness groups reported by Horne et al.,93 
a confirmatory factor analysis was conducted by 
computing the correlations between all of the 
factor loadings derived from the R e f l u x  data set 
and (1) a theoretical model, defined by assigning 
factor loadings of 1 to items expected to load on 
a factor, or else 0; and (2) the empirically derived 
factor loadings of Horne et al.93 The confirmatory 
factor analysis was based on three factors (general 
overuse/harm, specific necessity, specific concerns). 
Results of the confirmatory factor analysis are 
presented in Table 12. 
Exploratory principal components 
analysis on BMQ/BSQ items
A PCA (with oblimin rotation) was conducted 
on all BMQ and BSQ items together. Based on 
the structure of the BMQ for this sample, the 
combined BMQ/BSQ was expected to comprise 
up to six discriminable factors (corresponding to 
the two subscales for each of general medicine, 
specific medicine and general surgery). The scree 
plot (Figure 10) suggested that it was appropriate to 
extract five factors, which together accounted for 
50.95% of the variance in the scores. Using a cut-
off of 0.4 for item inclusion, only one item in the 
item pool did not load on to a factor and none of 
the 26 items had diffuse loading. Table 13 presents 
the item loadings reported by Horne et al.93 and 
the item loadings derived from the R e f l u x  data. 
In the solution for the combined BMQ/BSQ, 
beliefs about medicines in general again formed 
one factor; the two factors relating to beliefs about 
medicines specific to the reflux condition mapped 
perfectly on to the solution reported by Horne et 
al.,93 and beliefs about surgery also corresponded 
exactly to the pattern that was expected, based on 
the findings of Horne et al.93 Beliefs about surgery 
appeared to be clearly discriminable from beliefs 
about medicines, as all between-factor correlations 
were less than 0.3 (Table 14).
Discriminant function analysis 
The next question concerned the capacity of 
the BMQ/BSQ scores to discriminate between 
participants who chose to undergo surgery and 
those who chose to remain on medical treatment. 
Five composite belief scores were computed for 
each participant, corresponding to the five factors 
in the combined BMQ/BSQ factor solution. 
The five variables were entered as independent 
variables in a discriminant function analysis of data 
from the preference groups. This profile of scores 
resulted in the correct classification of 76% of the 
cases into surgery or medication groups. This was 
significantly greater than chance (χ2(5) = 178.93, 
p < 0.001). In contrast, discriminant function 
analysis of data from the randomised groups 
resulted in correct classification of 58% of the cases 
into surgery or medication groups. This was not 
significantly greater than chance (χ2(5) = 6.68, 
p > 0.05). Table 15 presents classification results for 
(a) the preference groups and (b) the randomised 
groups.Beliefs about medicines and surgery
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TABLE 12  Confirmatory factor analysis for the BMQ scales, testing factor loadings (on three factors) from the R e f l u x data set against 
the theoretical and the empirically derived models
Factor label
Pearson correlation of items with predicted factor loadings
Theoretical model Empirically derived model
General overuse/harm 0.90 0.92
Specific necessity 0.96 0.98
Specific concerns 0.90 0.92
For the merged factor ‘general overuse/harm’ the empirically derived factor loadings from the Horne et al.93 study were 
the highest loadings for items loading on the separate factors ‘general overuse’ and ‘general harm’ and the loadings closest 
to zero for the items loading on the other factors. This afforded the most stringent test of the r e f l u x  model against the 
empirically derived model.
Discussion
Baseline measures in the R e f l u x  trial provided 
support for the validity of the BMQ for individuals 
suffering from GORD. However, the two general 
medicine scales (labelled harm and overuse) 
merged in this factor solution. It is possible that 
specific characteristics of the sample may explain 
this. For example, GORD is a condition for which 
medication is taken symptomatically whereas the 
original validation study was conducted with people 
experiencing chronic illnesses in which medications 
are taken continuously. This could have increased 
the tendency of the GORD sample to discriminate 
between items relating to medications specific 
to the illness and correspondingly decreased the 
tendency to discriminate between the items in the 
general medicine scales. Furthermore, all of the 
current sample were trial participants and their 
involvement in the recruitment and informed 
consent processes of the trial may have made the 
GORD-specific items more salient and therefore 
more discriminable than the items about medicines 
in general.
FIGURE 10  Scree plot indicating that a five-factor solution would be appropriate.
Importantly, when participants were asked 
to answer questions relating to beliefs about 
surgery, their answers yielded factors that were 
discriminable from those relating to beliefs about 
medications, suggesting that these participants 
held distinctive patterns of beliefs about these two 
kinds of treatment, rather than about professional 
interventions in general. Furthermore, data from 
the BMQ and the BSQ provided evidence of 
criterion-related validity of the BMQ and the BSQ 
in that the profile of scores on the BMQ and the 
BSQ distinguished between the surgery group and 
the medication group in the preference arm of 
the trial but not in the randomised arm. In other 
words, knowing nothing about the participants 
other than their BMQ/BSQ scores allowed a 
reasonably good prediction of their treatment 
choices.
Beliefs about treatment have previously been 
investigated in relation to adherence to medication 
regimens but little research in this area has 
explored the issue of patient choices about 
treatment. The addition of a measure of beliefs 
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TABLE 14  Component correlation matrix for the BMQ/BSQ five-factor solution
Factor F1 F2 F3 F4 F5
F1: Medication in general: overuse/harm –
F2: Specific medication: necessity 0.014 –
F3: Surgery in general: overuse/harm 0.274 –0.053 –
F4: Specific medication: concerns 0.296 0.160 0.035 –
F5: Surgery in general: concerns –0.048 –0.051 0.119 –0.116 –
TABLE 15  Discriminant function analysis: classification results as frequencies (percentages) for participants in (a) the preference 
groups and (b) the randomised groups, based on scores for BMQ/BSQ
Predicted group membership
Surgical Medical Total
(a) Preference groups
Actual group membership Surgical 184 (75.7) 59 (24.3) 243 (100)
Medical 42 (23.9) 134 (76.1) 176 (100)
75.9% of original grouped cases correctly classified.
(b) Randomised groups
Actual group membership Surgical 99 (59.6) 67 (40.4) 166 (100)
Medical 72 (44.2) 91 (55.8) 163 (100)
57.8% of original grouped cases correctly classified.
about surgery to the existing measure of beliefs 
about medication provided the opportunity to 
explore such decisions. In addition, it may be that 
a patient’s score on the BSQ can provide important 
clinically relevant information. It is possible that 
people with less negative beliefs about surgery 
experience less anxiety associated with the surgery 
and, as there is evidence that anxiety is associated 
with poorer clinical outcomes post surgery,96  this 
could be important information for surgeons to 
be aware of. Furthermore, it may be that knowing 
the scores on these two questionnaires could help 
clinicians to counsel patients who have higher 
levels of concern or to help patients make better 
decisions about their treatment. It could be helpful 
to explore these possibilities in future research.
In terms of the common sense self-regulation 
model more generally, there is ample evidence 
that people’s illness perceptions influence their 
emotional and behavioural responses to an 
illness threat.92 Perceptions and beliefs about 
how an illness may be controlled – including the 
treatment options of medication and surgery – are 
potentially important factors that may link with 
other behaviours such as altered lifestyle. The 
development of additional measures that relate to 
other ways of controlling the symptoms of chronic 
illness could be useful in identifying people’s 
preferred ways of coping with illness.
In conclusion, the perceptions of people with 
chronic illness about potential treatments can be 
measured validly and reliably. Core elements of 
the factor structure of the BMQ (in particular the 
distinction between specific and general classes of 
beliefs) were replicated in this study. Furthermore, 
responses to the BSQ indicate that beliefs about 
surgery form a distinct pattern of treatment 
representations and there is no redundancy 
between these two scales. Used together, the two 
measures can significantly distinguish between 
groups of individuals who choose one form of 
treatment over the other.Beliefs about medicines and surgery
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Implications for 
future research
As proposed above, there is potentially important 
follow-up work to be carried out in this field. Some 
possibilities that could be followed up using the 
R e f l u x  data set are:
Can the correct classification rate be  1. 
improved further by the addition of other 
patient characteristics, for example severity 
of symptoms at baseline, sociodemographic 
factors, co-morbidities?
Can the recruitment of participants into the  2. 
randomised groups of the trial be predicted 
by using a discriminant function analysis as 
described above to classify those who chose (a) 
surgery, (b) continued medication, and (c) to be 
randomised?
Do underlying treatment beliefs modify  3. 
treatment effects? If so, can subgroups be 
identified who are more likely or less likely 
to respond well to alternative approaches 
to treatment, such as surgery or medical 
management?
Can the length of the questionnaire be reduced  4. 
without reducing its predictive power, for 
example by using item response theory97  to 
identify the discriminating items?
Are these treatment beliefs stable or do they  5. 
change over time or as a function of changes in 
symptom severity?
Could the questionnaire be adapted for use  6. 
as a communication tool by consultants and 
surgical teams? 
In conclusion, this work has thus generated a 
number of possibilities for continued work in this 
field. It appears that the BSQ is a valid instrument 
that has a number of potential applications in 
surgical practice and research.Health Technology Assessment 2008; Vol. 12: No. 31
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Chapter 6  
Trial results
Recruitment to the trial
Participants were recruited in 21 clinical centres, all 
within the UK (Table 16). Recruitment to the trial 
was open from March 2001 until the end of June 
2004, although not all centres enrolled over the 
total period because of the staggered introduction 
of centres and early closure for logistical reasons in 
a few places. 
Initial recruitment was limited to two centres 
(Aberdeen Royal Infirmary; St Mary’s Hospital, 
London) and these acted as pilot centres whilst 
systems for recruitment were developed. Roll-out 
of the trial to other centres started after 6 months 
T
his chapter describes the partially randomised 
patient preference trial that was the 
cornerstone of this project. The chapter starts 
with an explanation of how the trial groups were 
derived. It then describes the study groups at 
trial entry and the management that they actually 
received. The results at the two follow-up points 
are then reported, followed by a formal statistical 
analysis of the data for the principal measures of 
outcome. 
TABLE 16  Number of participants by centre
 Clinical centre
Randomised participants Preference participants
Surgical, n (%) Medical, n (%) Surgical, n (%) Medical, n (%)
Aberdeen: Aberdeen Royal Infirmary 38 (21.3) 40 (22.3) 20 (7.7) 21 (10.9)
Belfast: Royal Victoria Hospital 15 (18.4) 14 (7.8) 4 (1.5) 20 (10.4)
Bournemouth: Royal Bournemouth 
Hospital
4 (2.2) 3 (1.7) 20 (7.7) 3 (1.6)
Bristol: Bristol Royal Infirmary 12 (6.7) 11 (6.1) 18 (6.9) 20 (10.4)
Bromley: Princess Royal Infirmary 3 (1.7) 3 (1.7) 20 (7.7) 17 (8.9)
Edinburgh: Royal Infirmary of Edinburgh 11 (6.2) 11 (6.1) 1 (0.4) 15 (7.8)
Guildford: Royal Surrey County Hospital 10 (5.6) 10 (5.6) 17 (6.5) 10 (5.2)
Hull: Hull Royal Infirmary 7 (3.9) 7 (3.9) 1 (0.4) 2 (1.0)
Inverness: Raigmore Hospital 7 (3.9) 8 (4.5) 2 (0.8) 8 (4.2)
Leeds: Leeds General Infirmary 1 (0.6) 2 (1.1) 10 (3.8) 3 (1.6)
Leicester: Leicester Royal Infirmary 0 (0.0) 0 (0.0) 3 (1.1) 1 (0.5)
London: St Mary’s Hospital 8 (4.5) 7 (3.9) 4 (1.5) 10 (5.2)
London: Whipps Cross Hospital 4 (2.2) 3 (1.7) 16 (6.1) 5 (2.6)
Poole: Poole Hospital 10 (5.6) 10 (5.6) 25 (9.6) 13 (6.8)
Portsmouth: Queen Alexandra Hospital 10 (5.6) 10 (5.6) 15 (5.7) 1 (0.5)
Salford: Hope Hospital 0 (0.0) 1 (0.6) 6 (2.3) 3 (1.6)
Stoke-on-Trent: North Staffordshire 
Hospital 
5 (2.8) 6 (3.4) 20 (7.7) 9 (4.7)
Swansea: Morriston Hospital 8 (4.5) 8 (4.5) 14 (5.4) 9 (4.7)
Telford: Princess Royal Hospital 11 (6.2) 12 (6.7) 24 (9.2) 8 (4.2)
Yeovil: Yeovil District Hospital 9 (5.1) 8 (4.5) 18 (6.9) 8 (4.2)
York: York District Hospital 5 (2.8) 5 (2.8) 3 (1.1) 6 (3.1)
Total 178 (100) 179 (100) 261 (100) 192 (100)Trial results
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with gradual extension to all remaining centres 
over the following 3 years. Figure 11 shows the 
total recruitment: the dotted line was the expected 
rate of recruitment over the last 16 months of 
the trial based on earlier recruitment. As can be 
seen, it proved difficult to sustain recruitment to 
the randomised component, although there was 
evidence for an increase in recruitment towards the 
time of recruitment closing. 
A total of 357 participants were recruited to the 
randomised component, with 178 allocated to 
surgery and 179 allocated to medical management. 
In total, 453 participants agreed to join the 
preference component, 261 choosing surgery 
and 192 choosing medical management. Table 
16 shows recruitment by centre. Around 20% of 
the randomised participants were enrolled in 
Aberdeen; no centre contributed more than 11% of 
participants in the preference component. 
Analysis populations
Throughout the analyses presented later in 
this chapter the participants in the randomised 
component are kept separate from those in the 
preference component (other than for rare surgical 
events). Primary analyses of the comparisons 
between surgical and medical management in both 
of these components are based on the allocated 
management at trial entry, that is, they are based 
on the intention to treat (ITT) principle. This 
sustains the integrity of the randomisation in 
particular. However, as described later in this 
chapter, a sizeable minority of participants did not 
actually receive their allocated management. To 
allow exploration of the impact (‘blunting effect’) 
that this might have on any observed differences, 
secondary analyses based on those who actually 
received their allocated management – per 
protocol (PP) analyses – were also undertaken and 
are presented alongside the ITT analyses. 
FIGURE 11  Actual versus expected recruitment rates: (a) randomised component; (b) preference component.
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The number of participants in each of the four 
main analysis populations is shown in Table 17. 
All 357 who joined the randomised component 
are in the randomised intention to treat (RITT) 
population whereas only the 280 within this 
group who actually received their allocated 
management are in the randomised per protocol 
(RPP) population. Similarly, all 453 participants 
who joined the preference component are in the 
preference intention to treat (PITT) population, 
and the 407 of these who were managed as 
originally chosen are in the preference per protocol 
(PPP) population. 
Trial conduct
The derivation of the main study groups and their 
progress through the trial is shown in Figure 12. 
This is in the form of a CONSORT (Consolidated 
Standards of Reporting Trials) flow diagram. 
In total, 1078 patients were considered for trial 
TABLE 17  Number of participants in each analysis population
Surgical, n (%) Medical, n (%) Total, n
Randomised intention to treat (RITT) 178 (49.9) 179 (50.1) 357
Randomised per protocol (RPP) 111 (39.6) 169 (60.4) 280
Preference intention to treat (PITT) 261 (57.6) 192 (42.4) 453
Preference per protocol (PPP) 218 (53.6) 189 (46.4) 407
FIGURE 12  CONSORT diagram.
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entry. Of these, 200 were found not to meet 
one or more of the eligibility criteria. Of the 68 
patients eligible for the study but not recruited, 
51 declined to participate, 6 were subsequently 
deemed inappropriate for the study by the surgeon 
responsible for care, and the remaining 11 were 
missed.
In total, 357 participants were recruited to the 
randomised component, with 178 randomly 
allocated to surgery and 179 to best medical 
management. A further 453 patients who wished 
to have one or other of the alternative approaches 
to management agreed to join the preference 
component – 261 to the surgical group and 192 to 
the medical management group.
In the early stages of the trial a few participants 
failed to return baseline questionnaires. After the 
first meeting of the Data Monitoring Committee, 
procedures were changed to prevent this, such that 
formal entry to the study (and random allocation 
if appropriate) occurred only after full baseline 
questionnaires had been received. The 1-year 
follow-up questionnaires were received from 
approximately 90% of the study participants. There 
were no substantive differences in response rates 
between the groups.
Three participants died before the 1-year follow-up 
was reached, two in the preference surgery group 
and one in the randomised medical group. None of 
these participants actually had surgery.
Description of the 
groups at trial entry
Sociodemographic and 
clinical factors
Randomised arms
Table 18 shows a description of the groups at 
trial entry. The table is first divided into whether 
participants were in the randomised or preference 
component, then divided according to their 
allocation, and finally subdivided according to 
intention to treat or per protocol. Within the 
randomised groups there were no apparent 
imbalances between the medical and surgical 
intervention arms. On average the patients were 
46 years old, 66% were men and around two-thirds 
were in full employment; participants had been 
on GORD medication for a median of 32 months. 
The baseline characteristics in the randomised per 
protocol groups were similar.
Preference arms
The sociodemographic characteristics of the 
preference participants were broadly similar 
to those of the randomised groups. However, 
preference medical participants tended to be 
older (mean 50 years) and were more likely to be 
female, fewer were in full-time employment, and 
participants had been on GORD medication for a 
shorter period (approximately 6 months less than 
RCT participants).
Prescribed medications
The prescribed medications at the time of trial 
entry are shown in Table 19. There was a similar 
profile of prescribed medications across the 
randomised and preference groups. As would be 
expected, nearly all participants reported taking a 
reflux-related drug in the previous 2 weeks. Over 
90% had taken a PPI, of which lansoprazole was the 
most common.
Health status
Randomised arms
The HRQoL scores at study entry are displayed 
in Table 20. The scores were broadly similar in 
the randomised surgical and randomised medical 
groups, although they were slightly higher (better 
health) in the randomised medical group. As 
described in Chapter 2, after the Data Monitoring 
Committee first met after the first 143 participants 
had been recruited to the randomised component, 
we were asked to change the enrolment procedure 
to ensure that baseline questionnaires were 
completed before formal entry and randomisation. 
We understand that this is because the committee 
were concerned about an apparent imbalance 
between the randomised groups in baseline health 
status at that time. After satisfying themselves 
that this was not due to a breakdown in the 
randomisation procedure, the committee surmised 
that this might be due to prior knowledge of 
the treatment allocation affecting questionnaire 
responses (with those allocated surgery tending 
to project worse health status than those allocated 
medical management). Certainly, the groups based 
on the first 143 participants were well balanced in 
other respects, and there was subsequently good 
balance in health status as well. The apparent 
small imbalance between the total randomised 
groups in health status measures is therefore likely 
to be a reflection of the imbalance in the first 143 
participants. Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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The most prevalent reflux symptoms (those with 
lowest scores) were general discomfort and wind 
and frequency. The participants had lower SF-36 
and EQ-5D scores than a normal UK population 
with the same average age and sex characteristics 
(SF-36 population norm approximately 50 for all 
domains, and EQ-5D norm 0.88).
Preference arms
The preference for surgery participants reported 
worse R e f l u x  quality of life scores and worse health 
in general than the preference for medicine 
participants. It can be seen that the randomised 
participants reported quality of life measures in 
between these two extremes.
Surgical management
Table 21 gives details of the surgical management 
of those randomly allocated or in the preference 
for surgery group. For 47 allocated surgery there 
was subsequently a definite decision not to have 
surgery. For 25 of these, this was a clinical decision, 
most commonly the surgeon deciding that surgery 
was not appropriate. Most of the others changed 
their minds about having surgery for a variety of 
work- or home-related reasons, because of worries 
about the risks of surgery, because of a wish to 
avoid the preoperative tests, or because their 
symptoms had improved. A further 20 withdrew for 
uncertain reasons. There is no doubt, however, that 
a number of these participants suffered long delays 
before being formally offered surgery, and this was 
an important factor in their eventual decision to 
choose not to have surgery after all. The trial was 
conducted at a time when there was great pressure 
on surgical services in the NHS, with long delays 
for elective surgery for non-life-threatening benign 
conditions being common. Indeed, the average 
time between trial entry and surgery in the trial was 
8–9 months (see Table 23). 
In total, 111 (62.4%) of those randomised to 
surgery and 218 (83.5%) of the preference 
participants actually received surgery. Amongst 
the randomised participants, about 50% had a 
total wrap and 50% a partial wrap fundoplication. 
A total wrap was, however, the predominant 
procedure in the preference group (72.8%). 
The difference between the randomised and 
preference group fundoplication procedures was 
a reflection of the surgeon’s preferred procedure 
and not any systematic surgeon bias between a 
surgeon’s randomised and preference participants. 
This is illustrated in Figure 13, which shows that, 
within a given centre, the surgeon(s) performed 
the same procedures on their randomised and 
preference patients. The majority of operations 
were performed by a consultant and took around 2 
hours to complete.
Intra- and postoperative 
surgical outcomes
Table 22 shows the intra- and postoperative 
surgical outcomes in the randomised and 
preference surgical participants who actually had 
a fundoplication. Two (0.6%) participants out 
of the total of 329 participants who had surgery 
required conversion to an open procedure (95% 
CI 0.2%–2.2%), and 8 (2.4%) had a visceral injury 
(95% CI 1.2%–4.7%). One participant had a 
blood transfusion. Three were admitted to a high 
dependency unit, but none to an intensive care 
unit. Nearly all were discharged to their homes 
after a median length of stay of 2 days. Three 
participants (0.9%) required a reoperation (95% 
CI 0.3%–2.6%) – all in the preference group – and 
three had dilatation of an oesophageal stricture or 
food disimpaction within 12 months of their initial 
surgery.
Follow-up at the time 
equivalent to 3 months 
after surgery
Patient flow
As mentioned earlier, around 90% of all 
participants returned completed questionnaires. As 
shown in Table 23, by the time of the first follow-up, 
some participants had formally withdrawn, and so 
were not sent questionnaires, and others had lost 
contact with the study office. Of the participants 
for whom it was appropriate to send a follow-up 
questionnaire, approximately 95% returned it 
(Table 23). For the surgical participants, the median 
and interquartile range (IQR) time from surgery to 
the first questionnaire was approximately 90 days. 
However, given that there were substantial waiting 
times for surgical participants, the median time 
from randomisation to sending the 3-month follow-
up questionnaire was approximately 300 days (and 
this implied a waiting list time of 8–9 months). The 
median lag time from randomisation to follow-up 
was similar across all of the groups suggesting that 
our intention of pairing follow-up times between 
participants during the conduct of the trial (as 
described in Chapter 2) was successful.Health Technology Assessment 2008; Vol. 12: No. 31
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TABLE 21  Management received by those actually receiving surgery 
Surgical participants
Randomised (n = 178) Preference (n = 261)
Number declined surgery, n (%) 47 (26.4) 25 (9.6)
Number on waiting list, n (%) 0 (0.0) 2 (0.8)
Number withdrawn/lost to follow-up before surgery, n (%) 20 (11.2) 16 (6.1)
Number who received surgery, n (%) 111 (62.4) 218 (83.5)
Endoscopy before surgery, n (%) 97 (87.4) 196 (89.9)
pH monitoring before surgery, n (%) 77 (69.4) 158 (72.5)
Manometry before surgery, n (%) 73 (65.8) 164 (75.2)
Type of fundoplication, n (%) 
  Total wrap 52 (46.8) 158 (72.8)
  Partial – anterior 51 (45.9) 35 (16.1)
  Partial – posterior 8 (7.2) 24 (11.1)
Short gastric arteries divided, n (%) 38 (34.2) 98 (45.0)
Left hepatic from left gastric artery, n (%) 13 (11.7) 13 (6.0)
If present, left hepatic artery divided, n (%) 4 (3.6) 6 (2.8)
Hepatic branch vagus divided, n (%) 30 (27.0) 40 (18.3)
Hiatus hernia present, n (%) 50 (45.0) 101 (46.3)
Bougie used, n (%) 25 (22.5) 67 (30.7)
Crural repair, n (%) 87 (78.4) 167 (76.6)
Grade of operating surgeon, n (%) 
  Consultant 100 (91.7) 174 (80.6)
  Staff grade, associate specialist 5 (4.6) 10 (4.6)
  SPR 3 (2.8) 30 (13.9)
  Other 1 (0.9) 2 (0.9)
Operation time in minutes (mean) (SD ) 113 (38.0) 123 (64.4)
SPR, specialist registrar.
FIGURE 13  Type of fundoplication performed by centre.
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TABLE 22  Intra- and postoperative surgical outcomes
Surgical participants
Randomised (n = 111) Preference (n = 218)
Conversion, n (%) 2 (1.8) 0 (0.0)
Liver injury, n (%) 1 (0.9) 1 (0.5)
Splenic injury, n (%) 0 (0.0) 1 (0.5)
Pleural injury, n (%) 1 (0.9) 2 (0.9)
Oesophageal injury, n (%) 0 (0.0) 0 (0.0)
Other visceral injury, n (%) 0 (0.0) 0 (0.0)
Haemorrhage, n (%) 1 (0.9) 1 (0.5)
Pneumothorax, n (%) 0 (0.0) 2 (0.9)
Blood transfusion, n (%) 0 (0.0) 1 (0.5)
  Number of units transfused, mean (SD ) – 3 (–)
Other postoperative event, n (%) 3 (2.7) 5 (2.3)
ICU admission, n (%) 0 (0.0) 0 (0.0)
HDU admission, n (%) 1 (0.9) 2 (0.9)
Reoperation within 12 months, n (%) 0 (0.0) 3 (1.4)
Stricture dilatation or food disimpaction required within 12 
months, n (%)
1 (0.9) 2 (0.9)
Ward only, n (%) 104 (93.7) 206 (94.5)
Discharged status
  Home, n (%) 107 (96.4) 213 (97.7)
  Other, n (%) 4 (3.6) 5 (2.3)
Length of stay in days (median) (IQR) 2 (2–3) 2 (2–3)
HDU, high dependency unit; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.
Medications
The medications that participants were taking at 
the time of the 3-month follow-up are shown in 
Table 24. For the RITT surgery group, 33.3% were 
on a reflux-related drug compared with 92.4% 
of those randomised to medical management. 
When considering only randomised participants 
who received the intended management (the RPP 
groups), 9.2% of surgical participants and 92.7% of 
medical participants were on a reflux-related drug. 
The preference surgical and preference medical 
participants had a broadly similar proportion 
on medications as the randomised surgical and 
randomised medical groups respectively, although 
use of anti-reflux drugs was lower in the preference 
surgical ITT group than in the randomised 
surgical ITT group (as would be expected given 
that a higher proportion actually went on to have 
surgery).
Health status
The health status measures at the 3-month follow-
up are shown in Table 25. Within the randomised 
component (RITT groups) there were clear 
differences across all measures, with the surgery 
group having better scores than the medical 
group. The differences were larger when only the 
per protocol participants were considered (RPP 
groups). Details of the formal statistical testing of 
these differences are described in the section on 
statistical analyses.
The health status scores of the two preference 
groups were more similar, although they tended 
to slightly favour the preference surgical group. 
Overall levels were equivalent to those of the 
randomised surgical group. (It is important to bear 
in mind, however, that the baseline levels were 
clearly lowest in the preference surgical group – see 
Table 20.) Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
47
T
A
B
L
E
 
2
3
 
F
o
l
l
o
w
-
u
p
 
a
t
 
t
h
e
 
t
i
m
e
 
e
q
u
i
v
a
l
e
n
t
 
t
o
 
3
 
m
o
n
t
h
s
 
a
f
t
e
r
 
s
u
r
g
e
r
y
 
–
 
p
a
t
i
e
n
t
 
fl
o
w
R
a
n
d
o
m
i
s
e
d
 
p
a
r
t
i
c
i
p
a
n
t
s
P
r
e
f
e
r
e
n
c
e
 
p
a
r
t
i
c
i
p
a
n
t
s
S
u
r
g
i
c
a
l
M
e
d
i
c
a
l
S
u
r
g
i
c
a
l
M
e
d
i
c
a
l
I
T
T
 
(
n
 
=
 
1
7
8
)
P
P
 
(
n
 
=
 
1
1
1
)
I
T
T
 
(
n
 
=
 
1
7
9
)
P
P
 
(
n
 
=
 
1
6
9
)
I
T
T
 
(
n
 
=
 
2
6
1
)
P
P
 
(
n
 
=
 
2
1
8
)
I
T
T
 
(
n
 
=
 
1
9
2
)
P
P
 
(
n
 
=
 
1
8
9
)
L
o
s
s
 
t
o
 
f
o
l
l
o
w
-
u
p
,
 
n
1
0
0
8
 
8
5
4
0
0
F
o
r
m
a
l
l
y
 
w
i
t
h
d
r
a
w
n
,
 
n
1
1
0
2
2
9
1
2
2
Q
u
e
s
t
i
o
n
n
a
i
r
e
 
s
e
n
t
,
 
n
1
5
7
1
1
1
1
6
9
1
5
9
 
2
4
7
2
1
3
1
9
0
1
8
7
Q
u
e
s
t
i
o
n
n
a
i
r
e
 
r
e
t
u
r
n
e
d
,
 
n
 
(
%
)
1
5
0
 
(
9
5
.
5
)
1
0
9
 
(
9
8
.
2
)
1
5
8
 
(
9
3
.
5
)
1
5
0
 
(
9
4
.
3
)
2
3
0
 
(
9
3
.
1
)
2
0
2
 
(
9
4
.
8
)
1
8
2
 
(
9
5
.
8
)
1
7
9
 
(
9
5
.
7
)
L
a
g
 
i
n
 
d
a
y
s
 
(
m
e
d
i
a
n
)
 
b
e
t
w
e
e
n
 
s
u
r
g
e
r
y
 
a
n
d
 
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
(
I
Q
R
)
8
6
 
(
8
5
–
9
0
)
 
 
8
6
 
(
8
5
–
9
8
)
 
 
L
a
g
 
i
n
 
d
a
y
s
 
(
m
e
d
i
a
n
)
 
b
e
t
w
e
e
n
 
r
a
n
d
o
m
i
s
a
t
i
o
n
 
a
n
d
 
3
-
m
o
n
t
h
 
f
o
l
l
o
w
-
u
p
 
(
I
Q
R
)
3
2
5
 
(
2
6
6
–
4
3
5
)
2
7
8
 
(
2
1
5
–
3
1
4
)
3
1
9
 
(
2
1
0
–
4
5
5
)
 
2
8
7
 
(
2
1
4
–
3
4
2
)
 
I
Q
R
,
 
i
n
t
e
r
q
u
a
r
t
i
l
e
 
r
a
n
g
e
;
 
I
T
T
,
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
;
 
P
P
,
 
p
e
r
 
p
r
o
t
o
c
o
l
.Trial results
48
T
A
B
L
E
 
2
4
 
F
o
l
l
o
w
-
u
p
 
a
t
 
t
h
e
 
t
i
m
e
 
e
q
u
i
v
a
l
e
n
t
 
t
o
 
3
 
m
o
n
t
h
s
 
a
f
t
e
r
 
s
u
r
g
e
r
y
 
–
 
m
e
d
i
c
a
t
i
o
n
s
R
a
n
d
o
m
i
s
e
d
 
p
a
r
t
i
c
i
p
a
n
t
s
P
r
e
f
e
r
e
n
c
e
 
p
a
r
t
i
c
i
p
a
n
t
s
S
u
r
g
i
c
a
l
M
e
d
i
c
a
l
S
u
r
g
i
c
a
l
M
e
d
i
c
a
l
I
T
T
 
(
n
 
=
 
1
7
8
)
P
P
 
(
n
 
=
 
1
1
1
)
I
T
T
 
(
n
 
=
 
1
7
9
)
P
P
 
(
n
 
=
 
1
6
9
)
I
T
T
 
(
n
 
=
 
2
6
1
)
P
P
 
(
n
 
=
 
2
1
8
)
I
T
T
 
(
n
 
=
 
1
9
2
)
P
P
 
(
n
 
=
 
1
8
9
)
A
n
y
 
r
e
fl
u
x
-
r
e
l
a
t
e
d
 
d
r
u
g
,
 
n
 
(
%
)
5
0
 
(
3
3
.
3
)
1
0
 
(
9
.
2
)
1
4
6
 
(
9
2
.
4
)
1
3
9
 
(
9
2
.
7
)
4
5
 
(
1
9
.
6
)
1
7
 
(
8
.
4
)
1
7
6
 
(
9
6
.
7
)
1
6
1
 
(
8
9
.
9
)
P
r
o
t
o
n
 
p
u
m
p
 
i
n
h
i
b
i
t
o
r
s
,
 
n
 
(
%
)
 
A
n
y
 
p
r
o
t
o
n
 
p
u
m
p
 
i
n
h
i
b
i
t
o
r
4
7
 
(
3
1
.
3
)
8
 
(
7
.
3
)
1
4
0
 
(
8
8
.
6
)
1
3
3
 
(
8
8
.
7
)
4
1
 
(
1
7
.
8
)
1
3
 
(
6
.
4
)
1
6
7
 
(
9
1
.
8
)
1
5
2
 
(
8
4
.
9
)
 
O
m
e
p
r
a
z
o
l
e
 
(
L
o
s
e
c
)
1
6
 
(
1
0
.
7
)
5
 
(
4
.
6
)
4
5
 
(
2
8
.
5
)
4
5
 
(
3
0
.
0
)
1
5
 
(
6
.
5
)
3
 
(
1
.
5
)
5
7
 
(
3
1
.
3
)
5
7
 
(
3
1
.
8
)
 
L
a
n
s
o
p
r
a
z
o
l
e
 
(
Z
o
t
o
n
)
1
9
 
(
1
2
.
7
)
3
 
(
2
.
8
)
5
5
 
(
3
4
.
8
)
5
4
 
(
3
6
.
0
)
1
3
 
(
5
.
7
)
7
 
(
3
.
5
)
6
7
 
(
3
6
.
8
)
6
4
 
(
3
5
.
8
)
 
P
a
n
t
o
p
r
a
z
o
l
e
 
(
P
r
o
t
i
u
m
)
1
 
(
0
.
7
)
0
 
(
0
.
0
)
9
 
(
5
.
7
)
8
 
(
5
.
3
)
3
 
(
1
.
3
)
2
 
(
1
.
0
)
1
4
 
(
7
.
7
)
1
4
 
(
7
.
8
)
 
R
a
b
e
p
r
a
z
o
l
e
 
(
P
a
r
i
e
t
)
4
 
(
2
.
7
)
1
 
(
0
.
9
)
9
 
(
5
.
7
)
9
 
(
6
.
0
)
3
 
(
1
.
3
)
0
 
(
0
.
0
)
1
3
 
(
7
.
1
)
1
3
 
(
7
.
3
)
 
E
s
o
m
e
p
r
a
z
o
l
e
 
(
N
e
x
i
u
m
)
7
 
(
4
.
7
)
1
 
(
0
.
9
)
2
2
 
(
1
3
.
9
)
2
1
 
(
1
4
.
0
)
7
 
(
3
.
0
)
3
 
(
1
.
5
)
2
1
 
(
1
1
.
5
)
2
1
 
(
1
1
.
7
)
H
i
s
t
a
m
i
n
e
 
r
e
c
e
p
t
o
r
 
a
n
t
a
g
o
n
i
s
t
s
,
 
n
 
(
%
)
 
A
n
y
 
h
i
s
t
a
m
i
n
e
 
r
e
c
e
p
t
o
r
 
a
n
t
a
g
o
n
i
s
t
1
 
(
0
.
7
)
0
 
(
0
.
0
)
1
2
 
(
7
.
6
)
1
0
 
(
6
.
7
)
4
 
(
1
.
7
)
2
 
(
1
.
0
)
1
4
 
(
7
.
7
)
1
3
 
(
7
.
3
)
 
R
a
n
i
t
i
d
i
n
e
 
(
Z
a
n
t
a
c
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
8
 
(
5
.
1
)
8
 
(
5
.
3
)
2
 
(
0
.
9
)
1
 
(
0
.
5
)
1
0
 
(
5
.
5
)
9
 
(
5
.
0
)
 
F
a
m
o
t
i
d
i
n
e
 
(
P
e
p
c
i
d
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
1
 
(
0
.
5
)
1
 
(
0
.
6
)
 
C
i
m
e
t
i
d
i
n
e
 
(
T
a
g
a
m
e
t
)
1
 
(
0
.
7
)
0
 
(
0
.
0
)
1
 
(
0
.
6
)
1
 
(
0
.
7
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
 
N
i
z
a
t
i
d
i
n
e
 
(
A
x
i
d
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
1
 
(
0
.
5
)
1
 
(
0
.
6
)
O
v
e
r
-
t
h
e
-
c
o
u
n
t
e
r
 
h
i
s
t
a
m
i
n
e
 
r
e
c
e
p
t
o
r
 
a
n
t
a
g
o
n
i
s
t
0
 
(
0
.
0
)
0
 
(
0
.
0
)
4
 
(
2
.
5
)
4
 
(
2
.
7
)
2
 
(
0
.
9
)
1
 
(
0
.
5
)
3
 
(
1
.
7
)
3
 
(
1
.
7
)
P
r
o
k
i
n
e
t
i
c
s
,
 
n
 
(
%
)
 
A
n
y
 
p
r
o
k
i
n
e
t
i
c
s
7
 
(
4
.
7
)
3
 
(
2
.
8
)
6
 
(
3
.
8
)
5
 
(
3
.
3
)
7
 
(
3
.
0
)
6
 
(
3
.
0
)
5
 
(
2
.
7
)
4
 
(
2
.
2
)
 
D
o
m
p
e
r
i
d
o
n
e
 
(
M
o
t
i
l
i
u
m
)
3
 
(
2
.
0
)
1
 
(
0
.
9
)
6
 
(
3
.
8
)
5
 
(
3
.
3
)
3
 
(
1
.
3
)
2
 
(
1
.
0
)
4
 
(
2
.
2
)
3
 
(
1
.
7
)
 
M
e
t
o
c
l
o
p
r
a
m
i
d
e
 
(
M
a
x
o
l
o
n
)
4
 
(
2
.
7
)
2
 
(
1
.
8
)
0
 
(
0
.
0
)
0
 
(
0
.
0
)
4
 
(
1
.
7
)
4
 
(
2
.
0
)
1
 
(
0
.
5
)
1
 
(
0
.
6
)
O
t
h
e
r
 
p
r
e
s
c
r
i
b
e
d
 
d
r
u
g
s
,
 
n
a
 
 
A
l
g
i
n
a
t
e
s
 
(
G
a
v
i
s
c
o
n
,
 
e
t
c
.
,
 
T
o
p
a
l
)
0
0
4
4
0
0
2
2
 
A
n
t
i
-
s
p
a
s
m
o
d
i
c
s
 
(
e
.
g
.
 
d
i
c
y
c
l
o
v
e
r
i
n
e
 
)
0
0
1
1
2
2
0
0
 
C
h
e
l
a
t
e
s
 
(
s
u
c
r
a
l
f
a
t
e
)
0
0
0
0
0
0
0
0
 
O
t
h
e
r
 
u
l
c
e
r
-
h
e
a
l
i
n
g
 
d
r
u
g
s
0
0
0
0
0
0
0
0
 
A
n
t
a
c
i
d
s
:
 
M
u
c
o
g
e
l
0
0
0
0
0
0
1
1
 
A
n
t
a
c
i
d
s
:
 
A
s
i
l
o
n
e
0
0
0
0
0
0
0
0
 
N
o
n
-
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
1
1
0
0
2
1
1
1
 
A
n
t
i
-
m
o
t
i
l
i
t
y
0
0
0
0
1
1
0
0
I
T
T
,
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
;
 
P
P
,
 
p
e
r
 
p
r
o
t
o
c
o
l
.
a
 
 
N
u
m
b
e
r
 
o
f
 
p
r
e
s
c
r
i
p
t
i
o
n
s
;
 
m
o
r
e
 
t
h
a
n
 
o
n
e
 
p
r
e
s
c
r
i
p
t
i
o
n
 
p
e
r
 
p
e
r
s
o
n
 
p
o
s
s
i
b
l
eHealth Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
49
T
A
B
L
E
 
2
5
 
F
o
l
l
o
w
-
u
p
 
a
t
 
t
h
e
 
t
i
m
e
 
e
q
u
i
v
a
l
e
n
t
 
t
o
 
3
 
m
o
n
t
h
s
 
a
f
t
e
r
 
s
u
r
g
e
r
y
 
–
 
h
e
a
l
t
h
 
s
t
a
t
u
s
R
a
n
d
o
m
i
s
e
d
 
p
a
r
t
i
c
i
p
a
n
t
s
P
r
e
f
e
r
e
n
c
e
 
p
a
r
t
i
c
i
p
a
n
t
s
S
u
r
g
i
c
a
l
M
e
d
i
c
a
l
S
u
r
g
i
c
a
l
M
e
d
i
c
a
l
I
T
T
 
(
n
 
=
 
1
7
8
)
P
P
 
(
n
 
=
 
1
1
1
)
I
T
T
 
(
n
 
=
 
1
7
9
)
P
P
 
(
n
 
=
 
1
6
9
)
I
T
T
 
(
n
 
=
 
2
6
1
)
P
P
 
(
n
 
=
 
2
1
8
)
I
T
T
 
(
n
 
=
 
1
9
2
)
P
P
 
(
n
 
=
 
1
8
9
)
r
e
f
l
u
x
 
Q
o
L
,
 
m
e
a
n
 
(
S
D
)
8
3
.
9
 
(
1
9
.
4
)
8
5
.
9
 
(
1
9
.
0
)
7
0
.
6
 
(
2
4
.
6
)
7
0
.
8
 
(
2
4
.
4
)
8
0
.
4
 
(
2
1
.
6
)
8
2
.
5
 
(
2
0
.
3
)
8
0
.
2
 
(
1
8
.
2
)
8
0
.
6
 
(
1
7
.
7
)
r
e
f
l
u
x
 
s
y
m
p
t
o
m
 
s
c
o
r
e
,
 
m
e
a
n
 
(
S
D
)
 
G
e
n
e
r
a
l
 
d
i
s
c
o
m
f
o
r
t
 
s
y
m
p
t
o
m
 
s
c
o
r
e
8
4
.
8
 
(
1
7
.
3
)
8
9
.
4
 
(
1
4
.
0
)
6
6
.
9
 
(
2
6
.
2
)
6
6
.
5
 
(
2
6
.
0
)
8
4
.
1
 
(
1
9
.
6
)
8
7
.
2
 
(
1
6
.
6
)
7
5
.
7
 
(
1
9
.
6
)
7
6
.
0
 
(
1
9
.
5
)
 
W
i
n
d
 
a
n
d
 
f
r
e
q
u
e
n
c
y
 
s
y
m
p
t
o
m
 
s
c
o
r
e
5
8
.
1
 
(
1
9
.
7
)
5
5
.
9
 
(
1
9
.
7
)
5
3
.
7
 
(
2
2
.
6
)
5
4
.
4
 
(
2
2
.
5
)
5
2
.
2
 
(
2
1
.
1
)
5
2
.
6
 
(
2
0
.
7
)
6
0
.
7
 
(
2
2
.
2
)
6
0
.
9
 
(
2
2
.
3
)
 
N
a
u
s
e
a
 
a
n
d
 
v
o
m
i
t
i
n
g
 
s
y
m
p
t
o
m
 
s
c
o
r
e
9
1
.
5
 
(
1
5
.
7
)
9
3
.
1
 
(
1
5
.
7
)
8
2
.
1
 
(
2
0
.
7
)
8
2
.
3
 
(
2
0
.
2
)
9
0
.
2
 
(
1
5
.
2
)
9
1
.
6
 
(
1
3
.
7
)
8
9
.
5
 
(
1
2
.
9
)
9
0
.
0
(
1
1
.
9
)
 
A
c
t
i
v
i
t
y
 
l
i
m
i
t
a
t
i
o
n
 
s
y
m
p
t
o
m
 
s
c
o
r
e
8
8
.
2
 
(
1
7
.
0
)
8
9
.
9
 
(
1
6
.
7
)
8
1
.
6
 
(
1
9
.
6
)
8
1
.
9
 
(
1
9
.
0
)
8
8
.
4
 
(
1
8
.
0
)
8
9
.
7
 
(
1
7
.
5
)
8
7
.
9
 
(
1
3
.
2
)
8
8
.
0
 
(
1
3
.
3
)
 
C
o
n
s
t
i
p
a
t
i
o
n
 
a
n
d
 
s
w
a
l
l
o
w
i
n
g
 
s
y
m
p
t
o
m
 
s
c
o
r
e
7
9
.
2
 
(
2
0
.
0
)
7
8
.
7
 
(
2
0
.
7
)
7
5
.
8
 
(
2
0
.
9
)
7
7
.
0
 
(
1
9
.
8
)
7
7
.
1
 
(
2
1
.
2
)
7
6
.
9
 
(
2
1
.
3
)
8
4
.
2
 
(
1
6
.
9
)
8
4
.
6
 
(
1
6
.
5
)
S
F
-
3
6
 
s
c
o
r
e
s
,
 
m
e
a
n
 
(
S
D
)
 
N
o
r
m
-
b
a
s
e
d
 
p
h
y
s
i
c
a
l
 
f
u
n
c
t
i
o
n
i
n
g
4
9
.
2
 
(
1
0
.
0
)
4
9
.
3
 
(
1
0
.
4
)
4
6
.
5
 
(
1
1
.
5
)
4
6
.
6
 
(
1
1
.
6
)
4
9
.
9
 
(
9
.
7
)
5
0
.
4
 
(
9
.
4
)
4
7
.
6
 
(
1
0
.
3
)
4
7
.
5
 
(
1
0
.
4
)
 
N
o
r
m
-
b
a
s
e
d
 
r
o
l
e
 
p
h
y
s
i
c
a
l
4
7
.
7
 
(
1
1
.
8
)
4
7
.
4
 
(
1
2
.
1
)
4
4
.
8
 
(
1
2
.
1
)
4
5
.
0
 
(
1
2
.
1
)
4
8
.
1
 
(
1
1
.
3
)
4
8
.
7
 
(
1
0
.
7
)
4
7
.
1
 
(
1
0
.
4
)
4
7
.
1
 
(
1
0
.
4
)
 
N
o
r
m
-
b
a
s
e
d
 
b
o
d
i
l
y
 
p
a
i
n
4
8
.
5
 
(
1
0
.
3
)
4
8
.
8
 
(
1
0
.
8
)
4
5
.
3
 
(
1
1
.
4
)
4
5
.
3
 
(
1
1
.
3
)
4
8
.
4
(
1
1
.
3
)
4
9
.
0
 
(
1
1
.
2
)
4
6
.
5
 
(
1
0
.
2
)
4
6
.
5
 
(
1
0
.
3
)
 
N
o
r
m
-
b
a
s
e
d
 
g
e
n
e
r
a
l
 
h
e
a
l
t
h
4
6
.
3
 
(
1
1
.
0
)
4
7
.
4
 
(
1
1
.
0
)
4
0
.
7
 
(
1
1
.
2
)
4
0
.
7
 
(
1
1
.
2
)
4
7
.
2
 
(
1
1
.
3
)
4
8
.
2
 
(
1
1
.
1
)
4
2
.
5
 
(
1
0
.
5
)
4
2
.
6
 
(
1
0
.
4
)
 
N
o
r
m
-
b
a
s
e
d
 
v
i
t
a
l
i
t
y
4
7
.
1
 
(
1
1
.
9
)
4
8
.
0
 
(
1
2
.
1
)
4
3
.
9
 
(
1
2
.
4
)
4
4
.
3
 
(
1
2
.
2
)
4
8
.
0
 
(
1
1
.
9
)
4
8
.
4
 
(
1
1
.
9
)
4
4
.
7
 
(
1
1
.
4
)
4
4
.
8
 
(
1
1
.
4
)
 
N
o
r
m
-
b
a
s
e
d
 
s
o
c
i
a
l
 
f
u
n
c
t
i
o
n
i
n
g
4
7
.
2
 
(
1
1
.
5
)
4
7
.
5
 
(
1
2
.
1
)
4
3
.
6
 
(
1
2
.
7
)
4
3
.
8
 
(
1
2
.
6
)
4
6
.
8
 
(
1
2
.
3
)
4
7
.
6
 
(
1
2
.
0
)
4
6
.
9
 
(
1
0
.
5
)
4
6
.
9
 
(
1
0
.
5
)
 
N
o
r
m
-
b
a
s
e
d
 
r
o
l
e
 
e
m
o
t
i
o
n
a
l
4
8
.
3
 
(
1
2
.
3
)
4
8
.
4
 
(
1
2
.
5
)
4
3
.
9
 
(
1
4
.
2
)
4
4
.
1
 
(
1
4
.
2
)
4
7
.
0
 
(
1
2
.
6
)
4
8
.
9
 
(
1
1
.
7
)
4
7
.
0
 
(
1
1
.
4
)
4
6
.
9
 
(
1
1
.
4
)
 
N
o
r
m
-
b
a
s
e
d
 
m
e
n
t
a
l
 
h
e
a
l
t
h
4
8
.
7
 
(
1
2
.
0
)
4
9
.
7
 
(
1
1
.
9
)
4
4
.
5
 
(
1
2
.
2
)
4
4
.
7
 
(
1
1
.
9
)
4
8
.
3
 
(
1
2
.
2
)
4
9
.
2
 
(
1
1
.
8
)
4
7
.
1
 
(
1
0
.
6
)
4
7
.
1
 
(
1
0
.
7
)
E
Q
-
5
D
,
 
m
e
a
n
 
(
S
D
)
0
.
7
9
 
(
0
.
2
3
)
0
.
8
1
 
(
0
.
2
4
)
0
.
6
9
 
(
0
.
3
0
)
0
.
7
0
 
(
0
.
3
0
)
0
.
8
1
 
(
0
.
2
5
)
0
.
8
2
 
(
0
.
2
4
)
0
.
7
6
 
(
0
.
2
3
)
0
.
7
7
 
(
0
.
2
3
)
E
Q
-
5
D
 
V
A
S
,
 
m
e
a
n
 
(
S
D
)
7
4
.
8
 
(
1
9
.
7
)
7
7
.
0
 
(
1
8
.
4
)
6
7
.
8
 
(
2
0
.
8
)
6
8
.
1
 
(
2
0
.
7
)
7
5
.
1
 
(
1
8
.
6
)
7
6
.
3
 
(
1
8
.
3
)
7
0
.
8
 
(
1
7
.
6
)
7
0
.
9
 
(
1
7
.
5
)
I
T
T
,
 
i
n
t
e
n
t
i
o
n
 
t
o
 
t
r
e
a
t
;
 
P
P
,
 
p
e
r
 
p
r
o
t
o
c
o
l
;
 
Q
o
L
,
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
;
 
V
A
S
,
 
v
i
s
u
a
l
 
a
n
a
l
o
g
u
e
 
s
c
a
l
e
.Trial results
50
Follow-up at the time 
equivalent to 12 months 
after surgery
Patient flow
As with the 3-month follow-up, of the participants 
for whom it was appropriate to send a follow-
up questionnaire at 12 months, approximately 
95% returned it (Table 26). The median lag time 
from randomisation to this second follow-up 
was similar across all of the groups. It was also 
approximately 270 days after the 3-month follow-
up questionnaire, further demonstrating that the 
pairing of follow-up times between participants had 
been successful.
Medications
The medications that participants had taken 
during the previous 2 weeks at the time of the 
12-month follow-up are shown in Table 27. In the 
RITT groups, 38.3% of the randomised surgical 
participants had taken a reflux-related drug 
compared with 89.6% of the randomised medical 
participants (and nearly all of these were PPIs). 
When considering only randomised participants 
who received their intended management (the RPP 
groups), 14.4% of surgical participants and 92.9% 
of medical participants had been taking reflux-
related drugs. As at 3 months, the preference 
medical groups reported similar patterns of drug 
use to the randomised medical groups; however, 
the rate of drug use in the preference surgical ITT 
group was about one-half of that in the randomised 
surgical ITT group. Omeprazole and lansoprazole 
were equally commonly reported and this contrasts 
with the findings at study entry when lansoprazole 
was the predominant PPI used.
Health status
The health status measures at the 12-month follow-
up are shown in Table 28. Within the randomised 
trial (RITT groups) there were still substantial 
differences across all measures (of the order of 
magnitude of one-third or one-half of a standard 
deviation of the score), with the surgery group 
having better scores than the medical group. 
The differences were larger when only the per 
protocol participants were considered (RPP 
groups). Details of statistical testing of the health 
status scores can be found in the next section of 
this chapter. For the reflux symptoms, although 
there were improvements across all symptom 
groups for surgical participants, the largest 
improvement in symptom score was for the general 
discomfort dimension. A detailed description of 
the responses to each symptom question is given in 
the R e f l u x  questionnaire (see Appendix 2). These 
improvements were also reflected in the SF-36 
scores where the biggest differences were observed 
in the general health and bodily pain dimensions.
For preference participants the health status 
measure scores tended to favour the surgical group. 
However, the differences between the preference 
groups were less marked than the differences 
between the randomised groups, mainly because 
the preference medical group had better scores 
than the randomised medical group.
Graphical displays of the changes in R e f l u x  QoL 
scores and EQ-5D scores for all study groups are 
displayed in Figures 14 and 15 respectively. 
Three participants died, one in the randomised 
medical group (road traffic accident) and two in 
the preference surgical group, neither of whom 
had surgery (alcoholic liver disease and cause 
unknown). 
Statistical analyses
Primary outcome
The pre-chosen primary outcome was the R e f l u x  
QoL score at the time equivalent to 12 months 
after surgery. The mean and standard deviation of 
the score for each group at this follow-up are shown 
in Table 28. The differences between groups with 
corresponding 95% confidence intervals are shown 
in Table 29. Three types of analysis are presented 
for the randomised participants – intention to 
treat, per protocol and adjusted treatment received. 
Table 29 also displays the impact of including 
adjustment for baseline score and randomised 
group × baseline score interaction terms.
Intention to treat
For the intention to treat analysis there was a mean 
difference in favour of surgery of 11.2 between the 
groups when only the minimisation variables were 
adjusted for (p < 0.001). This was not the most 
parsimonious model – there was strong evidence 
of an interaction effect between the randomised 
group and baseline R e f l u x  QoL score (interaction 
term was –0.35; 95% CI –0.53 to 0.17; p < 0.001). 
This implied that as baseline R e f l u x  QoL 
score increased the treatment effect decreased. 
Estimating the treatment difference at the trial 
baseline mean R e f l u x  QoL score of 65.4 resulted 
in a trial effect size of 14.0 (95% CI 9.6–18.4 ). If 
the average patient had a lower mean R e f l u x  QoL Health Technology Assessment 2008; Vol. 12: No. 31
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FIGURE 15  EQ-5D scores at baseline and follow-up. Scores ranged from 100 (perfect health) to 0 (equivalent to death).
FIGURE 14  Re f l u x quality of life (QoL) scores at baseline and follow-up. Scores ranged from 0 to 100; the higher the score the better 
the patient felt.
score at baseline of 56.0, the effect size increased 
to 17.2 (95% CI 12.6–21.9). If the patient had a 
higher baseline score of 78.0, the treatment effect 
decreased to 9.5 (95% CI 4.5–14.5). All results, 
however, showed strong evidence of increases in 
R e f l u x  QoL scores, favouring surgery.
Per protocol
The per protocol analysis in Table 29 estimated the 
difference between the randomised groups using 
only participants who received their allocated 
GORD management. This provided an estimate 
of the efficacy of the treatments. The per protocol 
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analyses demonstrated larger effects in favour 
of surgery than the corresponding intention to 
treat analyses. Addition of the baseline score and 
interaction with the randomised group provided 
the best model fit resulting in a difference in 
favour of surgery of 18.4 (95% CI 13.6–23.2). 
Selection bias is to be expected in these estimates 
and indeed those who did not receive surgery in 
the randomised surgical group had higher (better) 
R e f l u x  QoL scores at baseline than those who did 
have surgery (69.0 versus 61.8). 
Adjusted treatment received
The adjusted treatment received analyses 
attempted to reduce the selection bias effect 
inherent in the per protocol analyses. The effect 
sizes using the adjusted treatment received 
approach produced slightly larger estimates 
of differences than the per protocol estimates 
(see Table 29); however, the confidence interval 
widths increased. Nevertheless, the estimates 
and confidence intervals of the efficacy of the 
treatments suggested large benefits of surgery.
Preference groups
The preference for surgery participants reported 
considerably worse mean R e f l u x  QoL scores 
at baseline than the preference for medicine 
participants (55.8 versus 77.5; Table 20). Despite 
starting from a much lower baseline score, at 
follow-up at the time equivalent to 12 months 
after surgery, the R e f l u x  QoL score favoured the 
surgical group using an intention to treat analysis 
(difference = 3.9; 95% CI –0.2 to 8.0; p = 0.064) 
and using a per protocol analysis (difference = 6.3; 
95% CI 2.4–10.2; p = 0.002).
Secondary outcomes
The secondary outcomes were the health status 
measures (EQ-5D, SF-36 and symptom scores) 
at the times equivalent to 3 and 12 months after 
surgery. The use of reflux medication at 12 months 
after surgery was also analysed.
At time equivalent to 12 
months after surgery
Table 30 shows the health status measures at 
the time equivalent to 12 months after surgery 
described by the same three analyses as for the 
primary outcome (intention to treat, per protocol 
and adjusted treatment received). 
Intention to treat
There were statistically significant improved R e f l u x  
symptom category scores in favour of surgery 
across all domains (with the exception of the 
constipation and swallowing domain, which non-
significantly favoured surgery). The bodily pain 
and general health scores had the largest SF-36 
changes (p ≤ 0.001); there were relatively small, 
non-statistically significant changes in SF-36 role 
physical, role emotional and mental health scores, 
although the directions of difference all favoured 
surgery. The EQ-5Dindex score was also higher in 
the surgery group, although the difference did not 
reach conventional levels of statistical significance 
(p = 0.07).
Per protocol and adjusted 
treatment received
All the per protocol analyses had larger differences 
than the corresponding intention to treat analyses, 
but the differences in SF-36 role physical, role 
emotional and mental health scores were still not 
statistically significant. The adjusted treatment 
received estimates were broadly similar to those 
derived from the per protocol analyses.
Use of medication
There were large differences between the groups 
in the numbers of participants requiring any 
reflux medication at the 12-month follow-up 
(Table 27). For the intention to treat analysis, the 
odds ratio of requiring any reflux medication in 
the surgical group was 0.07 (95% CI 0.04–0.125; 
p < 0.001) compared with the medical group 
(absolute difference 38.3% versus 89.6%). The 
odds ratios for the per protocol analysis and 
adjusted treatment received were 0.012 (95% CI 
0.005–0.029; p < 0.001) and 0.017 (95% CI 0.006–
0.048; p < 0.001) respectively. This is related to an 
absolute difference of 14.4% versus 92.9%. Across 
the 312 participants (randomised and preference) 
who received surgery and completed follow-up, 37 
(11.9%; 95% CI 8.7–15.9%) required any reflux 
medication and 21 (6.7%) required PPIs.
At time equivalent to 3 
months after surgery
Table 31 shows the health status measures at 
the time equivalent to 3 months after surgery 
described by the three analyses (intention to treat, 
per protocol and adjusted treatment received). 
In general, the scores were higher at 3 months 
than at 12 months. The differences in EQ-5D, in 
particular, were about twice as big at 3 months and 
were clearly statistically significant at that time. Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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Subgroup analyses
Removal of data from the single 
largest clinical centre (Aberdeen)
No formal exploration of centre effects was 
undertaken because of the small numbers of 
participants recruited in many of the clinical 
centres. However, a sensitivity analysis removing 
the data from the Aberdeen centre, the centre 
where the largest number of participants were 
recruited, did not significantly change the 
conclusions (adjusted difference in R e f l u x  score 
+15.4; 95% CI 10.2–20.6). 
Partial versus total wrap procedure
In an observational analysis there was no evidence 
of a difference between a total wrap procedure and 
a partial wrap procedure. The difference in the 
R e f l u x  QoL score between these procedures at the 
time equivalent to 12 months post surgery was –1.3 
(95% CI –7.9 to 5.2; p = 0.687).
Discussion
The trial provides strong evidence of improvement 
in GORD symptoms following laparoscopic 
fundoplication as judged by the R e f l u x  quality 
of life score and its constituent domains. There 
were large differences between the randomised 
groups in these respects at 3 months post surgery, 
which were broadly sustained 9 months later. 
Also, scores in the preference surgical group were 
somewhat higher than those in the preference 
medical group despite starting from much lower 
baseline levels. The estimated sizes of differences 
varied depending on the assumptions being made. 
However, significant differences were observed 
even in the most conservative of the three main 
analyses – that based on intention to treat – where 
about one-third of those randomised to surgery 
did not actually receive it. Similar differences were 
also seen in most of the other measures of health 
status. There is, however, some evidence of a 
narrowing of the differences when the 3-month and 
12-month follow-up results are compared. This was 
most marked for the EQ-5D, in which the surgical 
values had decreased and the medical values had 
increased somewhat (most easily seen in Figure 15).
We anticipated that this would be a difficult trial 
to deliver and so it proved. Trials comparing 
strikingly different interventions (such as surgery 
versus medical management) are often a challenge 
to recruit to. The explanation of such a trial 
needs to encompass a range of considerations 
and it is not unusual for some people, both 
clinicians and patients, to have strong views on 
the alternative procedures. As expected, many 
potential participants did have preferences for one 
approach or the other, and it was partly because 
we anticipated this that we included preference 
groups alongside the randomised core of the study. 
By enrolling surgeon/gastroenterologist pairs who 
were uncertain about the place of minimal access 
surgery in this context, we aimed to avoid clinician 
preferences. However, the differential recruitment 
to the preference groups in the clinical centres, 
in part reflecting which clinician actually first saw 
a potential participant, showed that there were 
differences in clinical perspective. This became a 
problem within the randomised comparison on 
the (relatively few) occasions in which a patient 
recruited by one clinician was deemed unsuitable 
for surgery by another clinician in the same centre.
To make the study more attractive to potential 
participants, those allocated medical management 
underwent a review of their medication to ‘optimise 
this’, rather than just carrying on with their existing 
regimen. This may be the reason why the types of 
PPI taken at follow-up differed from those at the 
time of trial entry (predominantly lansoprazole at 
entry, but omeprazole or lansoprazole equally at 
follow-up).
People suitable for the trial were not easy to 
identify. Most patients on long-term PPI treatment 
are managed in general practice, often through a 
repeat prescription system. We used a combination 
of three approaches: retrospective case note 
review to identify potentially eligible patients 
who had been seen in a participating hospital; 
prospectively, especially through endoscopy clinics; 
and (in selected centres) advertisements to the 
general public. All potentially eligible people had 
to be assessed clinically and they were only then 
formally approached about the trial. This was extra 
work over and above normal clinical duties, often 
through specially established monthly clinics. As 
described in Chapter 2, the numbers enrolled in 
individual centres tended to be small, reflecting all 
of these constraints. In the event, we found that 
those who agreed to join the randomised trial had 
characteristics mid-way between those of the two 
preference groups.
What we did not predict were the long waiting 
times for surgery in many centres. This was 
due to ambiguity about the responsibilities of 
participating hospitals in terms of the extra 
treatment costs of surgery. The intention had 
been that surgical slots would be pre-booked for Trial results
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the trial and that participants randomised to 
surgery would take the next available of these 
slots. In the event, emergencies such as cancer 
cases were given precedence, sometimes with 
repeated postponements of R e f l u x  trial patients. 
Anecdotally, long delays were an important factor 
in the decision of some of those participants 
allocated surgery ultimately not to have surgery. 
Delays became intractable in a few centres to 
the extent that special subvention funds were 
eventually found to allow the operations to be 
performed without any impact on normal clinical 
services. The availability of such funds to all centres 
from the start of the trial would almost certainly 
have overcome much of the waiting list problem.
In retrospect, given the long waits for surgery, it 
might have been better following enrolment to 
delay random allocation until there was a definite 
operation appointment. However, the likely impact 
would have been significant uncertainty amongst 
those enrolled about what they had agreed to, and 
greatly reduced numbers actually randomised (with 
some operations still postponed).
The standard rule in most trials is to time follow-
up from randomisation. This was not appropriate 
in this trial because of the variable time between 
randomisation and surgery, exacerbated by the 
waiting list problem. The protocol specified follow-
up at times equivalent to 3 and 12 months after 
surgery. It was important to have follow-up in the 
medical groups at equivalent times. We arranged 
this by pairing surgical and medical participants 
such that follow-up was linked and at (about) the 
same time after randomisation. The success of this 
manoeuvre can be assessed in Tables 23 and 26.
The large number of participants who did not get 
the management that they had been allocated to 
did have an impact on the results. For example, 
only 20% (10/50) of those allocated surgery 
who were taking reflux-related drugs at the 
3-month follow-up had actually had surgery. As 
discussed earlier in this chapter, we have gone 
to some lengths to explore the likely impact of 
this non-adherence to the trial allocation. One 
way is through per protocol analyses limited to 
those randomised who received their allocated 
management. The second way is through an 
adjusted approach as a way of attempting to 
circumvent the likely selection bias of per protocol 
analyses. In this study the direction of effects was 
so clear, irrespective of the way that the analysis 
was performed, that the main issue became the 
size of effects. These did vary substantially (see, for 
example, Table 29) and this could be very important 
when policy decisions are being made, for example 
in the context of an economic evaluation. The 
approach that we took to address this in our 
economic analyses is described in the next two 
chapters. 
One reason why we elected to have parallel non-
randomised preference groups was to get more 
experience of the two forms of management. This 
particularly applied to surgery. Complications 
amongst the 319 participants who actually had 
fundoplication were rare (Table 22). Two operations 
were converted to open procedures, there were 
six visceral injuries and two pneumothoraces, and 
there were three admissions to a high dependency 
unit with no admissions to an intensive care unit. 
Patients stayed in hospital for a median of only 
2 days. Three had reoperations and three had 
operations related to oesophageal stenosis. 
As discussed in the following two chapters, an 
important measure of outcome is the proportion 
of patients continuing to take reflux-related drugs, 
especially after surgery. Rates did go up somewhat 
between the 3-month and 12-month assessment. 
Our rate of 11–14% at 12 months is higher than 
that in some other studies although estimates do 
vary both above and below this. Funding for this 
project was for follow-up to the time equivalent 
to 12 months after surgery. We have, however, 
instituted further annual follow-ups using similar 
questionnaires to those used at 3 and 12 months. 
Further follow-up will be important for assessing 
whether the benefits of surgery are sustained or 
whether differences in health status further narrow 
over time. We expect to report this after 5 years of 
follow-up are available for all participants.
The next two chapters on the economic evaluation 
reflect the position that we are in currently, having 
only 1 year of follow-up data, while recognising that 
long-term lifetime effects are likely to determine 
whether laparoscopic fundoplication is cost-
effective. First, the within-trial cost-effectiveness 
analyses reported in Chapter 7 are developed 
within an economic framework. Then, an economic 
model is used to explore and extrapolate cost-
effectiveness over a longer-term perspective.Health Technology Assessment 2008; Vol. 12: No. 31
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Chapter 7  
Within-trial cost-effectiveness results
had revision of surgery or non-randomised surgery, 
but did not collect detailed use of health-care 
resources or length of stay for these patients. 
The use of anti-reflux medication taken in the 
previous 2 weeks was recorded at baseline and at 
each follow-up by questionnaires completed by 
the patients. There was a small amount of missing 
data for use of medication, which was handled as 
follows. If the patient confirmed that they were 
using an anti-reflux medication but did not report 
the dose, the median dose for other patients using 
that medication was imputed. All patients were 
assumed to be on medication at baseline as this was 
an inclusion criterion for entry into the R e f l u x  trial. 
If no medication was declared the missing data 
were imputed as the mean cost per day. We assume 
that all patients randomised to surgery undergo 
their procedure immediately and discontinue 
medication at that point unless they declare use 
of medication at a subsequent follow-up. The total 
cost per patient of anti-reflux medication was 
calculated using the trapezium rule using linear 
interpolation between follow-up points.98,99 
The R e f l u x  trial recorded use of the following 
health services for the previous 3 months at first 
follow-up (at a time equivalent to 3 months after 
surgery) and second follow-up (at a time equivalent 
to 12 months after surgery): visits to and from 
general practitioners; visits to outpatient clinics; 
and admissions to hospital during follow-up. These 
questionnaires did not record use of health services 
between the third month and the ninth month. To 
capture these data a postal survey of patients was 
undertaken in May 2006 asking patients about the 
use of health services at any time during the first 
year. The cost of use of hospital and community 
health services for each patient during the first year 
was estimated as the greater of the sum of the first 
and second follow-ups compared with the use of 
resources reported in the postal survey. 
Unit costs
Costs per patient were calculated by multiplying 
use of health-care resources as collected in the trial 
by unit costs taken from surveys and published data 
sources (Table 32). 
Introduction
This chapter presents the within-trial cost-
effectiveness analysis comparing laparoscopic 
fundoplication with medical management. 
Mean costs and health outcomes per patient 
are evaluated over 1 year using data from the 
R e f l u x  trial. The analysis is conducted from the 
perspective of the health and social care services. 
Costs are at 2006 prices and include the use of 
reflux-related health-care resources. Costs and 
outcomes are not discounted for this 1-year 
analysis. 
Methods
Patients included
We compare the treatment strategies of immediate 
laparoscopic fundoplication with continued 
medical management on an intention to treat basis. 
The analysis includes data from 318 R e f l u x  patients 
(154 in the surgery group and 164 in the medical 
management group) who were randomised to a 
treatment strategy and who were followed up for a 
time equivalent to at least 1 year after surgery. We 
do not model the wait for surgery, that is, we model 
a best practice situation.
Because, as described in Chapter 6, the 
management of a high proportion of patients 
did not comply with their randomised treatment 
allocation, we also conducted a secondary analysis 
of the use of resources, costs and HRQoL for 
patients who received randomised per protocol 
treatment. However, it should be noted that 
these data are potentially biased, as described in 
Chapter 6. 
Resource use
The use of the following health-care resources 
was collected retrospectively from clinical 
questionnaires for patients receiving randomised 
surgery: the use of endoscopy, pH monitoring 
and manometry prior to surgery; the length of 
time in surgery; and length of stay in wards, high 
dependency units and intensive therapy units post 
surgery. The trial also recorded whether patients Within-trial cost-effectiveness results
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The use and costs of consumable items and 
laparoscopic surgical equipment was collected by 
a survey in 2003 of five centres participating in 
the trial, described in detail in Chapter 3 of this 
report.100 This survey also estimated the mean cost 
per hour in surgical theatre in each centre, based 
on the use of staff in each centre and national 
salary scales.64 The mean unit costs estimated by 
this survey were then applied to all centres in the 
within-trial cost analysis, updated for inflation.64 
Quality-adjusted life-years
The outcome used in the cost-effectiveness analysis 
was the difference in mean QALYs between 
the treatment groups. HRQoL was assessed at 
baseline and at each follow-up using the EQ-
5D instrument. QALYs for each patient over 
the year of follow-up were calculated as the area 
under the curve using the trapezium rule, that is, 
assuming linear interpolation between follow-up 
points. The difference in mean QALYs per patient 
between the treatment groups was estimated 
using ordinary least squares regression, adjusting 
for baseline differences in EQ-5D between 
individuals. Bootstrap methods (resampling with 
replacement)101 were used to estimate confidence 
intervals for the differences in mean costs and 
QALYs and the correlation between them. 
Uncertainty regarding the treatment decision was 
represented using cost-effectiveness acceptability 
curves.74 These show the proportion of samples 
from the data in which each therapy is the more 
cost-effective across a range of alternative threshold 
values that the health-care system may be willing to 
pay for a QALY.102
Results
Use of health-care resources
Table 32 shows the average use of reflux-related 
health-care resources in the two groups at 1 year 
according to intention to treat. Nine patients 
randomised to medical management underwent 
laparoscopic surgery and 50 patients randomised 
to the surgical group did not receive surgery. 
Although the intention to treat analysis is unbiased, 
it is not very informative for describing the use 
of health-care resources, which depend on the 
treatment actually received. 
Table 33 shows the average use of health-care 
resources according to the randomised per 
protocol analysis. Patients randomised to and who 
received laparoscopic fundoplication spent an 
average of 115 minutes in theatre and 2.4 days 
in wards postoperatively. Only one patient out of 
104 required the use of a high dependency unit. 
During the year of follow-up similar numbers of 
patients in each group required use of general 
practitioner services but patients who had surgery 
tended to require more outpatient visits and 
day-case admissions. At the 12-month follow-up, 
14 out of 104 (13%) in the surgical arm (who 
had surgery) had used anti-reflux medications 
in the past 2 weeks compared with 144 out of 
155 (93%) in the medical arm who did not have 
surgery. A proportion of those not reporting use of 
prescription medications, however, were missing 
data, were using over-the-counter pharmaceuticals, 
had stopped temporarily or had stopped for 
non-reflux-related reasons such as pregnancy. No 
patients randomised to surgery required revision of 
the fundoplication procedure during the year. 
Costs
Total mean costs per patient over the year on an 
intention to treat basis were £1786 for patients 
randomised to surgery and £506 for patients 
randomised to medical management (Table 32), a 
difference of £1280 (95% CI £1054–£1468) (Table 
34). The mean cost per patient of the surgical 
procedure and hospital admission for those 
randomised to and who underwent surgery was 
£2012 (SE £41) (Table 33). 
Quality-adjusted life-years
The HRQoL of patients, measured using the EQ-
5D, tended to improve on average in the surgical 
group over the year of the analysis but not in the 
medical management group (Tables 35 and 36). 
After adjusting for baseline differences in HRQoL, 
patients gained 0.066 more QALYs (95% CI 0.026–
0.107) during the trial period compared with 
medical management using an intention to treat 
analysis. 
Cost-effectiveness
The estimated mean ICER is around £19,000 per 
QALY using intention to treat (Table 34). Bootstrap 
simulations were undertaken to estimate the 
uncertainty around the treatment decision. At a 
cost-effectiveness threshold ICER of £20,000 per 
QALY, surgery has a probability of 46% of being 
cost-effective, and at a threshold of £30,000 per 
QALY surgery is 86% likely to be cost-effective 
(Figure 16). This indicates that there is considerable 
uncertainty about whether surgery is cost-effective 
using the R e f l u x  trial data.Within-trial cost-effectiveness results
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TABLE 34  Cost-effectiveness results for patients according to intention to treat and followed up for 1 year
Mean (95% CI)
Difference in mean costs (£) 1280 (1054–1468)
Difference in mean QALYs 0.066 (0.026–0.107)
ICER (£/QALY) 19,288
Probability surgery is cost-effective when threshold = £20,000 46%
Probability surgery is cost-effective when threshold = £30,000 86%
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
TABLE 35  Predicted unadjusted HRQoL and QALY and adjusted QALY for baseline differences in HRQoL for patients according to 
intention to treat and followed up for 1 year
Medical (n = 164) Surgical (n = 154)
Mean SE Mean SE
Baseline EQ-5D index 0.723 0.020 0.721 0.020
First follow-up EQ-5D 0.693 0.024 0.781 0.020
Second follow-up EQ-5D 0.709 0.021 0.754 0.020
Unadjusted QALY 0.704 0.020 0.773 0.017
QALY adjusted for baseline differences in EQ-5D  0.703 0.014 0.770 0.015
QALY, quality-adjusted life-years; SE, standard error.
TABLE 36  Predicted unadjusted HRQoL and QALY and adjusted QALY for baseline differences in HRQoL for patients receiving 
randomised treatment per protocol and followed up for 1 year
Medical (n = 155) Surgical (n = 104)
Mean SE Mean SE
Baseline EQ-5D index 0.736 0.020 0.722 0.023
First follow-up EQ-5D 0.700 0.024 0.800 0.024
Second follow-up EQ-5D 0.710 0.022 0.777 0.023
Unadjusted QALY 0.710 0.019 0.786 0.020
QALY adjusted for baseline differences in EQ-5D  0.706 0.014 0.793 0.017
QALY, quality-adjusted life-years; SE, standard error.
Sensitivity analyses
Whether a hospital visit was classified as a day-
case admission or an outpatient visit could differ 
between providers even if similar procedures were 
undertaken. As a sensitivity analysis, if all of the 
visits classified as day-case admissions in the trial 
incurred the average cost of an outpatient visit, 
this would reduce the incremental mean cost by 
£90, from £1280 to £1190. If all visits incurred the 
average cost of a day-case admission, this would 
increase the incremental cost by £76 to £1356.
A cost-effectiveness analysis was also undertaken for 
patients who received randomised treatment per 
protocol and who were followed up for 1 year (Table 
37). This estimated a greater mean difference in 
health benefit than the intention to treat analysis 
(0.088 QALYs) but a greater difference in mean Within-trial cost-effectiveness results
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cost per patient (£2049), and found surgery to be 
slightly less cost-effective with an ICER of £23,284. 
Further sensitivity analyses were undertaken and 
are described in the cost-effectiveness modelling 
chapter (Chapter 8).
Discussion
Cost-effectiveness analysis is intended to 
inform two separate decisions. First, which 
strategy (medical management or laparoscopic 
fundoplication) is most cost-effective for the 
management of patients with reflux who are stable 
on medication from the perspective of the NHS 
and, second, what value there is in acquiring 
further information about these strategies.
This chapter presented the expected differences 
in costs and health outcomes between laparoscopic 
surgery and medical management over 1 year 
using the R e f l u x  trial data only. Surgery was on 
average more effective (in terms of QALYs gained 
over 1 year) but more costly. The ICER of £19,000 
suggests that laparoscopic fundoplication might 
be cost-effective given that the threshold value 
in England and Wales is between £20,000 and 
£30,000.102 However, there is still considerable 
uncertainty about this result (probability that 
surgery is cost-effective between 46% and 86%). 
The main limitation, however, is that the within-
trial analysis ignores events, costs and health 
benefits that accrue after 1 year. The benefits of 
surgery are likely to be experienced by patients 
over the longer term,104 and the costs of medical 
management, even with widespread use of 
generics, are considerable when continued over a 
patient’s lifetime. Conversely, although no revisions 
of laparoscopic fundoplication were observed in the 
randomised surgical group over 1 year in this trial, 
the procedure may fail in the longer term.105 
More generally, new trials have to be placed in the 
context of existing evidence. Other randomised 
trials, and observational studies, have evaluated 
these strategies in the United Kingdom and 
elsewhere. A modelling framework can be used to 
TABLE 37  Cost-effectiveness results for patients receiving randomised treatment per protocol and followed up for 1 year
Mean (95% CI)
Difference in mean costs (£) 2049 (1907–2198)
Difference in mean QALYs 0.088 (0.046–0.130)
ICER (£/QALY) 23,284
Probability surgery is cost-effective when threshold = £20,000 19%
Probability surgery is cost-effective when threshold = £30,000 80%
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-years.
FIGURE 16  Cost-effectiveness plane for laparoscopic surgery versus medical management using an intention to treat analysis. This 
figure shows the difference in mean cost  and difference in mean quality-adjusted life-years (QALYs) per patient in 1000 bootstrap 
simulations of the data.
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extrapolate events, costs and health outcomes over 
a longer time horizon and to synthesise data from 
different sources to evaluate cost-effectiveness.106 
A modelling framework can also inform decisions 
about whether, and with what purpose, further 
research is needed. Value of information analysis 
can help to identify which variables contribute 
most to the overall uncertainty in the treatment 
decision and to quantify the benefits that would 
arise from having further information about these 
parameters.107 To address these questions, a revised 
version of the decision model described in Chapter 
3, updated with the evidence from the first year of 
the R e f l u x  trial, is described in the next chapter of 
this report. Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
69
Chapter 8  
Cost-effectiveness analysis
administered during follow-up are usually well 
recorded in these reports. Therefore, the model 
has been revised to define treatment failure in 
terms of change in treatment rather than return 
of symptoms.
Methods
Model structure
In the model patients follow a strategy of either 
immediate laparoscopic surgery or continuation 
of medical management (without an option of 
surgery following failure of medical management). 
In principle, immediate open surgery is feasible 
in this patient group but it is not considered 
here because it is widely considered to have been 
superseded by laparoscopic surgery, although 
conversion to open surgery is an option when 
laparoscopic surgery fails. Patients are assumed to 
be male and aged 45 when entering the model, 
which is the median age and commoner gender 
of patients in the R e f l u x  trial. Costs and health 
benefits are discounted at 3.5% per year and the 
price year is 2006.
The model structure is represented by Figure 17. 
As mentioned above, we define treatment failure 
following surgery as a change of treatment. Two 
options are considered for patients who fail 
surgery: patients may return to the use of anti-
reflux medication or they may undergo a revision 
of surgery. 
Introduction
The R e f l u x  trial compared a strategy of 
laparoscopic surgery with one of continued 
medical management for patients with reasonable 
symptom control on anti-reflux medications. Data 
are now available from the clinical trial for at least 
1 year after surgery for all patients. However, as 
discussed in the preceding chapter, as reflux is a 
chronic disease, an analysis that considers only 
events, costs and health benefits accruing over 
1 year is too restricted. To accurately determine 
cost-effectiveness, and the value of conducting 
further research, a modelling approach is required 
that extrapolates costs and health benefits over an 
appropriate time horizon and allows the synthesis 
of evidence from different sources. This chapter 
describes a long-term decision-analytic model 
including evidence from the R e f l u x  trial and other 
sources. 
The model presented here differs somewhat from 
the preliminary model described in Chapter 6. 
The preliminary model required evidence of the 
underlying disease process, that is, knowledge 
of whether treatment failure was temporary or 
permanent. Further treatment, such as dose 
adjustment, withdrawal of medication or revision 
of surgery, was then carried out conditional on 
the type of failure that occurred. However, in the 
reports from clinical trials, including the R e f l u x  
trial, the follow-up points are infrequent and/or the 
underlying disease is rarely observed or described 
consistently. On the other hand, the treatments 
FIGURE 17  Model structure diagram.
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TABLE 38  Surgical patients requiring medical management: results of laparoscopic surgery arms of randomised trials or observational 
studies
Study
Number 
of 
subjects
Years of 
follow-
up
Exposure 
(person-
years)
Number 
of failures
Rate of 
failure per 
person-
year
Proportion of 
failures at end 
of study (%)
Mahon et al., 2005108 109 1 109 2 0.018 1.8
Booth et al., 200242 179 4 716 19 0.027 10.6
Bammer et al., 200157 171 6.3 1094 24 0.022 14.0
Contini et al., 200238 103 1 103 5 0.049 4.9
Pessaux et al., 200245 1470 3 4410 60 0.014 4.1
Papasaras et al., 2005 109 289 2 578 150 0.260 51.9
Granderath et al., 2002110 27 4 108 2 0.019 7.4
Dassinger et al., 2004111 52 5 260 11 0.042 21.2
Bloomston et al., 2003112 100 1 100 19 0.190 19.0
Bloomston et al., 2003112 84 4 336 31 0.092 36.9
Vidal et al., 2006105 124 4.3 533.2 10 0.019 8.1
Madan and Minocha, 2006104 100 3 300 80 0.267 80.0
Laine et al., 199767 18 1 18 0 0.000 0.0
re f l u x  trial, 2006 104 1 104 14 0.135 13.5
All studies 8769 427 0.049
It is assumed that patients randomised to receive 
surgery who are found to be using medication at 
the end of a clinical trial are doing so to control 
reflux symptoms or symptoms related to surgery. 
It is further assumed that such patients will incur 
costs of medication indefinitely.
Although, in practice, patients who fail surgery 
may recommence anti-reflux drugs followed by 
revision of surgery, data on sequences of therapies 
were not available and so these events are treated 
as mutually exclusive competing risks in the model. 
Patients are assumed to have the same prognosis 
following revision as surgical patients who were not 
reoperated on. 
To estimate the rates of return to medical 
management and revision of surgery, all of the 
available studies, whether randomised or not, are 
treated as observational data. The rates of failures 
could simply be estimated as the total number 
of events divided by the total patient years of 
exposure (Tables 38 and 39), which would estimate 
the rate of return to medical management as 4.8 
per 100 patient-years. This estimate ignores any 
between-study heterogeneity, which might arise 
from patient selection, definition of outcomes, 
study design, surgical technique or other sources. 
To assess the assumption of homogeneity we also 
estimated the rate using a random effects Poisson 
regression using the statistical package WinBUGS 
(see Appendix 11 for code).113 We also explored 
whether any observed factors (length of follow-
up, study design) might explain some of the 
heterogeneity, but these variables were not found 
to be statistically significant and were omitted from 
the final model.
A state of treatment failure for patients following 
medical management is not defined because there 
is no feasible alternative treatment, that is, in this 
model (unlike the preliminary model), surgery 
is not an option for patients following medical 
management. The estimates of mean HRQoL after 
successful surgery and after medical management, 
and the standard errors, are those observed in 
the randomised R e f l u x  trial at 1 year as there are 
no other randomised trials comparing surgery 
with medication that have used a preference-
based utility instrument (see Chapter 6 for details 
of HRQoL data collected in the trial). HRQoL 
following treatment failure is estimated by the 
mean EQ-5D of all surgical patients (preference or 
randomised to surgery) who returned to medical 
management or required revision of surgery by 
1 year. The base-case assumption in the model is Health Technology Assessment 2008; Vol. 12: No. 31
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that, although HRQoL decreases with age at the 
same rate as that in the age- and sex-matched 
general population, proportionate differences in 
HRQoL between health states are maintained over 
time.
To account for the decline in HRQoL with age, the 
HRQoL for each outcome observed at the end of 
the trial was compared with the average HRQoL of 
the general population aged from 45 to 55 years.70 
It was assumed that this proportionate decrement 
of HRQoL was constant as the cohort aged (Table 
40). The age- and sex-stratified rate of death was 
taken from life tables,115 assuming that this patient 
group has a similar life expectancy to the UK 
general population after surgery. There is a small 
risk of operative mortality, estimated in a literature 
review as 4 deaths in 4000 procedures (see Chapter 
3).
During the first year of follow-up, 35% of patients 
require an outpatient visit and 35% a day-case or 
hospital admission following surgery compared 
with 15% who require an outpatient visit and 14% 
a day-case or hospital admission following medical 
management  (see Table 32; Chapter 7). The Nordic 
GORD study62 found that only a small proportion 
of patients required endoscopy after 12 months in 
either group, and here it is assumed that no further 
hospital admissions or outpatient visits are needed 
after 1 year other than revisions of surgery. 
TABLE 39  Surgical patients requiring re-operation during follow-up: results of single arms of randomised trials or observational studies
Study
Number of 
subjects Exposure (years)
Number of 
failures Rate of failure
Mahon et al., 2005108 50 50 2 0.040
Booth et al., 200242 179 716 11 0.015
Bammer et al., 200157 171 1094 5 0.005
Contini et al., 200238 103 103 0 0.000
Pessaux et al., 200245 1470 4410 35 0.008
Laine et al., 199767 18 18 0 0.000
re f l u x  trial, 2006 104 104 0 0.000
All studies 6495 53 0.008
TABLE 40  Mean (SE) HRQoL parameters used in the model
Parameter Mean SE Source
HRQoL following medical management 0.711 0.018 re f l u x  trial EQ-5D in randomised 
medical arm at 1 year
Additional HRQoL following successful laparoscopic 
surgery compared with medical management
0.071 0.028 re f l u x  trial EQ-5D in randomised 
surgery arm at 1 year (off drugs)
HRQoL following unsuccessful laparoscopic surgery (on 
medication)
0.686 0.048 re f l u x  trial EQ-5D in all patients 
who failed surgery at 1 year
Average HRQoL during year if undergoing re-
intervention
0.686 0.048 As for unsuccessful surgery
HRQoL for general population aged 45–55: men; women 0.84; 0.85 Kind et al., 199971
HRQoL for general population aged 55–65: men; women 0.78; 0.81 Kind et al.,199971
HRQoL for general population aged 65–75: men; women 0.78; 0.78 Kind et al., 199971
HRQoL for general population aged 75+: men; women 0.75; 0.71 Kind et al., 199971
Prevalence of GORD in population aged 18–60 0.0045 McDougall et al., 1996;30 Trimble 
et al., 1995114
GORD, gastro-oesphageal reflux disease; HRQoL, health-related quality of life; SE, standard error.Cost-effectiveness analysis
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The model time horizon is a patient’s lifetime. 
However, there are significant sources of 
uncertainty surrounding several model 
parameters given that the main source of data in 
the model, the R e f l u x  trial, has reported only 1 
year of follow-up. To provide a point of reference, 
the model analysis starts from a set of assumptions 
that are similar to those used in the within-trial 
cost-effectiveness analysis presented in Chapter 
7, which assumed that there were no differences 
in cost or health benefits beyond 1 year. This 
is unlikely to be the case and so a series of 
scenarios that relax these assumptions is explored, 
described in Box 1. 
One way of proceeding with this analysis might 
be to vary the time horizon over which the model 
is run, from 1 year up to a lifetime, in a series of 
scenarios; however, this would be naïve. Reflux is a 
chronic disease and, therefore, the only reasonable 
analysis is over a lifetime. The role of scenario 
analysis is to explore different assumptions 
about HRQoL, costs and clinical events over this 
time horizon. The sources for the alternative 
assumptions are presented in Chapter 3.
Analysis
The model was implemented in R, a 
programming language,116 as a discrete-time 
Markov model with a cycle length of 1 year. The 
model outputs were mean costs and QALYs in 
each treatment cohort. A probabilistic sensitivity 
analysis was used to represent the uncertainties 
in the model inputs.117 Gamma distributions were 
assigned to the decrements in utility compared 
with perfect health and the costs used in the 
model. Log-normal distributions were assigned to 
the rates of surgical failure. Values were randomly 
sampled from these distributions in 1000 Monte 
Carlo simulations and these were used as inputs 
to the model to give 1000 calculations of costs and 
QALYs for the cohort. The ICER was calculated 
as the ratio of the difference in expected costs to 
the difference in expected QALYs. The overall 
uncertainty in the treatment decision arising from 
uncertainty in the model inputs is represented by 
the proportion of iterations in which laparoscopic 
surgery is cost-effective, given a threshold value for 
the ICER. 
Results
Base-case analysis
The base-case analysis assumed that the relative 
treatment benefit from surgery endured for a 
lifetime, provided patients did not experience 
treatment failure. A summary of the assumptions 
used in the base-case analysis, and in alternative 
scenarios, is shown in Box 1. 
Under base-case assumptions, surgery had an 
additional mean cost of £847 and additional mean 
QALYs of 0.37 over the lifetime of the patients 
(Table 41), which generates an incremental cost 
BOX 1  Assumptions used in the within-trial analysis and alternative scenarios explored using a series of sensitivity analyses (see 
Chapter 3 for data sources for assumptions)
Scenario number
Assumption
Duration of cost of 
medication 
Duration of relative 
health benefit of 
surgery
Annual rate of 
conversion from 
surgery to medical
Annual rate of 
reoperation
11 (within-trial 
analysis)
1 year 1 year 13% convert year 1, 
0.0% thereafter
0.0%
15 (temporary QoL 
advantage)
Lifetime 5 years 13% per year up 
to year 2, 4.9% 
thereafter
0.0% year 1, 0.8% 
thereafter
16 (low rate of 
surgical failure)
Lifetime Lifetime 4.9% 0.8%
17 (base-case) Lifetime Lifetime 13% per year up 
to year 2, 4.9% 
thereafter
0.0% year 1, 0.8% 
thereafter
18 (very high rate of 
surgical failure)
Lifetime Lifetime 13% per year 0.8%
19 (high rate of 
surgical failure)
Lifetime Lifetime 8% per year 0.8%Health Technology Assessment 2008; Vol. 12: No. 31
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who fail. The analysis requires an estimate of the 
percentage of the population who would be eligible 
for surgery if it were cost-effective. A Spanish 
population survey (both sexes, ages 40–79 years) 
found that 287 out of 2500 (11%) interviewees 
used anti-reflux drugs, and 119 (4.8%) were stable 
(not having had reflux symptoms in the past year), 
although 43 (1.7%) acknowledged taking anti-
reflux drugs to prevent symptoms.118 This might 
be considered a conservative estimate of patients 
who could be considered for surgery. If we assume 
that about one-half of these might be excluded 
because of age, preference or co-morbidity, then 
prevalence is estimated at 1% of this population, 
equivalent to about 160,000 people in the UK.115 
Figure 18 shows an estimate of population EVPI at a 
range of values of the threshold ICER. EVPI in this 
case is increasing with the threshold ICER because 
at higher values of the ICER we are more willing 
to pay for the health benefits associated with 
surgery (and therefore more certain that surgery 
is the correct decision), but the consequences 
of a wrong decision are also greater (in terms of 
loss of health and wasted resources) and we are 
willing to pay more to avoid the possibility of 
these losses. Because the population is large, the 
model indicates that the EVPI is £300 million at 
a threshold ICER of £30,000, indicating that we 
would be willing to pay up to this to eliminate all of 
the uncertainty in the decision.
Figure 18 also shows the partial EVPI for selected 
sets of parameters. Partial EVPI is greatest for 
the rate of return to medical management post 
surgery together with the HRQoL of patients who 
fail. This indicates that almost all of the variation 
affecting the treatment decision is due to the 
interaction of these two parameters. Relatively 
little information is available on the HRQoL of 
patients who fail surgery; this could be captured in 
a longer follow-up but does not necessarily require 
a randomised trial. Figure 18 shows relatively little 
value of information in other parameters. However, 
this analysis does not on its own capture all of the 
uncertainty in the decision for two reasons. First, 
we have used mean estimates of HRQoL collected 
in a short-term trial to extrapolate over the longer 
term, without adjusting standard errors to take 
account of this additional uncertainty. There is, 
therefore, additional uncertainty over long-term 
differences in HRQoL, which is not captured in 
this value of information analysis. Second, we 
have assumed that the pooled rates of failure from 
observational studies of between 1 and 6 years are 
generalisable to our population, and that these 
rates will continue over the long term. We have 
attempted to represent this uncertainty as a series 
per additional QALY of about £3000. Uncertainty 
arising from imprecision of estimates of mean 
parameter values using base-case assumptions 
was characterised using a probabilistic sensitivity 
analysis. This showed that, at a threshold ICER 
of £20,000, surgery was about 74% likely to be 
cost-effective. However, this underestimates the 
uncertainty because the base-case model assumes 
the same imprecision about mean values of 
parameters for all years in the model, whereas the 
data on HRQoL is available only for the first year.
Alternative scenarios
Under the base-case assumptions, laparoscopic 
fundoplication is cost-effective compared with 
medical management at a relatively low threshold 
ICER. This is because we assume that, although the 
annual costs of treatment on medical management 
are relatively modest, these costs accrue over 
a lifetime and offset much of the upfront cost 
of surgery. Furthermore, there is an HRQoL 
advantage of surgery over medical management 
that is assumed to persist in the long term. We 
explored how alternative assumptions would affect 
these conclusions using different scenarios (Table 
41). Surgery is not likely to be cost-effective if 
HRQoL after successful surgery is similar to that 
on medical management after 5 years (scenario 15) 
or if the annual percentage of patients who restart 
anti-reflux medication after surgery is similar to 
that observed in the first year of the R e f l u x  trial 
(13%) (scenario 18). 
Value of information analysis
The value of conducting additional research that, 
in principle, would reduce parameter uncertainty 
can be estimated using value of information 
analysis. The expected value of perfect information 
(EVPI) is the amount that a decision-maker should 
be willing to pay to eliminate all uncertainty that 
arises because of imprecision in the parameters of 
the model. The partial EVPI represents the amount 
a decision-maker should be willing to pay to 
eliminate all uncertainty in individual parameters 
or a subset of parameters, given the uncertainties 
elsewhere in the model. 
To illustrate this we estimated the EVPI and partial 
EVPI for five sets of parameters: (1) the HRQoL 
of patients who fail surgery; (2) the estimates of 
HRQoL for all other model states; (3) the estimates 
of the annual rates of failure of surgery; (4) the 
estimates of unit costs used in the model; and (5) 
the rate of return to medical management post 
surgery together with the HRQoL of patients Health Technology Assessment 2008; Vol. 12: No. 31
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of scenario analyses. Taken together, this implies 
value in a continuing long-term follow-up to the 
randomised trial. The question remains, however, 
over how long this follow-up should optimally be. 
Discussion
This chapter has presented a decision-analytic 
model comparing laparoscopic surgery with 
medical management, using data from the R e f l u x  
trial and other sources to estimate cost-effectiveness 
over a lifetime. The results of this model are 
similar to those of the preliminary model 
presented in Chapter 6, which indicated that 
surgery was cost-effective but with a high degree 
of uncertainty. Other authors have examined the 
cost-effectiveness of laparoscopic surgery versus 
medical management. Cookson et al.29 found that 
laparoscopic surgery broke even compared with 
medical management after 8 years and was cost 
saving thereafter. Romagnuolo et al.28 evaluated 
cost-effectiveness over 5 years in a Canadian 
setting, in which both surgery and medical therapy 
is on average more expensive (generic formulations 
were not used in that model) than that found in 
the R e f l u x  trial and by Cookson in a UK setting. 
They concluded that there was little difference in 
HRQoL between the treatments and that surgery 
broke even relative to medical management after 3 
years. Arguedas et al.119 evaluated the strategies in 
a US setting with costs similar to Canada, assuming 
a relatively higher rate of symptom recurrence and 
FIGURE 18  Expected value of perfect information (EVPI) assuming a population of 160,000 patients in England and Wales, and partial 
EVPI for three sets of parameters: (1) all HRQoL parameters; (2) HRQoL after surgery failure; and (3) failure rates for surgery.
failure of surgery, and relatively lower differences 
in HRQoL between the treatments, and concluded 
that medical therapy dominated surgery using a 
10-year time horizon.
Although surgery seems likely to be cost-effective 
in terms of expected (mean) costs and health 
effects, there remains considerable uncertainty 
about this conclusion. Balances between risks and 
benefits and between costs and health gain will 
depend on patient characteristics such as age, the 
presence of serious co-morbidity and the severity 
of GORD symptoms. Furthermore, there are a 
number of practical issues to consider before 
the NHS could consider offering surgery to a 
wider range of patients who are currently stable 
on medical management. In particular, surgical 
capacity and availability of trained surgeons are 
potential barriers to implementation and should be 
addressed.
We have estimated the value of reducing some 
of the model uncertainty in the analysis of EVPI 
and partial EVPI, and through a series of scenario 
analyses. These have indicated that continued 
follow-up of the randomised trial would be 
valuable, particularly to obtain more information 
on HRQoL following surgery failure and the long-
term difference in HRQoL between strategies. 
Further research to obtain more information on the 
long-term HRQoL and prognosis of patients would 
be valuable. 
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Chapter 9  
Discrete choice experiment to measure 
preferences for treatment options
performed by using literature reviews, group 
discussions, interviews and direct questioning 
of individual subjects. Sometimes there is a 
predefined policy question, in which case the 
dimensions may already be predefined,122 
although that is not the case in this study.
Assigning plausible, actionable levels that are  •	
capable of being traded off. Again, these may 
be defined from the literature or by using any 
of the mechanisms mentioned above. 
Identification of the profiles to present to  •	
potential respondents. These profiles describe 
all of the possible configurations of the 
dimensions and levels identified in the first 
two stages. As the number of dimensions and 
levels increases, the number of possible profiles 
increases. Because of the potentially very large 
number of profiles that might exist, it is not 
desirable to present each profile to potential 
respondents. Various methods, for example 
computer software, catalogues (e.g. Hahn and 
Shapiro), websites and expert advice, are used 
to reduce the number of profiles for inclusion 
in the questionnaire to a manageable number 
while still allowing utilities to be inferred 
for all possible profiles. Within the DCE the 
scenarios must then be placed in choice sets. 
A number of approaches have been used to do 
this that vary in the extent to which they meet 
specific statistical design criteria (orthogonality, 
balance, minimum overlap and balanced 
utilities). 
Presentation of the choice sets to study  •	
participants. In the DCE, respondents are 
presented with the choice sets and asked to 
state which intervention they prefer. They 
make a series of choices and each choice 
indicates which scenario in a choice set would 
lead to the higher level of utility (or satisfaction 
or benefit). 
Data input and analysis using regression  •	
techniques and interpretation. This stage of 
the DCE helps establish the overall importance 
of dimensions, their relative importance, 
willingness of respondents to trade between 
them, and benefits (or utility scores) for the 
different combinations of levels of dimensions.
Introduction
This chapter reports an application of a discrete 
choice experiment (DCE) to measure patient 
preferences for treatment options for GORD. 
DCEs are increasingly recognised as an important 
method in health services research for measuring 
the strength of patients’ preferences (utility) for 
treatments and methods of delivery of care.120 
The aims of this work were to identify the strength 
of the trial participants’ preferences for the 
different treatments and outcomes of GORD; 
to investigate whether these preferences differ 
between the different arms of the trial; and finally 
to identify whether the mean benefits associated 
with each treatment vary. It should be noted that 
the utilities produced by the DCE reflect the 
preferences of people with GORD for the treatment 
and outcomes of GORD. As such, they are different 
from the utilities used to generate QALYs, which 
were based on the responses to the EQ-5D 
questionnaire and reflect the public preferences for 
the outcomes following treatment of GORD. It is 
these latter utilities that are arguably most useful 
for priority setting within the NHS.102
In the following section a brief description of the 
DCE approach is provided. This is followed by the 
methods used to achieve the aims stated above and 
the subsequent results. Finally, a brief discussion is 
presented outlining the strengths and limitations of 
the approach and the implications of the findings.
The discrete choice 
experiment approach
DCEs are based on random utility theory,121 
which defines a set of assumptions about desires 
and transforms them into a demand function 
describing the actions of a consumer under a 
defined set of circumstances. The following five 
stages are undertaken when a DCE is performed: 
Identification of attributes (i.e. different  •	
dimensions of the process or outcome of 
care) that are potentially important to the 
people with the condition under study. This is Discrete choice experiment to measure preferences for treatment options
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In addition to these five standard stages for a DCE, 
a sixth stage, specific to this study, was also added. 
In this stage the results of the DCE are combined 
with data from the trial on the actual level observed 
for each dimension for each treatment group. 
This provides a summary score for each treatment 
group, the treatment group with the highest score 
being associated with the greatest benefit.
Methods
The study was performed in two stages: a 
methodological stage to develop the questionnaire 
and an applied stage to derive the utility estimates 
for the different treatments and outcomes for 
GORD. 
Identification of 
dimensions and levels
As reported earlier, a qualitative study was 
performed to identify the potential issues related 
to GORD and its treatment that are important to 
patients (Chapter 4). The dimensions selected, 
therefore, represent those issues that are concerns 
to patients undergoing treatment for GORD. 
Some of the identified factors were combined 
into themes and, from these, four dimensions 
were eventually defined. These dimensions are 
frequency of troublesome symptoms, chance of 
serious complications, chance of undergoing 
surgery and chance of needing lifelong medication. 
Several considerations were taken into account 
when identifying the levels of the dimensions. 
They had to be realistic and they had to be set 
up in such a way that individuals could consider 
trade-off between improvements. The levels of 
the dimensions were derived from the trial data 
and discussions with gastroenterology experts. 
Table 42 provides a detailed description of the 
dimensions and levels that were used to develop 
the questionnaire. 
Which scenarios to present
Once the dimensions and levels have been 
identified they are combined to generate 
combinations of dimension levels referred to as 
profiles. The four dimensions and four levels 
yield 246 possible profiles, too many to present to 
individuals. Therefore, a fractional factorial design 
was used to reduce the profiles to a manageable 
level while still being able to infer utilities for 
all possible profiles. Existing literature suggests 
that individuals can manage between 9 and 16 
pairwise comparisons before they become bored 
or tired.123 The identified design had 16 profiles 
and they were randomly split into two different 
questionnaires containing 8 questions (see 
Appendix 12). The design was derived from a web-
based catalogue.124–126
Although profiles from fractional factorial designs 
have statistical properties for the estimation of 
parameters of general linear models, we needed 
to ensure that the choice sets generated from 
these profiles were statistically efficient. Therefore, 
tests for the properties of an efficient design were 
performed. The properties of an efficient design 
include:
Level balance •	  – this occurs when the levels of a 
dimension occur with equal frequency. 
Orthogonality •	  – this is satisfied when dimension 
levels are not correlated, that is, the joint 
occurrence of any two levels of different 
dimensions appears in profiles with a 
frequency that is equal to the product of their 
marginal frequencies (Addelman 1962, cited 
in Zwerina et al., 1996126). Therefore, the 
levels of dimensions appear in choice sets with 
equal frequency to each level of each other 
dimension. 
Minimum overlap •	  – this means that the 
probability that a dimension level repeats 
itself in each choice set should be as small as 
possible, especially in instances when there is 
more than one choice, e.g. choice A and choice 
B. This is an important issue as the differences 
in dimension levels are only useful within a 
choice set if the respondents trade these levels. 
When this property is violated the choice sets 
provide no information on the dimension’s 
value. 
The set of alternatives is typically the same for all 
subjects and the explanatory variables are all choice 
specific. Individuals were asked to make a number 
of such choices, and using the responses from these 
the preferences for alternative profiles could be 
elicited. 
Eliciting preferences
Once the scenarios to be presented to patients were 
identified, preferences for these scenarios were 
obtained by using a forced choice approach. An 
example of the choices presented to participants is 
shown in Figure 19; respondents were asked which 
option they would choose, ‘A’ or ‘B’. Health Technology Assessment 2008; Vol. 12: No. 31
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TABLE 42  Dimensions and levels used to develop the questionnaire for the discrete choice experiment
Dimension and description Level of difficulty
Frequency of troublesome symptoms  This aspect describes the frequency with which 
you may experience troublesome symptoms of GORD. These symptoms could include 
heartburn (a burning sensation that moves up the chest), acid reflux (an acid taste in mouth), 
excessive wind in lower bowel or trapped in stomach, difficulty eating and swallowing food, 
troublesome bowel movements (diarrhoea/constipation), and experiencing difficulty with lying 
down or getting to sleep
Not at all
Once a week
Two or three times a week
Most days or every day
Chance of serious complications requiring hospitalisation  This aspect refers to the 
possibility that you may experience complications/side effects as a result of your GORD 
treatment. These complications/side effects could lead to you spending a few days in hospital. 
They could include bleeding that could lead to anaemia, scarring of the oesophagus, or 
difficulty or pain when swallowing
1 in 800 (0.1%) people
1 in 500 (0.2%) people
1 in 300 (0.3%) people
1 in 100 (1%) people
Chance of undergoing surgery  This aspect describes the chance that you might have to 
undergo any surgery to treat your GORD symptoms
1 in 20 (5%) people
1 in 3 (33%) people
2 in 3 (66%) people
5 in 6 (83%) people
Chance of needing lifelong medication  This aspect describes the chance that you might 
have to take medication (e.g. PPIs) over a long period of time (months or years) for GORD
1 in 20 (5%) people
1 in 3 (33%) people
2 in 3 (66%) people
5 in 6 (83%) people
GORD, gastro-oesophageal reflux disease; PPI, proton pump inhibitor.
FIGURE 19  Example of discrete choice experiment question presented to trial participants.
Choice 1  Which option would you choose?
Option A Option B
Frequency of troublesome symptoms Most days or 
every day
Not at all
Chance of serious complications requiring hospitalisation 1 in 500 1 in 300
Chance of undergoing surgery 1 in 3 2 in 3
Chance of needing lifelong medication 5 in 6  1  in 20
(Tick one box only)
option A option B
One important issue in preference elicitation is 
whose preferences should be elicited. Patients with 
the experience of both disease and treatment were 
considered appropriate for this study and therefore 
the completed questionnaire was sent to all active 
participants in the R e f l u x  trial during August 2006. 
Piloting the questionnaire
The sample for piloting the questionnaire 
was obtained from individuals attending a 
gastroenterology clinic in Aberdeen. Patients 
were screened by a clinician and those assessed as 
having GORD were asked to complete the DCE Discrete choice experiment to measure preferences for treatment options
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questionnaire with a researcher (LV). The aim of 
the pilot work was to ensure that the guidance 
notes provided with the questionnaire were clear 
and that patients could understand them and 
that they were able to perform the task of making 
choices. The respondents were asked to complete 
the questionnaire using the guidance information 
provided and they were then asked about its 
readability and acceptability. They indicated 
that the guidance notes were clear and easy to 
understand and that they were able to answer the 
questions without much difficulty. 
Consistency of responses
An important aspect of a DCE is that respondents 
should behave in a rational manner when making 
choices. Rationality within DCEs is mainly tested 
using non-satiation (dominance) tests. These tests 
are, however, perceived as easy to satisfy.120 For 
this reason more sophisticated expansion property 
tests were conducted.127 This involved adding two 
consistency questions to the questionnaire. 
Respondents were first asked to choose the worse 
of two situations (A or B). In the consistency 
question, which was presented as a non-consecutive 
question, this choice was widened to a set of three 
situations (A, B or C). As with the simple two 
situation question, respondents were asked to 
choose one of the three situations (see example of 
both questionnaires in Appendix 12). A respondent 
was believed to behave rationally if the choice 
they made in the two situation question did not 
conflict with the choice they made when faced with 
the three situation question. For example, if the 
respondent choose situation B in the first choice 
set, then they should not choose situation A in the 
expanded choice set. Similarly, if the respondent 
chose situation A in the first choice set, then they 
should not choose situation B in the expanded 
choice set. 
A sensitivity analysis was performed that excluded 
those respondents who failed the consistency test 
(i.e. they gave an inconsistent response in both 
consistency questions). 
Estimating utilities
To establish the importance of the various 
dimensions, the relationship between the 
dimensions and utility must be specified. The 
linear additive model assumes that the overall 
valuation or utility derived from any combination 
of dimensions is given by the sum of the values 
of the separate dimensions. In this model the 
reference group for the modelling analysis was 
the best level of each dimension. This means that 
the results from the DCE will be able to illustrate 
how the different combinations of dimensions and 
levels compare with the best possible combination 
of dimensions and levels from the DCE.
The linear additive model for a simple model was 
specified as: 
U = β1frequency + β2frequency + β3frequency + 
β4serious complications + β5surgery + β6lifelong 
medication
where ‘U’ is the utility or preference score for an 
outcome with a given level of each dimension; 
‘frequency’ is the occurrence of troublesome 
symptoms and, as it was a categorical variable, 
dummy values were used for the analysis for 
each level; ‘serious complications’ is the chance 
of complications requiring hospitalisation; 
‘surgery’ is the chance of undergoing surgery; 
and ‘lifelong medication’ is the chance of needing 
lifelong medication. The parameters β1–β6 are the 
coefficients of the model to be estimated. 
The coefficients indicate the relative importance, 
or weight, of a unit change in that dimension 
in terms of overall benefit. The rate at which 
respondents are willing to trade between these 
dimensions (i.e. how much of the dimension they 
are willing to give up for improvements in other 
dimensions) is shown by the ratio of the coefficients 
(i.e. the marginal rate of substitution). For example, 
β5/β6 indicates how much of a change in the chance 
of having lifelong medication would be required 
if there was a 10% change in the chance of having 
surgery so that overall utility remains constant.
The internal validity (the extent to which the 
results are consistent with economic theory or a 
priori expectations) of the DCE can be determined 
by the results from the regression analysis. Given 
that the higher the chance an episode will be 
experienced, the less it will be preferred, we 
anticipated that the dimensions would have a 
negative sign in the regression equation. 
Econometric techniques were used to analyse the 
DCE responses and to estimate a value such that 
the utility weights could be estimated for all of the 
outcomes in the instrument. As described above, 
the best level was used as the comparator for all 
dimensions. As participants provided multiple 
responses, a conditional fixed-effects logistic 
regression model was used to analyse the response 
data. Two models were estimated: a main model Health Technology Assessment 2008; Vol. 12: No. 31
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that measured preferences across the whole group 
and a further model that was used to establish 
whether the responses of individuals differed based 
upon the trial group to which they belonged. 
Although it would be possible to estimate a 
regression model for each arm of the study (i.e. 
to estimate four separate models), it would not 
be appropriate to make comparisons between the 
models. A more appropriate way of considering 
the effect that people’s initial preferences for a 
particular treatment have on the choices they 
make when responding to the DCE is to include 
interaction terms to explore the extent to which 
the preferences of those in the two preference 
arms differed. Interaction terms were included 
to explore whether the preferences of specific 
groups (e.g. preferred medicine, preferred surgery, 
randomised surgery, randomised medicine) for 
each dimension included in the model differed 
from the preferences of the whole model. 
Sensitivity analyses
The analyses described above included all 
responses, even those for which there was evidence 
that the responses were not consistent. Therefore, 
in a first sensitivity analysis the effect of excluding 
the inconsistent responses from the main model 
was investigated.
The methods described above involve making the 
assumption that preferences for a unit change in 
risk are independent of the scale of that risk (i.e. 
a 10% change in risk from 4% to 14% would be 
valued the same as a 10% change in risk from 70% 
to 80%). To investigate whether it was appropriate 
to assume a linear relationship between the levels 
of each dimension, a quadratic variable (surgery 1, 
lifelong medicines 1,  and serious complications 1) 
was included for each dimension. 
Calculation of utilities for 
each treatment group
The results of the econometric analyses can 
be used to estimate a utility score. This can be 
accomplished by combining the information on 
the levels for each dimension, which was derived 
directly from the trial, with the coefficient for that 
dimension. Table 43 gives an example of how a 
utility might be calculated for hypothetical levels 
and coefficients.
Similar scores can be calculated for data taken from 
each arm of the trial. The scores from the different 
arms could be compared relative to each other (i.e. 
the ratio of the scores from two groups), but, to aid 
this comparison, a score has been estimated for 
both the worst possible and the best case situation 
(which is by definition 0). Using the coefficient 
values from Table 43, and assuming that people 
experienced the worst level of each dimension (i.e. 
symptoms most days/every day, 100% chance of 
surgery, lifelong medications and a hypothetical 
maximum of 10% for complications), the worst case 
scenario would be associated with a score of –210. 
Therefore, if the worst case scenario was rescaled 
to 0, then the best case scenario would equal +210 
and the state described in Table 43 would have 
a score of 175 (i.e. 210–35). As a consequence it 
can be seen that the state described in Table 43 is 
equivalent to 0.833 (i.e. 175/210) of the utility of 
the hypothetical best case scenario. 
Selection of respondents
The sample of respondents used in this DCE was 
made up of R e f l u x  trial participants. They were 
considered to be the appropriate group as they 
had already undergone treatment. As described 
in earlier chapters, the trial was composed of four 
arms: two arms involved the randomisation of 
TABLE 43  Example of the calculation of a utility score from the results of a discrete choice experiment
Dimension Coefficient Actual level (%) Utility
Troublesome symptoms
  None 0.00 (baseline) 60 0.00
  Once a week –0.05 20 –1.00
  Two/three times a week –0.20 15 –3.00
  Most days/every day –0.40 5 –2.00
Serious complications –1.00 per 0.1% change 0.1 –1.00
Surgery –5.00 per 10% change 40 –20.00
Lifelong medication –2.00 per 10% change 40 –8.00
Total score –35.00Discrete choice experiment to measure preferences for treatment options
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individuals to either medical or surgical treatment 
and the other two arms included those who 
had expressed a preference for either medical 
management or surgical treatment.
Results
Of the 705 questionnaires sent out, 441 (63%) were 
returned; 17(3%) were returned uncompleted and 
424 (60%) were fully or partially completed. Of 
these 424 questionnaires, 87 (21%) were from the 
randomised surgical group, 103 (24%) were from 
the randomised medical group, and 109 (26%) and 
125 (29%) were from the preference medical and 
preference surgical groups respectively.
Consistency of responses
Ten (2%) people failed to answer the two 
consistency test questions consistently and so 
were excluded when the sensitivity analysis was 
performed. 
Econometric analysis 
The conditional logistic regression analysis was 
based on all of the respondents who returned 
completed questionnaires. Out of a possible 6784 
(424 × 16) observations from the 424 completed 
and partially completed questionnaires, there were 
6434 observations and 350 missing responses. Of 
these 6434 observations, 1392 (21%) were from the 
randomised surgical group, 1648 (24%) were from 
the randomised medical group, and 1744 (26%) 
and 2000 (29%) were from the preference medical 
and preference surgical groups respectively.
A sensitivity analysis performed after excluding the 
ten respondents who had failed both consistency 
tests was based on 6274 observations from 414 
respondents. 
Analysis based on the whole sample 
including inconsistent responses
The sign of the coefficient indicates the direction of 
the influence of preferences. All other things being 
equal, a higher negative coefficient indicates a 
higher negative influence on the overall preference 
(see Appendix 13). The regression coefficients all 
had the expected sign (negative) and decreased 
as expected (i.e. as more difficulty is experienced, 
the coefficient becomes larger). There was no 
statistically significant difference between the first 
two levels for the first dimension, frequency of 
troublesome symptoms. Therefore, in subsequent 
analyses these two levels were combined. 
The results of the regression model in which 
the first two levels for frequency of troublesome 
symptoms were combined are presented in Table 
44, and the results of the initial regression model 
in which the levels for frequency of troublesome 
symptoms were not combined are presented in 
Appendix 13. 
The absolute importance of the parameters 
included in the analysis can be established by 
comparing the sizes of the regression coefficients. 
As Table 44 illustrates, the most important factor 
was serious complications with a coefficient of 
–5.454, indicating that respondents experienced 
greater disutility for a unit increase (i.e. a 0.1% 
increase) in the probability of occurrence of serious 
complications than for a unit change in any other 
factor. The chance of undergoing surgery (–5.212 
per 10% change), the chance of having lifelong 
medications (–4.797 per 10% change) and the 
chance of having troublesome symptoms most days/
every day (–1.130 per 10% change) were the next 
largest dimensions.
TABLE 44  The regression model for the whole sample with the first two levels for frequency of troublesome symptoms combined
Dimension Coefficient Standard error p-value 95% CI
Troublesome symptoms
Two or three times a week –0.397 0.061 0.000 –0.516 to –0.277
Most days/every day –1.130 0.065 0.000 –1.258 to –1.001
Serious complications –5.454 0.661 0.000 –6.750 to –4.158
Surgery –5.212 0.845 0.000 –6.868 to –3.556
Lifelong medication –4.797 0.685 0.000 –6.139 to –3.455
CI, confidence interval.
Conditional (fixed-effects) logistic regression: number of obs = 6434, LR χ2(5) = 491, prob > χ2 = 0.0000.
Log likelihood = –1984.3546, pseudo r2 = 0.1101.Health Technology Assessment 2008; Vol. 12: No. 31
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TABLE 45  The regression model including interaction terms for surgery and lifelong medication 
Dimension Coefficient Standard error p-value 95% CI
Troublesome symptoms
Two or three times a week –0.406 0.062 0.000 –0.526 to –0.285
Most days/every day –1.146 0.066 0.000 –1.275 to –1.016
Serious complications –5.525 0.664 0.000 –6.826 to –4.224
Surgery –5.573 1.255 0.000 –8.034 to –3.112
Lifelong medication –3.495 1.009 0.001 –5.473 to –1.516
Interactions
Surgery for those that preferred 
medicine
–5.017 2.143 0.019 –9.218 to –0.816
Surgery for those that preferred 
surgery
5.491 2.008 0.006 1.555–9.427
Lifelong medication for those that 
preferred surgery 
–5.258 1.632 0.001 –8.457 to –2.059
Lifelong medication for those that 
preferred medicine
0.772 1.695 0.649 –2.549 to 4.094
CI, confidence interval.
Conditional (fixed-effects) logistic regression: number of obs = 6434, LR χ2(10) = 525.48, prob > χ2 = 0.0000.
Log likelihood = –1967.1124, pseudo r2 = 0.1178.
The relative importance of the coefficients was 
estimated by investigating the marginal rates 
of substitution between coefficients. In absolute 
terms (i.e. ignoring the sign of the coefficient) 
the smallest coefficient was that for experiencing 
troublesome symptoms two or three time per week. 
Experiencing symptoms most days was over 2.8 
times as important, whereas a 0.1% change in the 
risk of experiencing serious complications was 13.7 
times more important. Similar rates were calculated 
for a 10% change in the risks of surgery and 
lifelong medication, which were 1.3 times and 1.2 
times as important respectively (a full description 
of marginal rates of substitution between all 
coefficients is provided in Appendix 13).
Analysis to investigate whether 
preferences differ between the 
four groups of the r e f l u x  trial
Further analysis was performed to establish the 
effect of the treatment group that patients were 
assigned to, either through their own preferences 
or through randomisation. There was no evidence 
of any differences in preferences in the four 
treatment groups for either troublesome symptoms 
or serious complications. However, as would be 
anticipated, preferences did differ for surgery 
and lifelong medications. The exception to this 
was that there was no evidence of a statistically 
significant difference in the preferences for 
lifelong medication amongst those people that had 
expressed a preference for medication compared 
with the preferences from the whole sample. 
The results of the analysis investigating whether 
preferences varied between treatment groups 
is reported in Table 45 (interaction terms for 
troublesome symptoms or serious complications 
have been omitted as they were not statistically 
significant). 
As would be expected, the results of this analysis 
indicate that people who expressed a preference 
for one treatment would experience a further 
loss of utility if they received the other treatment 
(indicated by the negative signs for ‘surgery for 
those that preferred medicine’ and ‘lifelong 
medication for those that preferred surgery’). 
Similarly, individuals who received the treatment 
that they preferred would experience less loss of 
utility (indicated by the positive signs for ‘lifelong 
medication for those that preferred medicine’ and 
‘surgery for those that preferred surgery’).
Sensitivity analyses
Analysis based on the whole sample 
but excluding inconsistent responses
The econometric analysis was repeated for the 
whole sample, this time omitting those individuals Discrete choice experiment to measure preferences for treatment options
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TABLE 46  The regression model for the whole sample omitting the inconsistent responses
Dimension Coefficient Standard error p-value 95% CI
Troublesome symptoms
  Two or three times a week –0.415 0.062 0.000 –0.537 to –0.415
  Most days/every day –1.166 0.067 0.000 –1.297 to –1.166
Serious complications –5.649 0.673 0.000 –6.967 to –5.648
Surgery –4.754 0.858 0.000 –6.435 to –3.072
Lifelong medication –5.060 0.696 0.000 –6.425 to –3.696
CI, confidence interval.
Conditional (fixed-effects) logistic regression: number of obs = 6274, LR χ2(5) = 497.95, prob > χ2 = 0.0000.
Log likelihood = –1925.4265, pseudo r2 = 0.1145.
TABLE 47  The regression model for the whole sample but including quadratic functions for continuous variables
Dimension Coefficient Standard error p-value 95% CI
Troublesome symptoms
  Two or three times a week –0.398 0.061 0.000 –0.518 to –0.278
  Most days/every day –1.127 0.065 0.000 –1.256 to –0.999
Serious complications –27.853 4.142 0.000 –35.971 to –19.736
  Quadratic function 1948.761 353.906 0.000 1255.118–2642.404
Surgery –12.868 3.921 0.001 –20.554 to –5.182
  Quadratic function 9.109 4.390 0.038 0.505–17.713
Lifelong medication –4.828 2.858 0.091 –10.430 to 0.774
  Quadratic function –0.046 0.3133 0.988 –6.187 to 6.095
CI, confidence interval.
Conditional (fixed-effects) logistic regression: number of obs = 6434, LR χ2(8) = 525.85, prob > χ2 = 0.0000.
Log likelihood = –1966.929, pseudo r2 = 0.1179.
who failed the consistency tests (Table 46). As 
reported above, this had the effect of reducing 
the sample size by ten respondents and 160 
observations. The results of this analysis are 
reported in Table 46, although the values for all 
attributes are higher except for the chance of 
undergoing surgery.
Analysis based on the whole sample 
but including quadratic functions
Quadratic functions were used in the model to 
establish the linear relationships in the continuous 
variables. All coefficients, except the chance of 
having lifelong medication and its associated 
quadratic function, were significant at the 5% 
level (Table 47). The quadratic functions for 
serious complications and chance of surgery are 
both positive and this indicates that, as these 
risks increase, the disutility still increases, but at a 
decreasing rate. However, these results should only 
be used to indicate that there may not be a linear 
relationship for serious complications and surgery. 
This is because the quadratic function is only a 
simple method and can provide estimates of utility 
that are counterintuitive for some levels of risk, for 
example utility increases as risk increases. 
Estimation of utility scores 
for each treatment group
Table 48 reports the trial findings for the 
dimensions included in the DCE. Using these 
data and the results of the DCE regression model 
reported in Table 45 it is possible to calculate utility Health Technology Assessment 2008; Vol. 12: No. 31
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TABLE 48  Data on dimension levels for each group from the trial
Dimension
Randomised 
surgical
Randomised 
medical
Preference 
surgical
Preference 
medical
Frequency of troublesome symptoms (heartburn only, %)
  Not at all 63 29 73 32
  Once a week 12 22 11 29
  Two or three times a week 14 23 7 21
  Most days or every day 10 26 9 19
Chance of serious complications requiring hospitalisation (%)
Reflux related (obtained from different 
source)
1 0.12 1 0.12
Chance of undergoing surgery (%) 62.3 5.6 84.0 1.6
Chance of needing lifelong medication at 12 
months (%)
33.8 84.8 19.6 85.9
TABLE 49  Utility scores for each group in the trial and for the worst case scenario
Dimension
Randomised 
surgical
Randomised 
medical
Preference 
surgical
Preference 
medical Worst case
Frequency of troublesome symptoms (heartburn only)
  Not at all 0.00 0.00 0.00 0.00 0.00
  Once a week 0.00 0.00 0.00 0.00 0.00
  Two or three times a week –5.68 –9.34 –2.84 –8.53 0.00
  Most days or every day –11.46 –29.80 –10.31 –21.77 –114.60
Chance of serious complications requiring hospitalisation
  Reflux related (obtained from 
different source)
–55.25 –6.63 –5.52 –6.63 –552.48
Chance of undergoing surgery –34.72 –3.12 –46.81 –0.89 –55.73
Chance of needing lifelong medication 
at 12 months
–11.81 –29.64 –6.85 –29.92 –34.95
Interactions   
  Surgery for those who preferred 
medicine
      –0.80  
  Surgery for those who preferred 
surgery
    46.12  
  Lifelong medication for those who 
preferred surgery
    –17.77 –52.58
  Lifelong medication for those who 
preferred medicine
       
Total utility –118.92 –78.52 –43.99 –68.54 –810.4
scores for each of the four groups (Table 49). Also 
included in Table 49 are the utility scores for the 
worst case scenario (by default the utility score for 
the best case scenario is 0). Using the approach 
outlined in the methods section, the relative weight 
of each of the four trial groups relative to the 
best case scenario was estimated from these data 
(Table 50).
As Table 49 illustrates, the largest component of 
total utility comes from serious complications. The 
data presented in this table also serve to illustrate Discrete choice experiment to measure preferences for treatment options
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the importance of patients’ preferences for utility. 
For example, the utility gained by a person who 
prefers surgery receiving the treatment they prefer 
(46.1) is just less than the disutility associated with 
surgery (46.8). 
As indicated above, the comparisons between 
the four treatment groups are best informed by 
considering their relative weights. As there are 
several different relative weights that could be 
calculated, it was decided to compare the mean 
total utility for each arm with the total utility 
that is implied for the best possible combination 
of attributes and levels (the last column of Table 
50). As the data in this table illustrate, relative to 
the best case, the preference surgical group has 
the highest weight and the randomised surgical 
group has the lowest weight. In this situation the 
preference arms are associated with higher mean 
utilities than the randomised arms. 
Discussion
The aim of this chapter was to use a DCE to 
explore the strength of preference for the 
treatment and outcomes of GORD. This approach 
has been used to measure preferences of GORD 
patients previously128,129 but this earlier work 
sought to establish willingness to pay for complete 
symptom relief of GORD and for diagnostic 
uncertainty. The DCE reported in this chapter 
was different in that it attempted to explore 
preferences for the outcomes of treatment (e.g. 
troublesome symptoms and serious complications) 
and preferences for the process by which these 
outcomes were obtained. 
The results of the DCE indicate that the 
most important single dimension is serious 
complications, followed by a 10% change in the 
chance of having surgery or receiving lifelong 
medication. Suffering troublesome symptoms 
most days was less important, although the unit of 
analysis was a 1% chance of this event occurring. 
There was no evidence that respondents placed any 
importance on suffering troublesome symptoms 
once a week in comparison with no symptoms. 
The group that was associated with the highest 
utility relative to a best case situation was the 
preference surgical group, and the group that 
was associated with the lowest utility was the 
randomised surgical group. If the effect of serious 
complications is removed from the consideration 
of utility, then the preference groups are associated 
with higher levels of utility relative to the best case 
than the randomised groups. Furthermore, the 
surgical group is associated with higher utility than 
the medical group.
The exclusion of serious complications from 
the consideration of utility might be considered 
contentious. However, an analysis was conducted to 
explore whether the preferences for the continuous 
variables (risk of serious complications, risk of 
surgery and risk of receiving lifelong medication) 
in the econometric analysis were linear. The results 
of this analysis indicated that, although utility fell 
as risk increased, it fell at a decreasing rate for 
both the risk of serious complications and surgery 
(there was no evidence of this effect for lifelong 
medication). The implication of this is that it is 
possible that there is little or no difference in 
the loss of utility caused by serious complications 
TABLE 50  Relative utility of each trial arm relative to the utility of the best case scenario
Situation
Loss of utility from the 
best possible combination 
of attributes and levelsa
Gain in utility from 
the worst possible 
combination of attributes 
and levels 
Relative weight compared 
with the best case
Best case 0 810 1.000
Worst case –810 0 0.000
Randomised surgical –119 691 0.853
Randomised medical –79 732 0.903
Preference surgical –44 766 0.946
Preference medical –69 742 0.915
a Estimated from Table 49.Health Technology Assessment 2008; Vol. 12: No. 31
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between groups. Research is required to further 
investigate how this non-linearity in preferences 
might be most appropriately modelled, as the 
quadratic function would result in implausible 
utility estimates for higher risks of serious 
complications than were considered in the DCE 
questionnaire.
The results of the analysis presented in this chapter 
also provide some insight into the importance of 
people’s preferences for treatment with respect to 
utility. For example, people who have a preference 
for medicine but who actually undergo surgery 
experience almost twice the loss of utility (1.059 
or –0.557 + –0.502) as those people in the 
randomised arm who receive surgery (–0.557) for a 
1% increase in the risk of surgery. Similarly, people 
who preferred surgery and received surgery lost 
less utility (–0.008 or –0.557 + 0.549). This result 
indicates the importance of patient choice when 
decisions are made about which type of treatment 
to provide.
Some of the limitations of the analysis reported in 
this chapter have already been described but one 
further limitation relates to how the information 
derived by the DCE could have been used in 
the economic model reported earlier. It was 
not possible, nor was it planned, for these two 
‘economic’ elements to be integrated. Indeed, 
methods to integrate DCEs into a trial remain 
relatively undeveloped. However, future work 
should consider how a DCE and an economic 
model conducted as part of a trial analysis can be 
developed in an integrated fashion. It is likely that 
this will involve the attributes and levels of the 
DCE being reflected in the model structure, with 
the values of attribute levels being produced by the 
model and fed into the estimation of utilities as 
part of the DCE analysis. Any attempt to integrate 
these approaches would be facilitated by the use of 
a common continuous measure, such as willingness 
to pay, so that all dimensions could be valued in 
terms of this numeraire.
The methods used to analyse and present the 
results of the DCE have limitations. One of 
the main limitations is the limited handling of 
uncertainty in the analysis. In economic studies it is 
expected that an extensive sensitivity analysis would 
be conducted to assess how robust the conclusions 
are. Increasingly, as exemplified by the economic 
evaluation presented in Chapter 7, it is becoming 
expected that a probabilistic sensitivity analysis will 
be used to develop credible intervals around mean 
estimates. Although sensitivity analysis has been 
performed as part of the work reported in this 
chapter, probabilistic sensitivity analysis has not 
been conducted. Probabilistic sensitivity analysis 
would also help overcome a further limitation of 
the DCE. When analysing the DCE, we followed 
the common econometric convention of combining 
levels of dimensions when there was no evidence of 
a statistically significant difference and of dropping 
parameters from an analysis when the coefficients 
were not statistically significant. There is some 
debate about how appropriate this approach is as 
it reduces the information available to decision-
makers. However, with probabilistic sensitivity 
analysis a full model, including both statistically 
significant and insignificant coefficients, can be 
used to develop both mean utility scores and 
credible intervals. Therefore, further work might 
focus on conducting a probabilistic sensitivity 
analysis. 
DCEs use hypothetical questions and, as such, 
they have been criticised. This is because it is 
unclear whether people would pick these scenarios 
if they were faced with these choices in real life. 
Nevertheless, the respondents to the DCE all had 
experience of GORD and its treatment (either 
medical, surgical or both); hence, it was hoped 
that the respondents would be able to consider 
the choices and trade-offs involved in each choice 
question. 
A final concern relates to the number of choice 
questions to present to potential respondents. 
The greater the number of dimensions and 
levels that are considered relevant the greater 
the number of possible scenarios that individuals 
could potentially be presented with. Experimental 
design techniques were used to reduce the number 
of scenarios that were presented to individuals 
while still allowing for utilities to be inferred for 
all possible scenarios. However, even after the use 
of these techniques it was felt that the number of 
questions to be presented (n = 16) was too great. 
As a consequence, the questions were randomly 
split into two questionnaires, each containing eight 
questions. It was hoped that this would increase the 
completion rate of the questionnaire, although it 
did have the effect of reducing our ability to detect 
important differences in preferences. Overall, the 
completion rate achieved was quite high for a DCE 
questionnaire (which are thought to be cognitively 
demanding on respondents) and this may be 
attributed to the relatively short length of the 
questionnaire. Discrete choice experiment to measure preferences for treatment options
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Conclusions
The results of the DCE presented in this chapter 
complement the evidence reported in earlier 
chapters. The results also aid the interpretation 
of the clinical evidence by indicating the 
importance placed on type of treatment and 
the ability of a treatment to resolve symptoms. 
The most important single dimension is serious 
complications, followed by changes in surgery, 
lifelong medication and troublesome symptoms 
most days. There was no statistically significant 
evidence that respondents placed any importance 
on suffering troublesome symptoms once a week 
in comparison with no symptoms. Relative to 
a best case situation the trial arm associated 
with the highest mean utility was the preference 
surgical group and that associated with the lowest 
mean utility was the randomised surgical group. 
The utility associated with surgery is dependent 
upon the risk of serious complications, which 
was assumed to be greater than that for lifelong 
medical treatment. If the effect of serious 
complications is removed from the consideration 
of utility, the preference arms are associated with 
higher levels of utility than the randomised groups. 
Furthermore, the surgical arms are associated with 
higher utility than the medical arms. Thus, the 
results of the analysis indicate the importance of 
quantifying the risk of serious complications and 
of considering patient choice when decisions are 
made about which types of treatment to provide 
and the type of treatment to recommend. 
Additional further research is also indicated. Part 
of this research should focus on how approaches 
such as DCEs can be made more useful to trials-
based research. A more specific research need is 
to consider how best to describe the imprecision 
surrounding the mean estimates of utilities that are 
generated.Health Technology Assessment 2008; Vol. 12: No. 31
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Chapter 10  
Conclusions
 Implications for health care and 
recommendations for research
Current follow-up is to the equivalent of 12 months 
after surgery. In comparison with the results 
obtained at 3 months there were sustained better 
scores but with some evidence of attenuation of 
the differences. For example, the number taking 
reflux-related drugs after surgery went up from 
around 9% to 14%. Narrowing of differences was 
most marked for the EQ-5D health status measure. 
It is possible that some of the ‘improvement’ 
is due to a placebo effect of surgery and one 
explanation of any attenuation of difference is that 
the placebo effect has diminished over time. This 
could be clarified by further follow-up to find out if 
differences are sustained or whether there is more 
narrowing of the differences.
In addition to the randomised groups the trial 
also had two preference groups, which aid 
interpretation of the randomised trial results. As 
a group, the preference surgical participants had 
the lowest baseline R e f l u x  scores (worst symptoms) 
and the preference medical group the highest (with 
the randomised groups between them (see Figure 
14). After surgery the preference surgical group 
had scores that rose to the level of the preference 
medical group and by 12 months they were the 
better of the two groups. The preference groups 
give an indication of likely behaviour if surgery 
were to become more freely available. In addition 
to having the least well-controlled symptoms at 
baseline, the preference surgical group had been 
on medication longer and were less concerned 
about possible adverse effects of surgery (described 
in Chapter 5).
The preference groups also add extra information 
about clinical events, in particular rare serious 
adverse events. Taken at face value, laparoscopic 
fundoplication appears to be a relatively safe 
procedure; however, even the experience of all of 
the 329 participants who had surgery is too little to 
provide sufficiently precise estimates of uncommon 
events. So, questions still remain about the extent 
of possible adverse effects of surgery and their 
frequency.
T
he advent of less invasive fundoplication 
performed laparoscopically opened up new 
possibilities for the management of people with 
chronic symptoms of GORD. Good results obtained 
amongst people whose symptoms were not 
satisfactorily controlled by medical management 
raised questions about the place of relatively early 
surgery in people with GORD whose symptom 
control from long-term medical management was 
reasonably acceptable. Would surgery be more 
effective than continuing medical management? 
Would surgery be sufficiently safe? And would 
widening the use of laparoscopic fundoplication 
to such patients be cost-effective? These are the 
principal questions addressed in this study.
The study had two main components: a pragmatic 
randomised controlled trial to assess clinical 
effectiveness and an economic evaluation 
to explore cost-effectiveness and the wider 
implications for efficient health-care provision.
The trial provided clear evidence of effectiveness 
in respect of reflux-related quality of life. Even 
though the number of participants in the trial 
was not as large as originally intended, the sizes 
of differences observed in the condition-specific 
reflux quality of life measure were so large that 
they were highly statistically significant. As with 
other disease-specific measures, the magnitude of 
these differences is hard to conceptualise. However, 
broadly similar differences were also observed in 
most components of the more accessible generic 
health status measures, SF-36 and EQ-5D.
As described in Chapter 6, clear differences 
were observed even though as many as one-
third of those allocated surgery did not have 
fundoplication. Extra analyses explored how 
much of a blunting effect this might have had on 
the results and, arguably, these adjusted analyses 
provide better estimates of the true effects of 
surgery in this type of population as it might be 
used in normal clinical practice.Conclusions
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The within-trial (i.e. up to 12 months of follow-up) 
cost-effectiveness analysis related the extra mean 
costs associated with the surgical policy with the 
increase in mean QALYs that followed surgery to 
generate an incremental cost-effectiveness ratio. 
This was around £19,000 when the intention to 
treat approach to analysis was used. Taking into 
account uncertainties around the various estimates, 
it was calculated that the chances that the surgical 
policy would be cost-effective at a threshold of 
£20,000 per QALY was 46%. When a per protocol 
approach was used, the incremental cost per QALY 
increased to around £23,000, with a probability 
that this would be cost-effective at a threshold 
of £20,000 of only 19%. These results indicate 
considerable uncertainty at thresholds that are 
currently commonly applied to costs per QALY.
The within-trial analyses have significant 
limitations, however, as discussed in Chapters 7 
and 8. The most important is that they ignore 
events, costs and benefits that accrue after 1 year. 
It is likely that surgery will continue to bestow 
benefits after 1 year, although there could also be 
relapse of symptoms, and medical management 
may require lifelong medication with significant 
costs. For this reason, the R e f l u x  trial data were 
synthesised with other data to develop an extended 
cost-effectiveness model. This explored a number 
of possible scenarios. Assuming that the benefits 
of surgery persist throughout a lifetime, that 
without surgery mediation use would continue for 
a lifetime, that there would be a 4.8% annual rate 
of additional uptake of medication in the surgery 
group, and that there would be an annual 0.8% 
reoperation rate led to an estimated incremental 
cost per QALY of around only £2000, with a 74% 
probability of surgery  being considered cost-
effective at a threshold of £20,000 per QALY. 
Applying other plausible assumptions, however, 
gave a range of incremental costs per QALY of 
between £1000 and £44,000, again indicative of 
wide uncertainty. The factors most contributing 
to the uncertainty were the projected HRQoL 
parameters and the long-term rate of uptake of 
medication following surgery.
The DCE was performed to provide an alternative 
way of assessing the weights that people with 
GORD place on their outcome and treatment. The 
results were broadly in line with the other economic 
evaluation in this project, based on the EQ-5D. 
The DCE did show, however, that respondents put 
considerable weight on avoiding rare but serious 
risks. The economic analysis found that these risks 
have little impact on QALYs on average and that 
the uncertainty in the clinical results about their 
incidence does not affect the treatment decision at 
the population level, all other things being equal. 
Nevertheless, the DCE highlights that these risks 
may be important when patients choose whether to 
accept surgery if it is offered.
Currently available evidence from the R e f l u x  
trial indicates that surgery could be cost-effective 
at the thresholds (£20,000–£30,000) currently 
applied by the National Institute for Health and 
Clinical Excellence (NICE) but with considerable 
uncertainty. The extended model suggests that 
the true cost-effectiveness, when lifetime costs 
and benefits are taken into account, is likely to be 
more favourable. But this, too, is prone to major 
uncertainty.
Questions also remain about the generalisability 
of the study’s results. The economic model was 
based on a 45-year-old man, whereas many people 
receiving PPIs for GORD are older than this and 
can have significant co-morbidities. 
The most urgent need for further research, 
therefore, is to acquire improved estimates of 
longer-term benefits and costs. This could be 
accomplished relatively easily by continuing 
annual follow-up in the R e f l u x  trial, and indeed 
arrangements for this have been put in place. 
Funds have recently been awarded by the HTA 
Programme to support follow-up to 5 years after 
surgery. Our analyses of cost-effectiveness will then 
be updated to take these results and other changes 
(such as in the costs of PPIs) into account. In the 
meantime it may be worth exploring whether there 
are other longer-standing non-randomised cohorts 
that could be useful in this respect. Perceptions of 
the risks of rare adverse events may play a major 
role in decision-making about surgery. Such cohorts 
could also be useful for getting more precise 
estimates of uncommon events associated with both 
surgical and medical management.Health Technology Assessment 2008; Vol. 12: No. 31
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EFV6/05/01 
 
Participant Study No                                       Study Centre No                               
                                                           
(for completion by co-ordinating  
          centre in Aberdeen) 
 
 
 
 
PARTICIPANT ENTRY FORM 
 
CONFIDENTIAL 
 
 
This study is funded by the NIHR  
Health Technology Assessment Programme 
 
 
ELIGIBILITY 
 
Please mark relevant box as to whether participant has chosen to be randomised OR has 
declined and has opted for the preference arm. 
 
Please put an X in the relevant boxes   
 
                                           ELIGIBLE     
           
                         
           
                     
            RANDOMISED              PREFERENCE   
 
               
 
                                               SURGICAL      MEDICAL   SURGICAL   MEDICAL 
         
                               
                    (for office use only) Health Technology Assessment 2008; Vol. 12: No. 31
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PERSONAL INFORMATION 
 
Instruction for completion:  
if you make any errors while completing this form, please score through the incorrect data with a 
horizontal line and initial and date any changes 
 
Please put an x in the relevant boxes 
 
PERSONAL INFORMATION 
 
 Title (Mr, Mrs etc)  Surname                                           
                                                                               
 
 First Names                                                     
                                                                                       
 
 
 ADDRESS 
                                       
 House Name                                                                           
                                             
 House Number                                                                                 
                                             
 Street Name                                                                                 
                                             
                                                                                 
                                             
 Town/City                                     
                                           
                                             
 County                                     
                                           
                                             
 Postcode                                                                                 
                                     
                                     Telephone No 
 (including code)                                     
 
 
 Maiden name (if female and ever married)                               
                                                           
 
 NHS Number (if known)  Hospital Number (if known)                                           
                                                                                   
 
 CHI Number (if known - Scotland only)                                             
                                                                                   
 
 Appendix 1
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DESCRIPTIVE INFORMATION ABOUT THE PARTICIPANT 
 
   
  Day      Month   Year   
                           
 Date of Birth      /      /           
                           
 
 Sex     
     Male    Female   
 
           
   
   
 
     
 Height       .      m  or      ft      inches                             
             
   
   
 
     
 Weight       .      kg  or      st      lbs                             
 
  Day  Month      Year                               
1.  Date of Recruitment      /      /                                   
 
       Yes        No 
 
2.  Does the participant take prescribed reflux medication daily?         
 
3.  When was the participant first prescribed medicine for their reflux symptoms? 
 
     Month      Year                               
            /                                   
 
   Yes     No    Don’t know 
 
4.  Is the participant a current smoker?           
 
  Yes     No    Don’t know 
 
5.  Does the participant suffer from asthma?           
 
6.  Please tick the box which accurately describes when the participant first finished full 
     time education? 
                                                                                                                      16 years or less    
                                                                                                                      17-19 years old   
                                                                                                                     20 years or over   
 
7.  Since leaving, have they undertaken any more full-time or part-time education? 
                                                                                                                                          Yes    
                                                                                                                                           No   
 
 
 
Participant Study No                                       Study Centre No                               
                                                           
(for completion by co-ordinating  
centre in Aberdeen) Health Technology Assessment 2008; Vol. 12: No. 31
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8.  Please tick the box, which best describes the participant’s current employment status. 
 
                          Full time employment                                                         Housework   
                          Part time employment                                                      Seeking work   
                                                    Student                                                                    Other   
                                                     Retired       
 
 
GENERAL PRACTITIONER  
 
 Initials     Surname                                             
                                                                                       
                                       
 Practice Name                                                                           
                                             
 Street Number                                                                                 
                                             
 Street Name                                                                                 
                                             
                                                                                 
                                             
 Town/City                                     
                                           
                                             
 County                                     
                                           
                                             
 Postcode                                                                                 
                                     
                                     Telephone No 
 (including code)                                     
 
 
COLLABORATING CLINICIAN  
 
 Title (Mr, Mrs, Professor, Dr)  Surname                                           
                                                                               
 
 First Name(s) (if known)                                                     
                                                                                       
                                       
 Hospital                                                                           
                                       
 Clinic name                                                                           
 
 
 
Thank you for completing this information.  Please return it in a reply-paid envelope to: 
The REFLUX Trial Office, Health Services Research Unit (Flea), 
University of Aberdeen, Foresterhill, ABERDEEN AB25 2ZD 
Tel: 01224 000000  Fax: 01224 554580  E-mail: reflux@hsru.abdn.ac.uk Health Technology Assessment 2008; Vol. 12: No. 31
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BQV7/07/01   
Participant Study No 
           
                       
(for completion by co-ordinating 
          centre in Aberdeen) 
 
 
 
 
 
 
 
 
 
 
BASELINE QUESTIONNAIRE 
 
 
 
 
A questionnaire for people participating in the REFLUX trial,  
which aims to find out whether taking medication or having an operation  
is the best form of treatment for gastro-oesophageal reflux disease 
 
 
 
 
 
 
CONFIDENTIAL 
 
 
This study is funded by the NIHR Health Technology Assessment Programme  Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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  1   
 
 
BQV7/07/01 
 
 
PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE 
QUESTIONNAIRE 
 
Thank you for agreeing to take part in the study.  The responses you give in 
this questionnaire will help us find out if the treatments you get are helpful 
for your condition. 
 
The information you provide will be completely confidential.  
 
 
 
 
HOW TO FILL IN THE QUESTIONNAIRE 
 
For each section please put a cross in the appropriate box like this: 
 
 
Do you drive a car?      Yes       
           
          No 
 
 
 
If  you  make  any  errors  while  completing  this  questionnaire,  shade  out  the  incorrect  box 
completely and put a cross in the correct box like this: 
 
 
Do you drive a car?      Yes       
           
          No 
 
 
The intended answer above is No 
 
 
 
 
PLEASE USE A BLUE OR BLACK PEN TO FILL IN YOUR ANSWERS 
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BQV7/07/01 
REFLUX QUESTIONNAIRE 
 
For the questions in section A - F, please tick the box which best describes how often your 
symptoms have occurred and the effect they have had on your quality of life. 
 
SECTION A - HEARTBURN 
 
A1.  In the last two weeks, how often have you experienced heartburn (a burning sensation 
which moves up from your chest to your throat)? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
 
A2.  In the last two weeks, how often have you experienced any discomfort or pain in your 
chest? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
   Everyday 
 
A3.  In the last two weeks, how much has the heartburn or discomfort/pain in your chest 
affected your quality of life? 
  Not at all 
  A little 
  Moderately 
  A lot                                                                                                                                         
                                                                                                                                                Extremely 
 
  Participant Study No 
             
             
 
             
      (for completion by co-ordinating  
                centre in Aberdeen) 
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SECTION B - ACID REFLUX 
 
 
 
B1.  In the last two weeks, how often have you experienced acid reflux and/or had an acid 
taste in your mouth? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
B2.  In the last two weeks, how often have you been sick (vomited)? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 B3.       In the last two weeks, how often have you regurgitated (brought up) quantities of liquid                                               
   or solids into your mouth? 
 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
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BQV7/07/01 
B4.  In the last two weeks, how often have you experienced a feeling of nausea (without
  actually being sick or regurgitating)? 
 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 
B5.  In the last two weeks, how often have you wanted to be sick but physically been unable 
to? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 
B6.  In the last two weeks, how much have these reflux symptoms affected your quality of 
life? 
 
  Not at all 
  A little 
  Moderately 
  A lot 
  Extremely  
 
 
 
  Participant Study No 
             
             
 
             
      (for completion by co-ordinating  
                centre in Aberdeen) 
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BQV7/07/01 
SECTION C – WIND 
 
 
 
C1.  In the last two weeks, how often have you experienced a lot of wind from the lower 
bowel? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday   
 
 
C2.  In the last two weeks, how often have you experienced a lot of burping/belching? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday   
   
 
C3.  In the last two weeks, how often have you experienced bloatedness and/or a feeling of 
trapped wind, in your stomach? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday Appendix 2
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BQV7/07/01 
C4.  In the last two weeks, how often have you experienced loud gurgling noises from your 
  stomach? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 
C5.  In the last two weeks, how much have these wind problems affected your quality of 
life? 
 
  Not at all 
  A little 
  Moderately 
  A lot 
  Extremely  
 
 
 
SECTION D - EATING AND SWALLOWING 
 
 
 
D1.  In the last two weeks, how often have you experienced difficulty swallowing food or 
have you actually choked on food? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
 
 
  Participant Study No 
             
             
 
             
     (for completion by co-ordinating  
                centre in Aberdeen) 
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D2.  In the last two weeks, how often have your eating habits been restricted because of your 
condition?  Examples might be eating more slowly, having smaller portions or eating 
different foods. 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 
D3.  In the last two weeks, how much have these problems with eating affected your quality 
of life?   
 
  Not at all 
  A little 
  Moderately 
  A lot 
  Extremely  
 
 
SECTION E – BOWEL MOVEMENTS 
 
 
 
E1.  I n  t h e  l a s t  t w o  w e e k s ,  h o w  o f t en  have  you  experienced  diarrhoea  and/or  loose               
stools? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 Appendix 2
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E2.  In the last two weeks, how often have you experienced constipation and/or hard stools? 
 
  Not at all   
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 
E3.   In  the  last  two  weeks,  how  often  have  you  felt  an  urgent  need  to  have  a  bowel 
movement?       
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 
 
E4.  In the last two weeks, how often have you had a feeling of not emptying your bowels? 
 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most days 
  Everyday 
   
 
 
 
  Participant Study No 
             
             
 
             
      (for completion by co-ordinating  
                centre in Aberdeen) 
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E5.   In the last two weeks, how much have these bowel problems affected your quality of 
life? 
 
  Not at all 
  A little 
  Moderately 
  A lot 
  Extremely 
 
SECTION F – SLEEP 
 
 
 
F1.  In  the  last  two  weeks,  how  often  have  you  experienced  difficulty  in  lying  down  to 
sleep? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most nights 
  Every night 
   
F2.  In  the  last  two  weeks,  how  often  have  you  experienced  difficulty  getting  to  sleep 
because of your reflux symptoms? 
 
  Not at all 
  Once a week 
  Two or three times a week 
  Most nights 
  Every night 
 
 
 
 Appendix 2
116
 
  10   
 
 
BQV7/07/01 
F 3 .     I n  t h e  l a s t  t w o  w e e k s ,  h o w  o f ten  have  you  been  woken  up  because  of  your  reflux       
symptoms? 
 
  Not at all   
  Once a week 
  Two or three times a week 
  Most nights 
  Every night 
   
 
F4.  In  the  last  two  weeks,  how  much  have  these  sleep  related  problems  affected  your 
quality of life?                
 
   
  Not at all 
  A little 
  Moderately 
  A lot 
  Extremely 
 
 
 
 
 
 
 
 
 
    Participant Study No 
             
             
 
             
     (for completion by co-ordinating  
                centre in Aberdeen) 
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SECTION G – WORK, PHYSICAL AND SOCIAL ACTIVITIES 
 
 
 
For the following section, please tick the box which best applies to you. 
 
 
 
G1.  In  the  last  two  weeks,  have  your  reflux  symptoms  affected  you  at  work  (paid  or 
voluntary)? 
 
  Not applicable (I do not do paid or voluntary work)  
  No, my symptoms do not affect me 
  Yes, my symptoms have affected me but I still work 
  Yes, I have worked less often because of my symptoms 
                                     Yes, I have not worked in the last two weeks because of my symptoms    
                                                                          I no longer work because of my symptoms   
 
 
 
 
G2.  In the last two weeks, have your reflux symptoms affected your ability to perform less 
strenuous activities (such as going for a gentle walk, shopping or housework)? 
 
 
                 Not applicable (I do not perform these activities, though this is not due to my reflux  
                 symptoms)   
                        No, my symptoms do not affect me 
  
  Yes, my symptoms have affected me but I still perform these activities as often as ever                                        
                                                 Yes, I perform these activities less often because of my symptoms    
                                                      Yes, I have not performed these activities in the last two weeks    
             I no longer perform these activities at all because of my symptoms 
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G3.  In  the  last  two  weeks,  have  your  reflux  symptoms  affected  your  ability  to  perform 
strenuous activities (such as brisk walking or swimming)? 
 
   Not applicable (I do not perform these activities, though this is not due to my reflux  
                symptoms)   
                                                                                                     No, my symptoms do not affect me 
 
            Yes, my symptoms have affected me but I still perform these activities as often as ever    
                                                Yes, I perform these activities less often because of my symptoms   
                                                    Yes, I have not performed these activities in the last two weeks   
                                              I no longer perform these activities at all because of my symptoms 
 
 
G4.  In the last two weeks, have you found that your reflux symptoms have affected any of 
your social activities (such as going out for meals, going out for drinks or socialising 
with other people)? 
 
                 Not applicable (I do not perform these activities, though this is not due to my reflux  
                 symptoms)   
                                                                                            No, my symptoms do not affect me    
  Yes, my symptoms have affected me but I still perform these activities as often as ever 
  Yes, I perform these activities less often because of my symptoms 
  Yes, I have not performed these activities in the last two weeks 
                              I no longer perform these activities at all because of my symptoms  
 
G5.  In the last two weeks, how much has the effect of your reflux symptoms on your work, 
physical or social activities affected your quality of life? 
 
  Not at all 
  A little 
  Moderately 
  A lot 
  Extremely 
 
    Participant Study No 
             
             
 
             
      (for completion by co-ordinating  
                centre in Aberdeen) 
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SECTION H - YOUR VIEWS ABOUT MEDICINES PRESCRIBED TO YOU FOR YOUR  REFLUX  
 
 
 
•  We would like to ask you about your personal views about medicines prescribed for your 
reflux symptoms, now or in the past. 
 
•  Below are statements other people have made about their medicines. 
 
•  Please indicate the extent to which you agree or disagree with them by putting a cross in the 
appropriate box. 
 
•  There are no right or wrong answers.  We are interested in your personal views. 
 
 
  Strongly        Strongly 
     agree  Agree  Uncertain  Disagree  disagree 
 
My health, at present, depends on  
my medicines 
 
Having to take medicines worries me 
 
My life would be impossible without 
my medicines 
 
Without my medicines I would be  
very ill 
 
I sometimes worry about the long  
term effects of my medicines 
 
My medicines are a mystery to me 
 
My health in the future depends on  
my medicines 
 
My medicines disrupt my life 
 
I sometimes worry about becoming  
too dependent on my medicines 
 
My medicines protect me from  
becoming worse 
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SECTION I - YOUR VIEWS ABOUT MEDICINES IN GENERAL 
 
•  We would like to ask you about your personal views about medicines in general. 
 
•  Below are statements other people have made about medicines in general. 
 
•  Please indicate the extent to which you agree or disagree with them by putting a cross in the 
appropriate box. 
 
•  There are no right or wrong answers.  We are interested in your personal views. 
 
 
 
  Strongly        Strongly 
    agree  Agree  Uncertain  Disagree  disagree 
 
Doctors use too many medicines 
 
People who take medicines should 
stop their treatment for a while  
every now and again 
Most medicines are addictive 
Natural remedies are safer than  
medicines 
Medicines do more harm than good 
All medicines are poisons 
Doctors place too much trust on 
medicines 
If doctors had more time with  
patients they would prescribe fewer 
medicines 
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SECTION J - YOUR VIEWS ABOUT SURGERY IN GENERAL 
 
•  We would like to ask you about your personal views about surgery in general. 
 
•  Below are statements other people have made about surgery in general 
 
•  Please indicate the extent to which you agree or disagree with them by putting a cross in the 
appropriate box. 
 
•  There are no right or wrong answers.  We are interested in your personal views. 
 
 
 
   Strongly        Strongly 
     agree  Agree  Uncertain  Disagree  disagree 
 
I would be willing to have an  
uncomfortable test to assess my  
suitability for surgery 
 
Surgery does more harm than good 
 
Doctors rely on surgery too much 
 
I worry about the risks of surgery 
 
 
Doctors place too much trust in  
surgery 
 
Doctors are too quick to suggest  
surgery 
 
 
Surgery should only be undertaken 
as a last resort 
 
 
Surgery can result in new health  
problems 
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SECTION K - OTHER HEALTH PROBLEMS 
 
 
 
     1.    In the last two weeks, how many times have you experienced any of the following   
            problems?              
                                  
 
   Not at  Once a    2 or 3 times      Most           Every 
      all    week      a week      days     day 
 
         
Headaches (or migraine) 
 
Rashes   
 
Itching 
 
 
Lack of concentration 
 
Sweating 
 
Breathlessness 
 
 
Pains in stomach  
 
Lack of motivation 
 
Frustration 
 
 
Temperature 
 
Hot flushes 
 
Feeling low 
 
 
Shoulder pain 
 
Teeth problems 
     
Hunger pains   
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  Not at           Once a    2 or 3 times     Most            Every 
     all    week       a week     days     day 
 
 
Dizziness   
     
Tired/Fatigued   
 
Dry mouth 
 
 
Sore throat 
 
Pins and needles 
 
Drowsiness 
 
 
 
 
 
 2.   In the last two weeks, have you experienced any change in weight? 
   
             Yes       No         
   
                  Weight loss   
 
                  Weight gain 
 
         
                                                                        
             
 
3.  In the last two weeks, how much have the other health problems listed above affected your  
  quality of life? 
                                                                                                                                          Not at all 
                                                                                                                                              A little 
                                                                                                                                      Moderately 
                                                                                                                                                 A lot 
                                                                                                                                        Extremely 
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SECTION L – DESCRIBING YOUR OWN HEALTH TODAY 
 
 
 
By  placing  a  cross  in  one  box  in  each  group  below,  please  indicate  which  statements  best 
describe your own health state today 
 
 
Mobility  I have no problems in walking about 
                                                                                            I have some problems in walking about 
                                  I am confined to bed 
 
 
Self-care                                                                                      I have no problems with self-care 
   I have some problems washing or dressing myself 
                                    I am unable to wash or dress myself 
 
 
Usual Activities  I have no problems with performing my usual activities 
(e.g. work, study, 
housework, family or    I have some problems with performing my usual activities 
leisure activities) 
                         I am unable to perform my usual activities 
             
          
Pain/Discomfort  I have no pain or discomfort 
                             I have moderate pain or discomfort 
                                        I have extreme pain or discomfort 
 
 
Anxiety/Depression  I am not anxious or depressed 
                       I am moderately anxious or depressed 
                           I am extremely anxious or depressed 
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 DESCRIBING YOUR OWN HEALTH TODAY 
 
 
 
Please indicate on this scale        
how good or bad your own health  
state is today. 
 
The best health state you can 
imagine is marked 100 and the 
worst health state you can imagine 
is marked 0. 
  
Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
            state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
health state 
today Appendix 2
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SECTION M – GENERAL HEALTH 
 
Please fill in all the questions again by crossing the relevant box of the answer that applies to 
you. 
 
These questions ask for your views about your health and how you feel about life in general.  
Do not spend too much time in answering as your immediate response is likely to be the most 
accurate, but please make sure you answer every question. 
 
1.  In general, would you say your health is: 
   
  Excellent     Very good     Good  Fair  Poor  
   
 
 
 
2.  Compared to one year ago, how would you rate your health in general now?   
 
         Much better  Somewhat better  About the               Somewhat   Much worse 
       now than one  now than one  same as one  worse now than  now than one 
      year ago       year ago  year ago     one year ago    year ago 
 
 
 
 
3.  The following questions are about activities you might do during a typical day.  Does                          
           your health now limit you in these activities?  If so, how much? 
 
                                                                                         Yes   Yes       No, not
     limited   limited   limited 
     a lot       a little     at all 
    
  a) Vigorous activities, such as running, lifting heavy objects, 
      participating in strenuous sport 
  b) Moderate activities, such as moving a table, pushing     
       a vacuum cleaner, bowling or playing golf 
  c)  Lifting or carrying groceries 
  d) Climbing several flights of stairs   
       e)  Climbing one flight of stairs 
        f)  Bending, kneeling or stooping 
       g) Walking more than one mile 
       h) Walking several hundred yards 
        i)  Walking one hundred yards 
j)  Bathing or dressing yourself Health Technology Assessment 2008; Vol. 12: No. 31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
127
 
  21   
 
 
BQV7/07/01 
4.  D u r i n g  t h e  p a s t  4  w e e k s ,  h o w  m u c h  o f  t h e  t i m e  h a v e  y o u  h a d  a n y  o f  t h e  f o l l o w i n g                    
problems  with  your  work  or  other  regular  daily  activities  as  a  result  of  your  physical 
health? 
 
      All of       Most of      Some of    A little of   None of  
    the time    the time      the time    the time   the time 
     
a)  Cut down on the amount of time you spent 
on work or other activities 
 
b)  Accomplished less than you would like 
   
c)  Were limited in the kind of work or other 
activities 
 
d)  Had difficulty performing the work or other 
activities (for example, it took extra effort) 
 
 
 
 
5.  During  the  past  4  weeks,  how  much  of  the  time  have  you  had  any  of  the  following      
problems  with  your  work  or  other  regular  daily  activities  as  a  result  of  any  emotional 
problems (such as feeling depressed or anxious)? 
 
      All of  Most of    Some of    A little of   None of  
    the time  the time    the time  the time   the time 
     
a)  Cut down on the amount of time you spent 
on work or other activities 
 
b)  Accomplished less than you would like 
 
c)  Did work or other activities less  
carefully than usual   
 
   
 
6.    During the past 4 weeks, to what extent has your physical health or emotional  
       problems interfered with your normal social activities with the family, friends,   
  neighbours, or groups? 
 
             Not at all                   Slightly     Moderately   Quite a bit           Extremely 
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7.  How much bodily pain have you had during the past 4 weeks? 
   
              None    Very mild   Mild       Moderate     Severe    Very severe 
   
 
 
 
 
8.  During  the  past  4  weeks,  how  much  did  pain  interfere  with  your  normal  work  
(including both outside the home and housework)? 
   
            Not at all   A little bit      Moderately   Quite a bit            Extremely     
   
 
 
 
 
9.  These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question, please give the one answer that comes closest to the 
way you have been feeling.  How much of the time during the past 4 weeks… 
 
 
      All of  Most of     Some of  A little of    None of  
    the time  the time     the time    the time    the time 
     
a)  Did you feel full of life?     
 
b)  Have you been very nervous? 
 
c)  Have you felt so down in the dumps that    
  nothing could cheer you up? 
 
 
d)  Have you felt calm and peaceful? 
 
e)  Did you have a lot of energy? 
 
f)  Have you felt downhearted and depressed?   
   
   
    g)  Did you feel worn out?     
    
h)  Have you been happy? 
 
i)  Did you feel tired? 
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     10.  During the past 4 weeks, how much of the time has your physical health or emotional     
  problems interfered with your social activities (like visiting friends, relatives etc.)? 
   
   All of the    Most of the   Some of the      A little of the  None of the 
      time         time         time        time        time 
   
 
 
 
 
11.  How TRUE or FALSE is each of the following statements for you? 
 
    Definitely   Mostly   Don’t     Mostly  Definitely
         true        true   know   false       false 
     
a)   I seem to get sick a little easier than other 
   people 
 
b)     I am as healthy as anybody I know 
   
c)   I expect my health to get worse 
 
d)  My health is excellent 
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SECTION N – HEALTH CARE RELATED QUESTIONS 
 
In the following questions, we are trying to find out about some of the costs you incur as a result 
of your health problems.  
 
If you are not sure or cannot remember exact details, please give the best answer you can.   
 
1.   PRESCRIBED MEDICATION FOR REFLUX 
     
 Are you currently being PRESCRIBED medication for your reflux symptoms? 
 
   YES  NO     If NO, please go to question 2 on 
                  the next page 
       
   
 
If YES, please put a cross in the box against the current dose you are being prescribed and 
write in the number of tablets you have taken in the last two weeks. 
 
(Please note the dose can be found on the side of your tablet bottle or packet) 
 
 
                        Number of tablets  
                                    taken in the last  
            Dose (mg)                               2 weeks   
 
Omeprazole (Losec)  10mg  20mg             40mg  
 
Lansoprazole (Zoton)  15mg  30mg 
 
Pantoprazole (Protium)  20mg  40mg             
   
Rabeprazole (Pariet)  10mg  20mg 
 
Esomeprazole (Nexium)  20mg  40mg 
 
 
Rantidine (Zantac)  150mg             300mg 
 
Famotidine (Pepcid)  20mg   40mg 
 
Nizatidine (Axid)  150mg             300mg 
 
Cimetidine (Tagamet)  400mg             800mg 
   
       
Domperidone (Motilium)                10mg              20mg 
  
Metoclopramide (Maxolon)                  10mg  20mg 
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If you are prescribed any other medication (tablets or liquid) for your reflux symptoms that are 
not listed above, please list below the name(s) of the medicine(s) and include the number of 
times you have taken it in the last two weeks.  
   
 
           Number of times 
Names of medication     taken in last 2 weeks 
        
 
e.g. Gaviscon 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.  NON PRESCRIBED MEDICATION FOR REFLUX 
 
Please  list  below  the  names  of  any  NON  PRESCRIBED  (over  the  counter)  medication 
(tablets/liquid) you take for your reflux symptoms and include the number of times you have 
taken it in the last two weeks. 
 
            Number of times 
Names of medication       taken in last 2 weeks 
 
 
e.g Rennies 
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IF YOU HAVE ANY OTHER COMMENTS about your gastro-oesophageal reflux symptoms, 
your reflux treatment or this study, please write them below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
THANK YOU FOR YOUR HELP IN COMPLETING THIS 
QUESTIONNAIRE 
 
 
 
 
 
 
 
 
Once you have completed the form, please return it in the pre-paid envelope provided or to the 
following address: 
 
 
REFLUX Trial Office 
Health Services Research Unit (Flea) 
 Polwarth Building 
Foresterhill 
 Aberdeen   AB25 2ZD 
Tel: 01224 000000 
  Fax: 01224 554580 
  E-Mail: reflux@hsru.abdn.ac.uk Health Technology Assessment 2008; Vol. 12: No. 31
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Patient letter of invitation 
 
 
 
Date as postmark 
 
 
 
 
 
 
Dear  
 
You are invited to attend a review appointment at my outpatient clinic (see enclosed 
appointment card) for your reflux (heartburn/regurgitation) symptoms. 
 
I am writing to let you know that <<Hospital>> is part of a large national study 
funded by the NHS to look at the different types of treatment for reflux.  As someone 
who  is  taking  medication  for  their  reflux  symptoms,  you  may  be  eligible  for  the 
study. 
 
I have included two patient information leaflets about the study.  The first explains 
in further detail why the study is being done and the second explains what would 
happen if you were eligible to join the study.  I would be most grateful if you would 
take the time to read through the information.  There will be the opportunity to 
discuss the study in more detail during your appointment.   
 
If you would like any further information about the trial please call the trial office 
directly on 01224 000000. 
 
Yours sincerely 
 
 
 
 
 
 
 
<<Consultants name>> 
<<Consultants position>> 
Enc. 
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e
 
s
t
u
d
y
 
i
s
 
b
e
i
n
g
 
f
u
n
d
e
d
 
b
y
 
t
h
e
 
N
I
H
R
 
H
e
a
l
t
h
 
T
e
c
h
n
o
l
o
g
y
 
A
s
s
e
s
s
m
e
n
t
 
P
r
o
g
r
a
m
m
e
.
 
 
 
 
 
C
o
n
t
a
c
t
 
f
o
r
 
F
u
r
t
h
e
r
 
I
n
f
o
r
m
a
t
i
o
n
 
 
 
 
R
E
F
L
U
X
 
T
r
i
a
l
 
O
f
f
i
c
e
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
s
 
R
e
s
e
a
r
c
h
 
U
n
i
t
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
A
b
e
r
d
e
e
n
 
F
o
r
e
s
t
e
r
h
i
l
l
 
A
b
e
r
d
e
e
n
 
A
B
2
5
 
2
Z
D
 
T
e
l
.
 
0
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4
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0
 
F
a
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:
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4
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0
 
E
m
a
i
l
:
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e
f
l
u
x
@
h
s
r
u
.
a
b
d
n
.
a
c
.
u
k
 
 
 
 
 
 
 
T
h
a
n
k
 
y
o
u
 
f
o
r
 
r
e
a
d
i
n
g
 
t
h
i
s
 
C
o
n
s
u
m
e
r
s
 
f
o
r
 
E
t
h
i
c
s
 
i
n
 
R
e
s
e
a
r
c
h
 
(
C
E
R
E
S
)
 
p
u
b
l
i
s
h
 
a
 
l
e
a
f
l
e
t
 
e
n
t
i
t
l
e
d
 
‘
M
e
d
i
c
a
l
 
R
e
s
e
a
r
c
h
 
a
n
d
 
Y
o
u
’
.
 
 
T
h
i
s
 
l
e
a
f
l
e
t
 
g
i
v
e
s
 
m
o
r
e
 
i
n
f
o
r
m
a
t
i
o
n
 
a
b
o
u
t
 
m
e
d
i
c
a
l
 
r
e
s
e
a
r
c
h
 
a
n
d
 
l
o
o
k
s
 
a
t
 
s
o
m
e
 
q
u
e
s
t
i
o
n
s
 
y
o
u
 
m
i
g
h
t
 
w
a
n
t
 
t
o
 
a
s
k
.
 
 
A
 
c
o
p
y
 
m
a
y
 
b
e
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
C
E
R
E
S
,
 
P
O
 
B
o
x
 
1
3
6
5
,
 
L
o
n
d
o
n
 
N
1
6
 
0
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A
 
S
T
U
D
Y
 
O
F
 
G
A
S
T
R
O
-
O
E
S
O
P
H
A
G
E
A
L
 
R
E
F
L
U
X
 
D
I
S
E
A
S
E
 
 
 
 
P
A
T
I
E
N
T
 
I
N
F
O
R
M
A
T
I
O
N
 
L
E
A
F
L
E
T
 
 
 
 
2
.
 
W
H
A
T
 
H
A
P
P
E
N
S
 
I
F
 
I
 
J
O
I
N
 
T
H
E
 
S
T
U
D
Y
?
 
 
 
B
e
f
o
r
e
 
y
o
u
 
d
e
c
i
d
e
 
w
h
e
t
h
e
r
 
t
o
 
t
a
k
e
 
p
a
r
t
,
 
i
t
 
i
s
 
i
m
p
o
r
t
a
n
t
 
f
o
r
 
y
o
u
 
t
o
 
u
n
d
e
r
s
t
a
n
d
 
w
h
y
 
t
h
e
 
s
t
u
d
y
 
i
s
 
b
e
i
n
g
 
d
o
n
e
 
a
n
d
 
w
h
a
t
 
i
t
 
w
i
l
l
 
i
n
v
o
l
v
e
.
 
 
P
l
e
a
s
e
 
t
a
k
e
 
t
i
m
e
 
t
o
 
r
e
a
d
 
t
h
e
 
f
o
l
l
o
w
i
n
g
 
i
n
f
o
r
m
a
t
i
o
n
 
c
a
r
e
f
u
l
l
y
 
a
n
d
 
d
i
s
c
u
s
s
 
i
t
 
w
i
t
h
 
f
r
i
e
n
d
s
 
o
r
 
r
e
l
a
t
i
v
e
s
 
i
f
 
y
o
u
 
w
i
s
h
.
 
 
A
s
k
 
u
s
 
i
f
 
t
h
e
r
e
 
i
s
 
a
n
y
t
h
i
n
g
 
y
o
u
 
d
o
n
’
t
 
u
n
d
e
r
s
t
a
n
d
 
o
r
 
i
f
 
y
o
u
 
w
o
u
l
d
 
l
i
k
e
 
m
o
r
e
 
i
n
f
o
r
m
a
t
i
o
n
.
 
 
T
a
k
e
 
t
i
m
e
 
t
o
 
d
e
c
i
d
e
 
w
h
e
t
h
e
r
 
o
r
 
n
o
t
 
y
o
u
 
w
i
s
h
 
t
o
 
t
a
k
e
 
p
a
r
t
.
 
 
 
 
W
h
a
t
 
i
s
 
t
h
e
 
p
u
r
p
o
s
e
 
o
f
 
t
h
e
 
s
t
u
d
y
?
 
 
 
T
h
e
 
t
w
o
 
m
a
i
n
 
f
o
r
m
s
 
o
f
 
t
r
e
a
t
m
e
n
t
 
r
o
u
t
i
n
e
l
y
 
u
s
e
d
 
i
n
 
t
h
e
 
N
H
S
 
t
o
 
t
r
e
a
t
 
G
O
R
D
 
a
r
e
 
m
e
d
i
c
a
t
i
o
n
 
a
n
d
 
s
u
r
g
e
r
y
.
 
 
A
t
 
p
r
e
s
e
n
t
 
w
e
 
d
o
 
n
o
t
 
k
n
o
w
 
w
h
e
t
h
e
r
 
m
e
d
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
(
d
r
u
g
s
 
i
n
 
t
h
e
 
f
o
r
m
 
o
f
 
t
a
b
l
e
t
s
)
 
o
r
 
s
u
r
g
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
i
s
 
b
e
t
t
e
r
 
f
o
r
 
t
r
e
a
t
i
n
g
 
p
e
r
s
i
s
t
e
n
t
 
s
y
m
p
t
o
m
s
 
o
f
 
r
e
f
l
u
x
.
 
 
T
h
e
 
m
a
i
n
 
p
u
r
p
o
s
e
 
o
f
 
t
h
i
s
 
s
t
u
d
y
 
i
s
 
t
o
 
f
i
n
d
 
o
u
t
 
w
h
i
c
h
 
f
o
r
m
 
o
f
 
t
r
e
a
t
m
e
n
t
 
i
s
 
b
e
s
t
.
 
 
 
 
T
o
 
f
i
n
d
 
o
u
t
 
w
h
i
c
h
 
i
s
 
t
h
e
 
b
e
s
t
 
w
a
y
 
o
f
 
t
r
e
a
t
i
n
g
 
p
e
o
p
l
e
 
w
i
t
h
 
G
O
R
D
 
w
e
 
n
e
e
d
 
t
o
 
m
a
k
e
 
c
o
m
p
a
r
i
s
o
n
s
 
b
e
t
w
e
e
n
 
g
r
o
u
p
s
 
o
f
 
p
e
o
p
l
e
 
r
e
c
e
i
v
i
n
g
 
m
e
d
i
c
a
t
i
o
n
 
o
r
 
s
u
r
g
e
r
y
.
 
 
I
n
 
t
h
i
s
 
s
t
u
d
y
,
 
p
e
o
p
l
e
 
a
r
e
 
a
l
l
o
c
a
t
e
d
,
 
b
y
 
a
 
c
o
m
p
u
t
e
r
,
 
t
o
 
o
n
e
 
o
f
 
t
w
o
 
d
i
f
f
e
r
e
n
t
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
:
 
(
1
)
 
m
e
d
i
c
a
l
 
t
r
e
a
t
m
e
n
t
,
 
o
r
 
(
2
)
 
s
u
r
g
e
r
y
.
 
 
T
h
e
 
c
o
m
p
u
t
e
r
 
s
e
l
e
c
t
s
 
p
e
o
p
l
e
 
t
o
 
t
h
e
s
e
 
t
w
o
 
g
r
o
u
p
s
 
b
y
 
c
h
a
n
c
e
 
(
t
h
i
s
 
i
s
 
c
a
l
l
e
d
 
r
a
n
d
o
m
i
s
a
t
i
o
n
)
.
 
 
T
h
i
s
 
i
s
 
d
o
n
e
 
s
o
 
t
h
a
t
 
w
e
 
c
a
n
 
b
e
 
s
u
r
e
 
t
h
a
t
 
b
o
t
h
 
g
r
o
u
p
s
 
w
i
l
l
 
i
n
c
l
u
d
e
 
t
h
e
 
s
a
m
e
 
m
i
x
 
o
f
 
p
e
o
p
l
e
 
–
 
m
a
l
e
 
o
r
 
f
e
m
a
l
e
,
 
o
l
d
e
r
 
o
r
 
y
o
u
n
g
e
r
 
–
 
a
n
d
 
t
h
e
 
o
n
l
y
 
d
i
f
f
e
r
e
n
c
e
 
b
e
t
w
e
e
n
 
t
h
e
 
g
r
o
u
p
s
 
i
s
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
t
h
e
y
 
w
i
l
l
 
r
e
c
e
i
v
e
.
 
 
 
 
H
a
l
f
 
t
h
e
 
p
e
o
p
l
e
 
p
a
r
t
i
c
i
p
a
t
i
n
g
 
w
i
l
l
 
r
e
c
e
i
v
e
 
l
o
n
g
-
t
e
r
m
 
m
e
d
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
a
n
d
 
t
h
e
 
o
t
h
e
r
 
h
a
l
f
 
w
i
l
l
 
r
e
c
e
i
v
e
 
a
n
 
o
p
e
r
a
t
i
o
n
.
 
 
T
h
o
s
e
 
i
n
 
t
h
e
 
m
e
d
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
 
w
i
l
l
 
c
o
n
t
i
n
u
e
 
w
i
t
h
 
m
e
d
i
c
a
t
i
o
n
 
t
o
 
c
o
n
t
r
o
l
 
t
h
e
i
r
 
s
y
m
p
t
o
m
s
.
 
 
F
o
r
 
m
a
n
y
 
t
h
i
s
 
i
s
 
l
i
k
e
l
y
 
t
o
 
b
e
 
t
h
e
 
s
a
m
e
 
t
y
p
e
 
o
f
 
t
a
b
l
e
t
s
 
a
s
 
p
r
e
s
c
r
i
b
e
d
 
p
r
e
v
i
o
u
s
l
y
,
 
b
u
t
 
f
o
r
 
s
o
m
e
 
p
e
o
p
l
e
,
 
o
t
h
e
r
 
t
a
b
l
e
t
s
 
m
a
y
 
b
e
 
t
r
i
e
d
 
t
o
 
i
m
p
r
o
v
e
 
s
y
m
p
t
o
m
 
c
o
n
t
r
o
l
.
 
 
T
h
o
s
e
 
i
n
 
t
h
e
 
s
u
r
g
e
r
y
 
g
r
o
u
p
 
w
i
l
l
 
h
a
v
e
 
a
n
 
o
p
e
r
a
t
i
o
n
 
p
e
r
f
o
r
m
e
d
 
b
y
 
a
n
 
e
x
p
e
r
i
e
n
c
e
d
 
s
u
r
g
e
o
n
,
 
u
s
i
n
g
 
‘
k
e
y
-
h
o
l
e
’
 
s
u
r
g
e
r
y
.
 
 
I
n
 
t
h
i
s
,
 
t
h
e
 
u
p
p
e
r
 
p
a
r
t
 
o
f
 
t
h
e
 
s
t
o
m
a
c
h
 
i
s
 
w
r
a
p
p
e
d
 
a
r
o
u
n
d
 
t
h
e
 
l
o
w
e
r
 
e
n
d
 
o
f
 
t
h
e
 
o
e
s
o
p
h
a
g
u
s
.
 
 
T
h
i
s
 
r
e
i
n
f
o
r
c
e
s
 
t
h
e
 
‘
v
a
l
v
e
’
 
b
e
t
w
e
e
n
 
t
h
e
m
 
a
i
m
i
n
g
 
t
o
 
s
t
o
p
 
t
h
e
 
r
e
f
l
u
x
.
 
 
 
 
 
W
h
a
t
 
w
i
l
l
 
h
a
p
p
e
n
 
i
f
 
I
 
j
o
i
n
 
t
h
e
 
s
t
u
d
y
?
 
 
 
 
•
 
I
t
 
i
s
 
u
p
 
t
o
 
y
o
u
 
t
o
 
d
e
c
i
d
e
 
w
h
e
t
h
e
r
 
o
r
 
n
o
t
 
y
o
u
 
w
o
u
l
d
 
l
i
k
e
 
t
o
 
t
a
k
e
 
p
a
r
t
 
i
n
 
t
h
e
 
s
t
u
d
y
.
 
 
I
f
 
y
o
u
 
d
o
 
d
e
c
i
d
e
 
t
o
 
t
a
k
e
 
p
a
r
t
 
y
o
u
 
w
i
l
l
 
b
e
 
a
s
k
e
d
 
t
o
 
s
i
g
n
 
a
 
c
o
n
s
e
n
t
 
f
o
r
m
 
a
n
d
 
f
i
l
l
 
i
n
 
a
 
q
u
e
s
t
i
o
n
n
a
i
r
e
.
 
 
 
•
 
Y
o
u
 
w
i
l
l
 
b
e
 
s
e
n
t
 
q
u
e
s
t
i
o
n
n
a
i
r
e
s
 
b
y
 
p
o
s
t
,
 
o
n
e
 
a
f
t
e
r
 
a
b
o
u
t
 
6
 
m
o
n
t
h
s
 
a
n
d
 
a
n
o
t
h
e
r
 
9
 
m
o
n
t
h
s
 
l
a
t
e
r
,
 
w
h
i
c
h
 
w
i
l
l
 
t
a
k
e
 
a
b
o
u
t
 
h
a
l
f
 
a
n
 
h
o
u
r
 
t
o
 
c
o
m
p
l
e
t
e
.
 
 
C
o
n
t
a
c
t
 
m
a
y
 
c
o
n
t
i
n
u
e
 
f
o
r
 
s
o
m
e
 
y
e
a
r
s
 
a
f
t
e
r
 
t
h
a
t
.
 
 
Y
o
u
 
a
r
e
 
f
r
e
e
 
t
o
 
d
e
c
l
i
n
e
 
t
o
 
a
n
s
w
e
r
 
a
n
y
 
o
f
 
o
u
r
 
q
u
e
s
t
i
o
n
s
 
w
i
t
h
o
u
t
 
g
i
v
i
n
g
 
a
 
r
e
a
s
o
n
 
a
t
 
a
n
y
 
t
i
m
e
.
 
•
 
I
n
f
o
r
m
a
t
i
o
n
 
r
e
l
a
t
i
n
g
 
t
o
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
o
f
 
y
o
u
r
 
r
e
f
l
u
x
 
s
y
m
p
t
o
m
s
 
m
a
y
 
b
e
 
c
o
l
l
e
c
t
e
d
 
f
r
o
m
 
y
o
u
r
 
m
e
d
i
c
a
l
 
n
o
t
e
s
.
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W
h
a
t
 
a
r
e
 
t
h
e
 
a
d
v
a
n
t
a
g
e
s
 
a
n
d
 
d
i
s
a
d
v
a
n
t
a
g
e
s
 
o
f
 
t
h
e
 
t
w
o
 
t
y
p
e
s
 
o
f
 
t
r
e
a
t
m
e
n
t
s
 
b
e
i
n
g
 
c
o
m
p
a
r
e
d
?
 
 
 
 
T
h
e
 
a
d
v
a
n
t
a
g
e
s
 
o
f
 
m
e
d
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
a
r
e
:
 
 
•
 
i
t
 
i
s
 
e
f
f
e
c
t
i
v
e
 
i
n
 
r
e
d
u
c
i
n
g
 
s
y
m
p
t
o
m
s
,
 
i
f
 
t
h
e
r
e
 
a
r
e
 
a
n
y
 
•
 
i
t
 
d
o
e
s
 
n
o
t
 
r
e
q
u
i
r
e
 
h
o
s
p
i
t
a
l
i
s
a
t
i
o
n
 
o
r
 
t
i
m
e
 
o
f
f
 
w
o
r
k
.
 
 
T
h
e
 
d
i
s
a
d
v
a
n
t
a
g
e
s
 
o
f
 
m
e
d
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
a
r
e
:
 
 
•
 
i
t
 
h
a
s
 
t
o
 
b
e
 
g
i
v
e
n
 
i
n
d
e
f
i
n
i
t
e
l
y
,
 
a
n
d
 
m
a
y
 
o
c
c
a
s
i
o
n
a
l
l
y
 
c
a
u
s
e
 
s
i
d
e
-
e
f
f
e
c
t
s
 
s
u
c
h
 
a
s
 
h
e
a
d
a
c
h
e
s
,
 
r
a
s
h
,
 
m
u
s
c
l
e
 
a
n
d
 
j
o
i
n
t
 
p
a
i
n
 
a
n
d
 
s
t
o
m
a
c
h
 
u
p
s
e
t
s
 
•
 
i
t
 
m
a
y
 
i
m
p
a
i
r
 
t
h
e
 
n
o
r
m
a
l
 
f
u
n
c
t
i
o
n
s
 
o
f
 
s
t
o
m
a
c
h
 
a
c
i
d
 
i
n
 
d
i
g
e
s
t
i
n
g
 
f
o
o
d
 
a
n
d
 
c
o
n
t
r
o
l
l
i
n
g
 
b
a
c
t
e
r
i
a
.
 
 
I
t
 
s
h
o
u
l
d
 
b
e
 
r
e
m
e
m
b
e
r
e
d
 
t
h
a
t
 
i
n
 
G
O
R
D
,
 
a
c
i
d
 
p
r
o
d
u
c
t
i
o
n
 
b
y
 
t
h
e
 
s
t
o
m
a
c
h
 
i
s
 
u
s
u
a
l
l
y
 
n
o
r
m
a
l
;
 
i
t
 
s
i
m
p
l
y
 
g
e
t
s
 
i
n
t
o
 
t
h
e
 
w
r
o
n
g
 
p
l
a
c
e
,
 
i
.
e
.
 
t
h
e
 
o
e
s
o
p
h
a
g
u
s
.
 
 
 
 
T
h
e
 
a
d
v
a
n
t
a
g
e
s
 
o
f
 
t
h
e
 
s
u
r
g
i
c
a
l
 
o
p
e
r
a
t
i
o
n
 
a
r
e
:
 
 
•
 
i
t
 
c
o
r
r
e
c
t
s
 
t
h
e
 
u
n
d
e
r
l
y
i
n
g
 
c
a
u
s
e
 
o
f
 
t
h
e
 
p
r
o
b
l
e
m
,
 
n
a
m
e
l
y
 
t
h
e
 
f
a
u
l
t
y
 
v
a
l
v
e
 
•
 
i
t
 
p
r
e
s
e
r
v
e
s
 
t
h
e
 
n
o
r
m
a
l
 
a
c
i
d
 
p
r
o
d
u
c
t
i
o
n
 
o
f
 
t
h
e
 
s
t
o
m
a
c
h
 
•
 
i
t
 
g
r
e
a
t
l
y
 
r
e
d
u
c
e
s
 
t
h
e
 
n
e
e
d
 
f
o
r
 
l
i
f
e
l
o
n
g
 
m
e
d
i
c
a
t
i
o
n
.
 
 
T
h
e
 
d
i
s
a
d
v
a
n
t
a
g
e
s
 
o
f
 
t
h
e
 
s
u
r
g
i
c
a
l
 
o
p
e
r
a
t
i
o
n
 
a
r
e
:
 
 
•
 
i
t
 
r
e
q
u
i
r
e
s
 
o
n
e
 
t
o
 
t
h
r
e
e
 
d
a
y
s
 
i
n
 
h
o
s
p
i
t
a
l
 
a
n
d
 
a
p
p
r
o
x
i
m
a
t
e
l
y
 
t
w
o
 
t
o
 
s
i
x
 
w
e
e
k
s
 
o
f
f
 
w
o
r
k
 
•
 
i
t
 
m
a
y
 
c
a
u
s
e
 
t
e
m
p
o
r
a
r
y
 
d
i
f
f
i
c
u
l
t
y
 
i
n
 
s
w
a
l
l
o
w
i
n
g
 
s
o
l
i
d
s
,
 
a
 
f
e
e
l
i
n
g
 
o
f
 
f
u
l
l
n
e
s
s
 
a
f
t
e
r
 
e
a
t
i
n
g
 
a
n
d
 
a
 
c
h
a
n
g
e
 
i
n
 
b
o
w
e
l
 
h
a
b
i
t
s
 
•
 
i
t
 
m
a
y
 
o
c
c
a
s
i
o
n
a
l
l
y
 
f
a
i
l
 
t
o
 
a
b
o
l
i
s
h
 
t
h
e
 
s
y
m
p
t
o
m
s
 
o
f
 
r
e
f
l
u
x
 
•
 
a
s
 
w
i
t
h
 
a
l
l
 
s
u
r
g
e
r
y
,
 
i
t
 
i
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
a
 
r
i
s
k
,
 
a
l
b
e
i
t
 
a
 
v
e
r
y
 
l
o
w
 
r
i
s
k
,
 
o
f
 
o
p
e
r
a
t
i
v
e
 
d
e
a
t
h
 
o
r
 
s
e
r
i
o
u
s
 
c
o
m
p
l
i
c
a
t
i
o
n
s
.
 
 
 
 
 
W
h
a
t
 
a
r
e
 
t
h
e
 
p
o
s
s
i
b
l
e
 
b
e
n
e
f
i
t
s
 
o
f
 
t
a
k
i
n
g
 
p
a
r
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?
 
 
W
e
 
h
o
p
e
 
t
h
a
t
 
t
h
e
 
t
r
e
a
t
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e
n
t
 
y
o
u
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e
c
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v
e
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i
l
l
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o
n
t
r
o
l
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o
u
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G
O
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o
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H
o
w
e
v
e
r
,
 
t
h
i
s
 
c
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b
e
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u
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r
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t
e
e
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h
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i
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l
 
g
e
t
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b
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R
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.
 
 
 
W
e
 
w
a
n
t
 
t
o
 
r
e
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s
s
u
r
e
 
y
o
u
 
t
h
a
t
:
 
 
 
 
•
 
Y
o
u
r
 
i
n
v
o
l
v
e
m
e
n
t
 
i
n
 
t
h
e
 
s
t
u
d
y
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s
 
e
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t
i
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e
l
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o
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u
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.
 
 
 
•
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u
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i
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c
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t
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x
p
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t
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i
c
i
p
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n
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c
t
 
p
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v
a
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m
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l
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r
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n
c
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,
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f
 
y
o
u
 
d
o
 
h
a
v
e
 
i
n
s
u
r
a
n
c
e
,
 
p
l
e
a
s
e
 
c
h
e
c
k
 
w
i
t
h
 
t
h
e
 
c
o
m
p
a
n
y
 
b
e
f
o
r
e
 
a
g
r
e
e
i
n
g
 
t
o
 
t
a
k
e
 
p
a
r
t
 
i
n
 
t
h
e
 
s
t
u
d
y
.
 
 
 
•
 
A
l
l
 
i
n
f
o
r
m
a
t
i
o
n
 
c
o
l
l
e
c
t
e
d
 
f
o
r
 
t
h
e
 
s
t
u
d
y
 
w
i
l
l
 
b
e
 
t
r
e
a
t
e
d
 
a
s
 
c
o
n
f
i
d
e
n
t
i
a
l
 
a
n
d
 
u
s
e
d
 
o
n
l
y
 
f
o
r
 
t
h
e
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r
p
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e
 
o
f
 
t
h
e
 
s
t
u
d
y
.
 
 
 
•
 
A
l
l
 
p
e
o
p
l
e
 
t
a
k
i
n
g
 
p
a
r
t
 
w
i
l
l
 
b
e
 
k
e
p
t
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n
f
o
r
m
e
d
 
a
b
o
u
t
 
t
h
e
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t
u
d
y
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d
 
w
i
l
l
 
b
e
 
s
e
n
t
 
a
 
s
u
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o
f
 
t
h
e
 
r
e
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l
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.
 
 
T
h
e
 
r
e
s
u
l
t
s
 
o
f
 
t
h
e
 
s
t
u
d
y
 
w
i
l
l
 
b
e
 
p
u
b
l
i
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e
d
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n
 
m
e
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i
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l
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o
u
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n
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.
 
 
P
a
r
t
i
c
i
p
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n
t
s
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i
l
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o
t
 
b
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e
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i
f
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.
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i
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h
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c
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R
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h
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f
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o
u
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r
e
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b
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e
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c
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l
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m
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.
 
 
I
f
 
y
o
u
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r
e
 
h
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e
d
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e
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c
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c
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i
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e
g
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f
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o
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h
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v
e
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y
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e
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o
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m
p
l
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n
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y
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p
e
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o
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t
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e
 
w
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y
o
u
 
h
a
v
e
 
b
e
e
n
 
a
p
p
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o
a
c
h
e
d
 
o
r
 
t
r
e
a
t
e
d
 
d
u
r
i
n
g
 
t
h
e
 
c
o
u
r
s
e
 
o
f
 
t
h
i
s
 
s
t
u
d
y
,
 
t
h
e
 
n
o
r
m
a
l
 
N
H
S
 
c
o
m
p
l
a
i
n
t
s
 
m
e
c
h
a
n
i
s
m
s
 
a
r
e
 
a
v
a
i
l
a
b
l
e
 
t
o
 
y
o
u
.
 
 
 
 
C
o
n
t
a
c
t
 
f
o
r
 
F
u
r
t
h
e
r
 
I
n
f
o
r
m
a
t
i
o
n
 
 
 
R
E
F
L
U
X
 
T
r
i
a
l
 
O
f
f
i
c
e
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
s
 
R
e
s
e
a
r
c
h
 
U
n
i
t
 
U
n
i
v
e
r
s
i
t
y
 
o
f
 
A
b
e
r
d
e
e
n
 
F
o
r
e
s
t
e
r
h
i
l
l
 
A
b
e
r
d
e
e
n
 
A
B
2
5
 
2
Z
D
 
T
e
l
.
 
0
1
2
2
4
 
0
0
0
0
0
0
 
F
a
x
:
 
0
1
2
2
4
 
5
5
4
5
8
0
 
E
m
a
i
l
:
 
r
e
f
l
u
x
@
h
s
r
u
.
a
b
d
n
.
a
c
.
u
k
 
 
 
C
o
n
s
u
m
e
r
s
 
f
o
r
 
E
t
h
i
c
s
 
i
n
 
R
e
s
e
a
r
c
h
 
(
C
E
R
E
S
)
 
p
u
b
l
i
s
h
 
a
 
l
e
a
f
l
e
t
 
e
n
t
i
t
l
e
d
 
‘
M
e
d
i
c
a
l
 
R
e
s
e
a
r
c
h
 
a
n
d
 
Y
o
u
’
.
 
 
T
h
i
s
 
l
e
a
f
l
e
t
 
g
i
v
e
s
 
m
o
r
e
 
i
n
f
o
r
m
a
t
i
o
n
 
a
b
o
u
t
 
m
e
d
i
c
a
l
 
r
e
s
e
a
r
c
h
 
a
n
d
 
l
o
o
k
s
 
a
t
 
s
o
m
e
 
q
u
e
s
t
i
o
n
s
 
y
o
u
 
m
i
g
h
t
 
w
a
n
t
 
t
o
 
a
s
k
.
 
 
A
 
c
o
p
y
 
m
a
y
 
b
e
 
o
b
t
a
i
n
e
d
 
f
r
o
m
 
C
E
R
E
S
,
 
P
O
 
B
o
x
 
1
3
6
5
,
 
L
o
n
d
o
n
 
N
1
6
 
0
B
W
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PAFV11/04-01 
 
Patient Details (or affix stamp) 
 
 
 
 
 
 
 
 
 
 
Patient Assessment Form 
Name:   
Address:   
   
   
Sex:    DoB:  
Hosp ID:  
 
 
Participant Study No 
         
                   
 
Hospital:   
Date:  /  / 
 
Please tick the box which best describes the patient:- 
Eligibility Criteria  Yes  No 
1    Evidence of GORD (endoscopy and/or pH monitoring)     
2    Symptoms > 12 months     
3    Currently requiring maintenance PPI symptom control     
4    Suitable for either policy (ASA Grade I or II)     
 
Reasons for Exclusion  Yes  No 
5    BMI > 40 kg/m
2     
6    Barrett’s oesophagus (!3cm)     
7    Paraoesophageal hernia     
8    Oesophageal strictures     
9    One type of management is clinically indicated for another reason     
10    Other (state)      
 
If there is a tick in every shaded box the patient is eligible 
 
 
Has the patient had erosive oesophagitis? (please circle)  Yes  No 
 
 
Please pass on this form with the patient to the research nurse       
Recruitment and Co-morbidity Information (to be completed by the research nurse) 
 
Source of recruitment  Retrospective                Prospective   
 
Reasons for non-recruitment 
Clinician chose not to recruit   Patient declined  Patient not approached/missed 
H.Pylori test  (CLO test) 
Positive (subsequently treated)  Positive (subsequently untreated)  Negative  Uncertain 
 
Hiatus Hernia  pH monitoring  
Yes  No  Yes  No 
 
                   
     
 
Consultant’s Details 
Name:   
Signature:   
Height  m / ft 
Weight  kg / st Health Technology Assessment 2008; Vol. 12: No. 31
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P
A
T
I
E
N
T
 
I
N
F
O
R
M
A
T
I
O
N
 
L
E
A
F
L
E
T
 
 
 
L
A
P
A
R
O
S
C
O
P
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R
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R
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P
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r
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i
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i
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.
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p
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i
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c
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.
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l
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p
i
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r
g
e
r
y
?
 
 
 
L
a
p
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p
i
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(
k
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l
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)
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c
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p
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c
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p
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r
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R
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R
e
f
l
u
x
 
D
i
s
e
a
s
e
)
 
a
r
e
 
a
w
a
r
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c
i
d
 
a
n
d
 
f
l
u
i
d
.
 
 
T
h
i
s
 
i
s
 
u
s
u
a
l
l
y
 
w
o
r
s
e
 
o
n
 
b
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p
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p
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b
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h
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b
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p
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p
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p
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      Participant Study No 
                     
                                           
 
Trial Consent Form 
 
Copy 1 
Participant’s Copy to Keep 
 
 
REFLUX Trial Office,  Health Service Research Unit (Flea), University of Aberdeen, Foresterhill, ABERDEEN AB25 2ZD 
Tel: 01224 000000    Fax: 01224 554580    Email: REFLUX@abdn.ac.uk 
RCFV3/02/01 
 
 
I have: 
• !!Discussed the study with 
 
 
Yes  No 
•  Been given the Information Leaflets about the study        
       
•  Received satisfactory answers to questions 
 
     
       
•  Been given satisfactory information about the study 
 
     
 
I understand that: 
•  I have chosen to be randomly allocated to either having surgery or continuing with 
medication for the treatment of my reflux symptoms  
•  I will be sent questionnaires at specified time intervals after starting the study 
•  I may be approached to find out how I am, for some years after starting the study 
•  Information related to treatment of reflux may be collected from my medical notes 
•  My family doctor will be notified that I am taking part in the study 
•  I am free to withdraw from the study at any time without having to give a reason 
•  If I withdraw, this will not affect my future care 
 
I agree to take part in the study 
 
 
Signature of participant 
Name (in block capitals) 
Date 
!
I  confirm  that  I  have  explained  to  the  person  named  above,  the  nature  and 
purpose of the study and the procedures involved 
 
 
Signature of researcher 
Date!
!
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  Participant Study No 
                     
                                           
 
Trial Consent Form 
 
Copy 2 
To Return to The REFLUX Trial Office 
 
 
REFLUX Trial Office,  Health Service Research Unit (Flea), University of Aberdeen, Foresterhill, ABERDEEN AB25 2ZD 
Tel: 01224 000000    Fax: 01224 554580    Email: REFLUX@abdn.ac.uk 
RCFV3/02/01 
 
I have: 
• !!Discussed the study with 
 
 
Yes  No 
•  Been given the Information Leaflets about the study        
       
•  Received satisfactory answers to questions 
 
     
       
•  Been given satisfactory information about the study 
 
     
 
I understand that: 
•  I have chosen to be randomly allocated to either having surgery or continuing with 
medication for the treatment of my reflux symptoms  
•  I will be sent questionnaires at specified time intervals after starting the study 
•  I may be approached to find out how I am, for some years after starting the study 
•  Information related to treatment of reflux may be collected from my medical notes 
•  My family doctor will be notified that I am taking part in the study 
•  I am free to withdraw from the study at any time without having to give a reason 
•  If I withdraw, this will not affect my future care 
 
I agree to take part in the study 
 
 
Signature of participant 
Name (in block capitals) 
Date 
!
I  confirm  that  I  have  explained  to  the  person  named  above,  the  nature  and 
purpose of the study and the procedures involved 
 
 
Signature of researcher 
Date!
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  Participant Study No 
                     
                                           
 
Preference Consent Form 
 
Copy 1 
Participant’s Copy to Keep 
 
 
REFLUX Trial Office,  Health Service Research Unit (Flea), University of Aberdeen, Foresterhill, ABERDEEN AB25 2ZD 
Tel: 01224 000000    Fax: 01224 554580    Email: REFLUX@abdn.ac.uk 
PCFV3/02/01 
 
 
I have: 
• !!Discussed the study with 
 
 
Yes  No 
•  Been given the Information Leaflets about the study        
       
•  Received satisfactory answers to questions 
 
     
       
•  Been given satisfactory information about the study 
 
     
 
I understand that: 
•  I have chosen to have surgery / continue with medication* for the treatment of my 
reflux symptoms (*delete as appropriate) 
•  I will be sent questionnaires at specified time intervals after starting the study 
•  I may be approached to find out how I am, for some years after starting the study 
•  Information related to treatment of reflux may be collected from my medical notes 
•  My family doctor will be notified that I am taking part in the study 
•  I am free to withdraw from the study at any time without having to give a reason 
•  If I withdraw, this will not affect my future care 
 
I agree to take part in the study 
 
 
Signature of participant 
Name (in block capitals) 
Date 
!
I  confirm  that  I  have  explained  to  the  person  named  above,  the  nature  and 
purpose of the study and the procedures involved 
 
 
Signature of researcher 
Date!
!
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  Participant Study No 
                     
                                           
 
Preference Consent Form 
 
Copy 2 
To Return to The REFLUX Trial Office 
 
 
REFLUX Trial Office,  Health Service Research Unit (Flea), University of Aberdeen, Foresterhill, ABERDEEN AB25 2ZD 
Tel: 01224 000000    Fax: 01224 554580    Email: REFLUX@abdn.ac.uk 
PCFV3/02/01 
 
I have: 
• !!Discussed the study with 
 
 
Yes  No 
•  Been given the Information Leaflets about the study        
       
•  Received satisfactory answers to questions 
 
     
       
•  Been given satisfactory information about the study 
 
     
 
I understand that: 
•  I have chosen to have surgery / continue with medication* for the treatment of my 
reflux symptoms (*delete as appropriate) 
•  I will be sent questionnaires at specified time intervals after starting the study 
•  I may be approached to find out how I am, for some years after starting the study 
•  Information related to treatment of reflux may be collected from my medical notes 
•  My family doctor will be notified that I am taking part in the study 
•  I am free to withdraw from the study at any time without having to give a reason 
•  If I withdraw, this will not affect my future care 
 
I agree to take part in the study 
 
 
Signature of participant 
Name (in block capitals) 
Date 
!
I  confirm  that  I  have  explained  to  the  person  named  above,  the  nature  and 
purpose of the study and the procedures involved 
 
 
Signature of researcher 
Date!
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Appendix 8  
Laparoscopic fundoplication  
operative data formAppendix 7
156 SFV6/08-01 
Patient Details (or affix stamp to both copies) 
Name:   
Address:   
   
   
Sex:    DoB:  
Hosp ID:  
 
 
 
 
 
 
 
 
 
Laparoscopic Fundoplication 
Operative Data 
  
Date of admission  /  / 
Date of operation  /  / 
Date of discharge  /  / 
PREOPERATIVE DETAILS  
1) Tests before surgery  (tick against tests performed) 
Endoscopy    pH monitoring    Manometry   
  Other (state)   
  2) Previous abdominal surgery (state)   
 
OPERATIVE DETAILS 
1) Operating surgeon’s name   
  2) Grade of operating surgeon  (tick against grade) 
Consultant    Staff, Assoc. Spec    SpR   
  Other (state)   
 
3) Operation times  24 hour    4) Type of fundoplication  (tick against type) 
Time into anaesthetic room        Total wrap   
  Time into recovery room        Partial - anterior   
     - posterior   
  5) Operative  (tick if yes)  Other (state)   
Liver injury       
Splenic injury      6) Technical  (tick if yes) 
Pleural injury      Short gastric arteries divided   
Oesophageal injury      Left hepatic from left gastric artery   
Other visceral injury        If present, left hepatic artery divided   
    Hepatic branch vagus divided    Haemorrhage (requiring change to normal 
procedure)    Hiatus Hernia present   
7) Crural repair  (tick if yes)      Bougie used   
 
8) Conversion to open  (tick if yes)     
Reason (state)   
 
POSTOPERATIVE DETAILS (to be completed by the Research Nurse) 
1) Post-op level of care  (tick if yes)      2) Early post operative event  (tick if yes) 
Ward only      Pneumothorax (requiring intervention)   
HDU admission      Blood transfusion required   
ICU admission        Number of units transfused (state)   
Re-operation (describe below)      Other (state)   
  3) Outcomes  (tick if yes)   
  Discharged  - home   
    - other   
 
  Died   
Participant Study No 
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Appendix 9  
Search strategies for literature searches
Search strategies 
1. fundoplication or fundiplication or 
fundoplast$or stretta).mp.
2. (euroqol or EQ-5D or eq-5d or (eq adj 5d) or hui 
or qwb or utility or utilities).mp.
3. quality of life/
4. 1 and (2 or 3)
Reference manager/
MEDLINE
(SF-36) OR (sf 36)
(EQ-5D) OR (eq 5d) OR (euroqol) OR (euro qol)
(short form 36) OR (shortform 36) OR (sf thirtysix) 
OR (sf thirty six) OR (short form thirty six)
(hrql) OR (hrqol) OR (h qol) OR (hql) OR (hqol)
or (hye) OR (hyes) OR (health$year$equivalent$) 
OR (health util$)
or rosser
or (quality of life) OR (quality adjusted life year) 
OR (health status indicator) OR (qaly) OR (quality 
adjusted life) OR (life quality)
(ppi) OR (omeprazole) OR (pantoprazole) 
OR (lansoprazole) OR (esomeprazole) OR 
(rabeprazole)
(SF-36) OR (sf 36)
(EQ-5D) OR (eq 5d) OR (euroqol) OR (euro qol)
(short form 36) OR (shortform 36) OR (sf thirtysix) 
OR (sf thirty six) OR (short form thirty six)
or (64) OR (hrqol) OR (h qol) OR (hql) OR (hqol)
or (hye) OR (hyes) OR (health$year$equivalent$) 
OR (health util$)
or rosser
or (quality of life) OR (quality adjusted life year) 
OR (health status indicator) OR (qaly) OR (quality 
adjusted life) OR (life quality)
and (H2-blocker) OR (ranitidine) OR (famotidine) 
OR (cimetidine) OR (nizatidine)Health Technology Assessment 2008; Vol. 12: No. 31
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Appendix 10  
Costs of surgery and cost loadings
Total surgical costs (£)
Centre 1 Centre 2 Centre 3 Centre 4 Centre 5
Preoperative 
procedures
£314.66 £299.42 £314.66 £321.66 £364.66
Theatre staff £545.20 £289.92 £455.06 £441.46 £520.39
Disposables  £725.30 £853.52 £1051.08 £635.93 £816.46
Capital equipment  £9.22 £9.22 £9.22 £9.22 £9.22
Bed costs £1140.72 £1140.72 £1140.72 £1140.72 £1140.72
Consumables  £47.57 £47.57 £47.57 £47.57 £47.57
Total/centre £2782.67 £2640.37 £3018.31 £2596.56 £2899.02
Mean cost of LNF  £2787.39
SD £175.95
Cost loadings (for complications)
Cost of open fundoplication (conversion) allowing for longer LOS  £4490.67
Probability of conversion being required 0.05
Cost of dilatation £165
Probability of dilatation being performed 0.021
Total cost of surgery £3015.39
LNF,  laparoscopic Nissen fundoplication; LOS, length of stay.Health Technology Assessment 2008; Vol. 12: No. 31
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Appendix 11
#recalculate intercept on natural scale
rate < –exp(beta0)
tau < –1/(sigma × sigma)
}
inits
#list(beta0 = 0, tau = 1,
b = c(0,0,0,0,0
0,0,0,0,0,
0,0,0,0,0
))
list(beta0 = 0, sigma = 0.5,
b = c(0,0,0,0,0,  0,0,0,0,0,
0,0,0,0,0
))
data
list(N = 15,
n_cases = c(2,14,19,24,5,
10,60,150,2,11,
19,31,10,80,0
),
total = c(109,104,716,1094,103,
411,4410,578,108,260,
100,336,533,300,18
))
END
P
rogramming code using the WinBUGS 
statistical package to estimate the pooled rate 
of surgery patients requiring medical management, 
using a random study effect
Model
#filename “poisson6.odc”
{
for (i in 1:N) {
#likelihood poisson family
n_cases[i] ~ dpois(mu[i])
#beta0 = intercept
#no covariates
#total is the offset term (coefficient forced to = 1)
#estimate random effects b[i]
#log (multiplicative) link function
log(mu[i]) < –log(total[i]) + b[i]
#prior for random study effect
b[i] ~ dnorm(beta0,tau)
}
#prior for log(pooled rate)
beta0 ~ dnorm(0,1.0E-6)
#various priors are possible for precision 
#eg (gamma(0.001,0.001) on tau,uniform(0,10) on 
sigma)
sigma ~ dunif(0,10)Appendix 11
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Appendix 12  
Discrete choice experiment questionnairesAppendix 12
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For office use only  Participant Study No             
                       
 
(for completion by co-ordinating 
          centre in Aberdeen) 
 
 
 
 
 
 
 
 
 
 
 
 
GASTRO-OESOPHAGEAL REFLUX 
DISEASE (GORD) TREATMENT CHOICE 
QUESTIONNAIRE 
 
 
 
 
 
 
CONFIDENTIAL 
 
 
 
 
This study is funded by the NIHR Health Technology 
Assessment Programme 
 
  
A   
G
O
R
D
 
T
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THE FOLLOWING TWO PAGES ARE FOR INFORMATION ONLY 
 
 
Thank you for taking part in this survey.   
 
The responses you give will help us find out which reflux treatment option has the biggest 
impact on overall health and quality of life.  The information you provide will be completely 
confidential. 
 
 
 
 
HOW TO FILL IN THE QUESTIONNAIRE 
 
In  this  questionnaire,  you  are  presented  with  10  questions  relating  to  different  GORD 
treatment choices, each describing two or three treatment options: Option A or Option B and 
sometimes Option C.   
 
When answering these questions, we would like you to imagine that your gastroenterologist 
is offering you the choice of treatment options (A or B or C) and that (s)he would like you to 
pick the option you prefer.   You would do this by putting a tick in the appropriate box.   
 
Although,  you  may  not  like  either  treatment  option,  please  choose  the  one  that  is  most 
preferable to you.   
 
Please tick just ONE box for every question. Appendix 12
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PLEASE REFER TO THE GUIDANCE NOTES ENCLOSED WITH THIS QUESTIONNAIRE 
TO HELP YOU MAKE YOUR DECISIONS 
 
 
Here is an EXAMPLE QUESTION to help you fill out the following questions: 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  None at all  Once a week 
Chance of serious complications requiring 
hospitalisation 
1 in 500  1 in 800 
Chance of undergoing surgery  2 in 3  1 in 20 
Chance of needing lifelong medication  1 in 20   2 in 3 
 
 
  
 
 
 
IN THIS CASE YOU WOULD PREFER TO: 
 
Have the option of no symptoms, having a 1 in 500 chance of serious complications, having 
a 2 in 3 chance of undergoing surgery, and a 1 in 20 chance of needing lifelong medication. 
 
RATHER THAN: 
 
The  option  of  having  symptoms  once  a  week,  having  a  1  in  800  chance  of  serious 
complications,  having  a  1  in  20  chance  of  undergoing  surgery,  and  a  2  in  3  chance  of 
needing lifelong medication. 
 
 
 
 
Please remember, there is no right or wrong answer.  
We just want to know what YOU think. 
 
Example question Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B 
!   Health Technology Assessment 2008; Vol. 12: No. 31
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  Option A  Option B 
Frequency of troublesome symptoms  Once a week  Two or three times a 
week 
Chance of serious complications requiring 
hospitalisation 
1 in 500  1 in 100 
Chance of undergoing surgery  1 in 20  1 in 3 
Chance of needing lifelong medication  5 in 6  1 in 3 
 
 
  
 
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Two or three times a 
week 
Most days/everyday 
Chance of serious complications requiring 
hospitalisation 
1 in 100  1 in 500 
Chance of undergoing surgery  1 in 3  2 in 3 
Chance of needing lifelong medication  1 in 20  2 in 3 
 
 
  
 
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Two or three times a 
week 
Most days/everyday 
Chance of serious complications requiring 
hospitalisation 
1 in 500  1 in 100 
Chance of undergoing surgery  5 in 6  1 in 20 
Chance of needing lifelong medication  2 in 3  1 in 20 
 
 
 
 
Choice 1    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
Choice 2    Which option would you choose?                  
Choice 3    Which option would you choose?                  Appendix 12
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  Option A  Option B 
Frequency of troublesome symptoms  Most days/everyday  Not at all 
Chance of serious complications requiring 
hospitalisation 
1 in 300  1 in 800 
Chance of undergoing surgery  1 in 3  2 in 3 
Chance of needing lifelong medication  5 in 6  1 in 3 
 
 
  
 
 
 
 
 
 
  Option A  Option B  Option C 
Frequency of troublesome 
symptoms 
Two or three times 
a week 
Most 
days/everyday 
Two or three times 
a week 
Chance of serious 
complications requiring 
hospitalisation 
1 in 100  1 in 500  1 in 100 
Chance of undergoing 
surgery 
1 in 3  2 in 3  2 in 3 
Chance of needing 
lifelong medication 
1 in 20  2 in 3  1 in 3 
 
 
  
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Once a week  Two or three times a 
week 
Chance of serious complications requiring 
hospitalisation 
1 in 100  1 in 500 
Chance of undergoing surgery  2 in 3  5 in 6 
Chance of needing lifelong medication  1 in 3  5 in 6 
 
 
 
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
Choice 4    Which option would you choose?                  
Choice 5    Which option would you choose?                  
Choice 6    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B  Option C 
     Health Technology Assessment 2008; Vol. 12: No. 31
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  Option A  Option B 
Frequency of troublesome symptoms  Not at all  Once a week 
Chance of serious complications requiring 
hospitalisation 
1 in 800  1 in 300 
Chance of undergoing surgery  1 in 20  1 in 3 
Chance of needing lifelong medication  1 in 20  2 in 3 
 
 
  
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Most days/everyday  Not at all 
Chance of serious complications requiring 
hospitalisation 
1 in 800  1  in 300 
Chance of undergoing surgery  5 in 6  1 in 20 
Chance of needing lifelong medication  1 in 3   5 in 6 
 
 
  
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Not at all  Once a week 
Chance of serious complications requiring 
hospitalisation 
1 in 300  1 in 800 
Chance of undergoing surgery  2 in 3  5 in 6 
Chance of needing lifelong medication  2 in 3  1 in 20 
 
 
  
 
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
Choice 7    Which option would you choose?                  
Choice 8    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B 
   
Choice 9    Which option would you choose?                  Appendix 12
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  Option A  Option B  Option C 
Frequency of troublesome 
symptoms 
Most 
days/everyday 
Not at all  Most 
days/everyday 
Chance of serious 
complications requiring 
hospitalisation 
1 in 300  1 in 800  1 in 100 
Chance of undergoing surgery  1 in 3  2 in 3  2 in 3 
Chance of needing lifelong 
medication 
5 in 6  1 in 3  5 in 6 
 
 
  
 
 
 
 
 
IF YOU HAVE ANY OTHER COMMENTS about your gastro-oesophageal reflux 
symptoms, your reflux treatment or this study, please write them below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Choice 10    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B    Option C 
     Health Technology Assessment 2008; Vol. 12: No. 31
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THANK YOU FOR YOUR HELP IN COMPLETING 
THIS QUESTIONNAIRE 
 
 
 
Once you have completed the form, please return it in the pre-paid envelope 
provided or to the following address: 
 
 
REFLUX Trial Office 
Health Services Research Unit  
 Polwarth Building 
Foresterhill 
 Aberdeen   AB25 2ZD 
Tel: 01224 000000 
Fax: 01224 554580 
  E-mail: reflux@hsru.abdn.ac.uk Appendix 12
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For office use only   
Participant Study No             
                       
 
(for completion by co-ordinating 
          centre in Aberdeen) 
 
 
 
 
 
 
 
 
 
 
 
 
GASTRO-OESOPHAGEAL REFLUX 
DISEASE (GORD) TREATMENT CHOICE 
QUESTIONNAIRE 
 
 
 
 
 
 
CONFIDENTIAL 
 
 
 
 
This study is funded by the NIHR Health Technology 
Assessment Programme 
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THE FOLLOWING TWO PAGES ARE FOR INFORMATION ONLY 
 
 
Thank you for taking part in this survey.   
 
The responses you give will help us find out which reflux treatment option has the biggest 
impact on overall health and quality of life.  The information you provide will be completely 
confidential. 
 
 
 
 
HOW TO FILL IN THE QUESTIONNAIRE 
 
In  this  questionnaire,  you  are  presented  with  10  questions  relating  to  different  GORD 
treatment choices, each describing two or three treatment options: Option A or Option B and 
sometimes Option C.   
 
When answering these questions, we would like you to imagine that your gastroenterologist 
is offering you the choice of treatment options (A or B or C) and that (s)he would like you to 
pick the option you prefer.   You would do this by putting a tick in the appropriate box.   
 
Although,  you  may  not  like  either  treatment  option,  please  choose  the  one  that  is  most 
preferable to you.   
 
Please tick just ONE box for every question. Appendix 12
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PLEASE REFER TO THE GUIDANCE NOTES ENCLOSED WITH THIS QUESTIONNAIRE 
TO HELP YOU MAKE YOUR DECISIONS 
 
 
Here is an EXAMPLE QUESTION to help you fill out the following questions: 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  None at all  Once a week 
Chance of serious complications requiring 
hospitalisation 
1 in 500  1 in 800 
Chance of undergoing surgery  2 in 3  1 in 20 
Chance of needing lifelong medication  1 in 20   2 in 3 
 
 
  
 
 
 
IN THIS CASE YOU WOULD PREFER TO: 
 
Have the option of no symptoms, having a 1 in 500 chance of serious complications, having 
a 2 in 3 chance of undergoing surgery, and a 1 in 20 chance of needing lifelong medication. 
 
RATHER THAN: 
 
The  option  of  having  symptoms  once  a  week,  having  a  1  in  800  chance  of  serious 
complications,  having  a  1  in  20  chance  of  undergoing  surgery,  and  a  2  in  3  chance  of 
needing lifelong medication. 
 
 
 
 
Please remember, there is no right or wrong answer.  
We just want to know what YOU think. 
 
Example question Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B 
!   Health Technology Assessment 2008; Vol. 12: No. 31
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  Option A  Option B 
Frequency of troublesome symptoms  Once a week  Two or three times a 
week 
Chance of serious complications requiring 
hospitalisation 
1 in 800  1 in 300 
Chance of undergoing surgery  1 in 3  2 in 3 
Chance of needing lifelong medication  2 in 3  1 in 20 
 
 
  
 
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Two or three times a 
week 
Most days/everyday 
Chance of serious complications requiring 
hospitalisation 
1 in 300  1 in 800 
Chance of undergoing surgery  1 in 20  1 in 3 
Chance of needing lifelong medication  1 in 3  5 in 6 
 
 
  
 
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Two or three times a 
week 
Most days/everyday 
Chance of serious complications requiring 
hospitalisation 
1 in 800  1 in 300 
Chance of undergoing surgery  2 in 3  5 in 6 
Chance of needing lifelong medication  5 in 6  1 in 3 
 
 
 
 
Choice 1    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
Choice 2    Which option would you choose?                  
Choice 3    Which option would you choose?                  Appendix 12
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  Option A  Option B 
Frequency of troublesome symptoms  Most days/everyday  Not at all 
Chance of serious complications requiring 
hospitalisation 
1 in 100  1 in 500 
Chance of undergoing surgery  1 in 20  1 in 3 
Chance of needing lifelong medication  2 in 3  1 in 20 
 
 
  
 
 
 
 
 
 
  Option A  Option B  Option C 
Frequency of troublesome 
symptoms 
Once a week  Two or three times 
a week 
Two or three times 
a week 
Chance of serious 
complications requiring 
hospitalisation 
1 in 800  1 in 300  1 in 100 
Chance of undergoing 
surgery 
1 in 3  2 in 3  5 in 6 
Chance of needing 
lifelong medication 
2 in 3  1 in 20  1 in 20 
 
 
  
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Once a week  Two or three times a 
week 
Chance of serious complications requiring 
hospitalisation 
1 in 300  1 in 800 
Chance of undergoing surgery  5 in 6  1 in 20 
Chance of needing lifelong medication  1 in 20  2 in 3 
 
 
 
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
Choice 4    Which option would you choose?                  
Choice 5    Which option would you choose?                  
Choice 6    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B  Option C 
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  Option A  Option B 
Frequency of troublesome symptoms  Not at all  Once a week 
Chance of serious complications requiring 
hospitalisation 
1 in 500  1 in 100 
Chance of undergoing surgery  1 in 3  2 in 3 
Chance of needing lifelong medication  1 in 3  5 in 6 
 
 
  
 
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Most days/everyday  Not at all 
Chance of serious complications requiring 
hospitalisation 
1 in 500  1 in 100 
Chance of undergoing surgery  2 in 3  5 in 6 
Chance of needing lifelong medication  1 in 20  2 in 3 
 
 
  
 
 
 
 
 
 
  Option A  Option B 
Frequency of troublesome symptoms  Not at all  Once a week 
Chance of serious complications requiring 
hospitalisation 
1 in 100  1 in 500 
Chance of undergoing surgery  5 in 6  1 in 20 
Chance of needing lifelong medication  5 in 6   1 in 3 
 
 
  
 
(Tick one box only)  
 
  Option A  Option B 
   
(Tick one box only)  
 
  Option A  Option B 
   
Choice 7    Which option would you choose?                  
Choice 8    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B 
   
Choice 9    Which option would you choose?                  Appendix 12
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  Option A  Option B  Option C 
Frequency of troublesome 
symptoms 
Most 
days/everyday 
Not at all  Most 
days/everyday 
Chance of serious 
complications requiring 
hospitalisation 
1 in 500  1 in 100  1 in 300 
Chance of undergoing surgery  2 in 3  5 in 6  5 in 6 
Chance of needing lifelong 
medication 
1 in 20   2 in 3  1 in 3 
 
 
  
 
 
 
 
 
IF YOU HAVE ANY OTHER COMMENTS about your gastro-oesophageal reflux 
symptoms, your reflux treatment or this study, please write them below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Choice 10    Which option would you choose?                  
(Tick one box only)  
 
  Option A  Option B    Option C 
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THANK YOU FOR YOUR HELP IN COMPLETING 
THIS QUESTIONNAIRE 
 
 
 
Once you have completed the form, please return it in the pre-paid envelope 
provided or to the following address: 
 
 
REFLUX Trial Office 
Health Services Research Unit  
 Polwarth Building 
Foresterhill 
 Aberdeen   AB25 2ZD 
Tel: 01224 000000 
Fax: 01224 554580 
  E-mail: reflux@hsru.abdn.ac.uk 
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Appendix 13  
Further results of the discrete  
choice experiment (DCE)
The regression model for the whole sample
Dimension Coefficient Standard error p-value 95% confidence interval
Troublesome symptoms
  Once a week –0.068 0.066 0.299 –0.197 to 0.061
  Two or three times a week –0.445 0.077 0.000 –0.596 to –0.295
  Most days/every day –1.156 0.071 0.000 –1.295 to –1.018
Serious complications –5.471 0.661 0.000 –6.767 to –4.174
Surgery –5.176 0.844 0.000 –6.830 to –3.521
Lifelong medication –4.815 0.685 0.000 –6.159 to –3.472
Conditional (fixed-effects) logistic regression: number of obs = 6434; LR χ2(6) = 492.08; prob > χ2 = 0.0000.
Log likelihood = –1983.8155; pseudo r2 = 0.1103. 
Relative importance of dimensions
Troublesome symptoms
Serious 
complications Surgery
Lifelong 
medication
Two or three 
times Most days
Troublesome symptoms
  Two or three times 1.00 2.85 13.74 13.13 –12.08
  Most days 0.35 1.00 4.83 4.61 –4.25
Serious complications 0.07 0.21 1.00 0.96 –0.88
Surgery 0.08 0.22 1.05 1.00 –0.92
Lifelong medication –0.08 –0.24 –1.14 –1.09 1.00
Example: having symptoms most days is 2.85 times as important as having symptoms two or three times a week, whereas 
having a 0.1% chance of a serious complication is 13.7 times more important than having symptoms two or three times per 
week.Health Technology Assessment 2008; Vol. 12: No. 31
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